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ABSTRACT 
 
Poor quality and unrefreshing sleep is one of the most common symptom complaints in 
Chronic Fatigue Syndrome (CFS). Despite this, the links between sleep dysfunction and CFS 
are not well understood, and there has been an absence of good quality research into the nature 
of sleep problems in CFS, which also lack consistency in the data reported. However, it 
remains plausible that sleep problems may help to maintain and exacerbate other existing 
symptoms. Given the dispute in models ranging from the biological to the psychological, 
competing to explain symptomology, it is a critical time by which we try to understand the 
relationship between poor sleep, fatigue, endocrine activity and CFS, in an attempt to short-
circuit this debate.  
 
With an aim to redress this, this thesis intended to examine the role of sleep from several 
angles, utilizing a range of assessment methods;  
 
Study 1 addressed the lack of in depth qualitative interview studies, to understand the extent to 
which sleep, its management and problems, are linked to the lived experience of CFS, and how 
it interacts with other symptoms (chapter 3). Patient narratives demonstrated that sleep 
disturbances experienced were highly unpredictable and variable over time, but played a key 
role in symptom maintenance;  
 
Study 2 examined self-reported sleep (via sleep diaries) in CFS patients, exploring whether 
sleep quality and daytime napping had an impact on daytime fatigue, sleepiness and cognitive 
functioning (key dimensions of the illness experience) (chapter 4). The results were highly 
variable but indicated that afternoon-evening napping was associated with greater impairment 
in daytime cognitive functioning in CFS patients. It was also evident that CFS patients with 
longer wake time and a shorter diagnosis had more severe fatigue; 
 
Study 3 explored the possibility that sleep problems in this population are not homogeneous 
and revealed four sleep-specific phenotypes to exist, which are amenable to different treatment 
approaches. The initial cross-sectional examination of single-night polysomnography (PSG) 
data identified 30% of the sample had a primary sleep disorder (PSD), which underscores the 
need to assess for PSDs in CFS populations (chapter 5);  
 
Study 4 was conducted to address the principle aim of this thesis; to determine the feasibility 
of a detailed, 3-night sleep assessment protocol in a small cohort of CFS patients. By utilising 
iv 
a range of methods including ambulatory PSG and a gold-standard protocol for sampling of 
diurnal salivary cortisol, the study piloted the most comprehensive assessment of sleep ever 
attempted in a CFS population. The findings established a successful protocol that was 
acceptable to patients (chapter 6), a key advancement in this field where effective and 
thorough sleep assessment is needed. Preliminary sleep data confirmed a notable variability of 
sleep problems to exist. Further, the temporal stability of sleep variables was established; sleep 
continuity (sleep duration, wake duration, sleep efficiency) and main architectural (sleep 
stages) parameters were consistent across two nights of assessment (chapter 7).  
 
The results presented in this thesis indicate that disturbed sleep is a major problem for patients 
with CFS, albeit highly variable between and within individuals. The identification of sleep 
phenotypes also confirms the heterogeneity of sleep in CFS. Interestingly, light sleep and 
arousability was a recurring sleep characteristic in patients that was mirrored by the studies 
presented throughout the thesis, highlighting a potential autonomic component. This should be 
a consideration for forthcoming work, along with the possibility that sleep disturbances may 
mediate the maintenance and exacerbation of symptoms, fuelling a reciprocal cycle that keeps 
the condition going. 
 
The preliminary findings presented throughout this trajectory of research will help to form the 
systematic development of a sleep characterisation and intervention programme. With this 
field moving towards more patient-centred medicine and tailored treatments, by combining 
data from the objective and subjective sleep measures, we aim to design a definitive multi-
centre study, using sleep-specific interventions, amenable to the four phenotypes identified. 
The long-term goal is to improve treatments that will enhance symptom management, which is 
crucial in this condition, at least until the CFS research understands the pathogenesis of this 
debilitating disease. 
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CHAPTER ONE                                                                                            
CHRONIC FATIGUE SYNDROME (CFS): CLASSIFICATION, MODELS 
AND SYMPTOM MANAGEMENT 
 
 
1.1 Introduction 
What is CFS?  
Most people feel overly tired at some time or another and in 10% of people who see 
their GP, fatigue presents as the principle symptom. However, 1-2% of the population 
experience severely disabling and ongoing fatigue. It is this significant minority of 
patients enduring the profound and unexplained fatigue that has been the topic of 
debate for the past 30 years. Naming the illness has been a topic of controversy dating 
back to the early 1980’s where patients were considered to be having a reaction to 
stressors from modern society, otherwise labelled as “yuppie flu” (Wessely, 1997). 
Conflicting arguments advocating an organic cause of the illness advanced a series of 
names to reflect this, such as postviral fatigue syndrome and myalgic 
encephalomyelitis (ME). 
 
In response to the debates surrounding the use of terminology with the condition, and 
in an attempt to define a homogenous patient group for the purpose of research, a 
renaming of the condition to chronic fatigue syndrome (CFS) was coined by the Centre 
for Disease Control in Atlanta, who also published the first standardised diagnostic 
criteria for the condition (Holmes et al., 1988). Following this, a number of related 
definitions were published from the UK, Australia and Canada (Oxford, 1991; Fukuda 
et al., 1994; Carruthers et al., 2003; Reeves et al., 2005; NICE, 2007), and these case 
definitions are discussed further later in the chapter. 
 
Fukuda and colleagues endeavoured to standardise the diagnosis of CFS across 
countries, in their publication of a consensus definition for the illness (Fukuda et al., 
1994). The definition specified that fatigue is the primary symptom, which should be 
of definite onset and cause significant disruption to the person’s life. In addition to 
fatigue, at least four other key symptoms are required to fulfil these diagnostic criteria, 
including muscle and joint pain, headache, cognitive dysfunction and unrefreshing 
2 
sleep. The NHS estimated that 250,000 people in the UK have CFS (Choices, NHS, 
2011). Sleep disturbances are frequently reported in CFS, and these complaints have 
been shown to persist throughout the course of the illness (Nisenbaum et al., 2003). 
The symptom presentation and issues with the diagnostic criteria are discussed further 
in the following sections. 
 
1.2 CFS and its clinical presentation 
CFS is a severely disabling condition, and with no consistently identifiable 
biomarkers, diagnosis relies upon symptom report criteria. Patients with CFS 
experience a multitude of symptoms. These range from those of a physical nature (i.e. 
severe malaise and fatigue following physical activity, muscle and joint pain/myalgia) 
to those that suggest ongoing abnormalities in immune system function (i.e. sore 
throat, swollen/painful glands, headaches, temperature control, intermittent flu-like 
feelings), to brain and central nervous system symptoms (i.e. dizziness, mental fatigue, 
cognitive dysfunction, palpitations and symptoms associated with low blood 
pressure/postural hypotension, fainting). Other symptoms include sleep disturbances 
(often increased requirements for sleep at illness onset followed by problems with 
sleep maintenance or onset and waking unrested) and irritable bowel symptomology. 
Over time, patients can also develop emotional lability and mood disturbances. Not all 
symptoms are experienced by all patients, and besides the widespread symptoms 
described, there are also a myriad of “minor” ones. Fluctuation in symptom severity is 
common and patients often report as having “good” and “bad” days. Nonetheless, 
individuals experience marked functional disability (Tiersky et al., 2001) and face 
significant reductions in their quality of life (Anderson & Ferrans, 1997). 
 
1.3 Diagnostic challenges 
In order to accurately diagnose an illness or disease, it is important to have a reliable 
set of criteria for researchers and clinicians. That said, diagnosing CFS can be 
complicated by a number of factors. There is no generally accepted diagnostic test to 
reliably diagnose or exclude CFS (i.e. no lab test or biomarker for CFS), and fatigue 
and other symptoms of CFS are common to many illnesses. Further, the illness has a 
3 
pattern of remission and relapse, and symptoms vary from person to person in type, 
number and severity.  
 
Whilst CFS affects at least 250,000 people in the UK (Choices, NHS, 2011), the 
variance in the rates reported from epidemiological studies (0.23% to 2.6%, Jason et 
al., 2009; Reyes et al., 2003), are a likely result of the differing published criteria and 
the guidance they set out. A meta-analysis to examine variability among prevalence 
estimates for CFS suggested observed heterogeneity in CFS prevalence may also be 
due to differences in the method of assessment used (Johnston et al., 2013). The 
following section will discuss the difficulties that surround classification of CFS, based 
on the differing case definitions that there are to describe CFS clinically. 
 
1.3.1 Case Definitions 
There are many aspects to CFS that are controversial, from its etiology through to 
pathophysiology, treatments and even to the naming of the condition. The 
classification including the case definitions and problems surrounding varied clinical 
descriptions of CFS are the key issue when it comes to agreement on naming the 
condition, and this disagreement occurs among researchers, medical practitioners and 
patients. This is problematic for a field of research that is attempting to redress the 
uncertainty. Despite there being some overlap of symptoms between the clinical 
descriptions, the definitions differ (see table 1.1 for CFS definitions, chronologically). 
 
The Fukuda Case Definition (CDC 1994 Criteria) is the international consensus 
definition that is most widely used. It specifies that in addition to being present for at 
least six months, fatigue must have a definite onset, cause substantial disruption to the 
individual’s day to day activities, and should not be caused by continual exertion. At 
least four additional key symptoms, such as muscle and joint pain, headaches, 
unrefreshing sleep and cognitive dysfunction need to be reported. There is also a final 
requirement that other known causes of chronic fatigue must have been ruled out, 
specifically clinical depression, side effects of medication, eating disorders and 
substance abuse.  
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Notes: ICC, international consensus criteria 
 
 
Table 1.1: Case definitions for CFS, (adapted from Brurberg et al., 2014) 
 
 
 
 
 
 
 
  
 
Case definitions 
(chronologically) 
 
Developed from other criteria or 
definitions? 
 
Institution & country of first 
author 
 
CDC-1988/Holmes et al 
   
Centers for Disease Control, 
Atlanta, USA 
 
Oxford-1991/ Sharpe et al  University of Oxford, Oxford, UK 
 
CDC-1994/Fukuda et al CDC-1988  Centers for Disease Control, 
Atlanta, USA 
 
Working case definition-
1996/Komaroff  et al 
CDC-1988  Brigham and Women’s Hospital 
Massachusetts, USA 
 
CFS-1998/Hartz et al CDC-1994  Medical College of Wisconsin, 
USA 
 
Canadian-2003/ Carruthers et al  Royal College of Physicians and 
Surgeons of Canada, Canada 
 
Empirical CDC-2005/ 
Reeves et al 
CDC-1994  Centers for Disease Control and 
Prevention, Atlanta, USA 
 
Empirical-2007/ Jason et al
 
 
 DePaul University, Chicago, USA 
NICE-2007 Guidelines  National Institute for Health and 
Clinical Excellence, London, UK 
 
Revised Canadian-2010/       
Jason et al 
CDC-1994, Empirical CDC-2005, 
Canadian-2003 
 
DePaul University, Illinois, USA 
ICC-2011/ Carruthers et al Canadian-2003   Independent, Canada 
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The Holmes Definition (CDC 1988 Criteria) differs from the 1994 CDC criteria in that 
it excludes patients with psychiatric diagnoses and requires the presence of eight 
secondary symptoms, not just four. The Oxford Criteria, published in 1991, include 
both CFS of unknown etiology and a subtype of CFS called post-infectious fatigue 
syndrome which "either follows an infection or is associated with a current infection." 
(Sharpe et al., 1991). An important difference is that the presence of mental fatigue is 
necessary to fulfil the criteria. It is also worth noting the London Criteria (1994) and 
the 2011 ‘international consensus criteria for ME’ (Carruthers, 2011). These 
definitions refer to the condition as ‘M.E.’, however they are also considered as 
definitions of CFS, further highlighting the contentious nature in the naming of this 
condition. The Canadian Criteria, published in 2003 indicates that for diagnosis, there 
is a requirement for "two or more neurological/cognitive manifestations" and one or 
more symptoms from at least two of the categories of autonomic, neuroendocrine and 
immune manifestations, in addition to multiple major criteria of fatigue, post 
exertional malaise and/or fatigue, chronic pain and sleep dysfunction (Carruthers, et 
al., 2003).  
 
With the Canadian clinical case definition (Carruthers, et al., 2003), there is the 
requirement for specific CFS/ME symptoms (i.e. post-exertional malaise and 
memory/concentration problems) to be present and the definition tends to be more 
complex to apply, it is thus rarely used for research and clinical diagnosis purposes, 
compared with the more widely used Fukuda definition. This creates methodological 
problems for research that is carried out in different settings, where investigators 
recruit samples of patients with different levels of each of the core symptoms. This in 
turn generates problems when comparing research studies on patients, as study groups 
are potentially heterogeneous. 
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HOLMES 
 
 
FUKUDA 
 
REEVES 2005 
 
OXFORD 
 
ICC 
Minimum duration of 
illness 
6 Months 6 Months NA 6 Months NA 
Onset type Distinct New or definite NA Distinct Infectious or gradual. 
Lab tests used Minimum battery of 
standard laboratory 
screening tests looking for 
known cause of fatigue. 
 
Minimum battery of standard laboratory 
screening tests looking for known cause 
of fatigue. 
Routine analysis of blood and 
urine 
None None listed. 
Exclusions Clinical conditions that 
would produce 
similar symptoms 
Unless clinically indicated no additional tests 
are required to exclude other diagnosis. 
Findings, lab or imaging test suggesting the 
presence of a condition that may explain 
chronic fatigue must be resolved 
(meaning is not clear) before further 
classification. 
 
A list of permanent medical and 
psychiatric exclusions is given, 
as well as possible exclusions. 
Medical conditions that cause 
chronic fatigue. Range of mental 
health disorders. 
Organic brain disease 
Unless clinically indicated no 
additional tests are required to 
exclude other diagnosis. Primary 
psychiatric disorders, somatoform 
disorder and substance use are 
excluded. 
Depression and 
anxiety 
Not excluded Not excluded, only major depressive 
disorder WITH psychotic OR 
melancholic feature is excluded. 
Not excluded, only major 
depressive disorder WITH 
psychotic OR melancholic 
feature is excluded for 5 
years before onset of illness. 
Not excluded Not excluded, reactive depression 
is. 
PEM Increased symptoms of 
fatigue as a result of 
exercise (previously 
tolerated). Recovery 24 
hours or longer. 
PEM not required for this diagnosis, but 
can be included as a minor symptom. 
Increased symptom of malaise after 
exertion. 
Recovery 24 hours or longer. 
Increased symptoms of 
fatigue a result of any activity 
that is not a demanding 
schedule. 
No version of PEM included in 
the criteria. 
Increased symptoms of fatigue a 
result of any level of activity. No 
duration of recovery required. 
Fatigue  Debilitating fatigue or 
fatiguability 
Persistent or relapsing chronic fatigue 
that is not the result of ongoing 
exertion, not substantially alleviated by 
rest that substantially reduces activity 
level. 
Fatigue is incorporated into 
the 3 self-report scales. 
Fatigue of psychiatric or 
idiopathic origin. 
Fatigue is included under the term 
PENE: a pathological inability to 
produce sufficient energy on 
demand. 
 
Continued on next page 
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Minor symptoms 6 or more of the 11 
symptom criteria and 2 or 
more of the 3 physical 
criteria; or 8 or more of the 
11 symptoms listed. 
Minimum of 6 to 8 
symptoms) 
4 or more of 8 symptoms listed NA May be present 1 symptom from each of the 3 
symptom categories of pain, sleep 
disturbance and cognitive 
symptoms. 3 symptoms from a 
mix of immune and 
neuroendocrine/autonomic 
symptoms. 1 symptom from 
autonomic symptoms (minimum 
of 7 symptoms). 
Pain New headaches, muscle 
discomfort or myalgia. 
Migratory arthralgia 
without joint swelling or 
redness. 
New headaches. Muscle pain. Multi 
joint pain without swelling or redness. 
NA NA Headaches. Non inflammatory 
muscle pain or joint pain. 
Abdomen or chest pain. 
Sleep disturbance 
symptoms 
Sleep disturbance Unrefreshing sleep NA NA Sleep disturbance. Unrefreshing 
sleep. 
Cognitive/ 
Neurological 
symptoms 
Neuropsychological 
complaints. Muscle 
weakness. 
Symptoms related to cognitive 
impairment. 
NA NA Symptoms related to cognitive 
impairment. 
Perceptual and sensory 
disturbances. Ataxia. Muscle 
weakness. Fasciculations. Sensory 
overload. 
Autonomic symptoms Fever (temp 37.5°C to 
38.6) or chills. 
 NA NA Symptoms related to blood 
pressure, gastric and urinary 
systems, cardiac involvement. 
Neuroendocrine 
symptoms 
NA NA NA NA Symptoms related to 
temperature. Genitourinary 
symptoms. 
Immune symptoms Painful lymph nodes, sore 
throat. 
Painful lymph nodes, sore throat. NA NA Symptoms such as painful lymph 
nodes, sore throat, flu like 
symptoms, sensitivities to food, 
medicine and/or chemicals. 
Notes: NE, not applicable; ICC, international consensus criteria for ME; PEM, post-exertional malaise; PEN, Post-Exertional Neuroimmune Exhaustion 
 
Table 1.2: Overview of the different case definitions for CFS (adapted from Morris and Maes, 2013) 
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These issues with classification only add to the contentious nature of the illness (see 
table 1.2 for an overview of case definitions). With disagreements already existing 
between patients, clinicians and researchers over its etiology, treatment and name, 
classification of this condition is an area that warrants further work. That said, the 
1994 CDC case definition (Fukuda) appears to be the most reliable clinical assessment 
tool available at the current time (Johnston et al., 2013) and has been recommended for 
use in the UK clinical services (NICE, 2007). However, improving clinical case 
definitions and their adoption internationally will enable better comparisons of 
findings and inform health-care systems about the true burden of CFS. 
  
The etiology and pathophysiology of CFS remains as disputed as the nosology, with 
several theories proposed ranging from viral infections (Wessely & Powell, 1989), 
immunological and neurobiological factors (Cho et al., 2006; Cleare, 2004), to 
psychological stress (Van Houdenhove et al., 2002). Given that CFS is not likely to be 
explained by one single etiological mechanism, it has been proposed that it is the 
interaction of multiple factors that serves to precipitate and/or maintain CFS. This 
more generic bio-psychosocial model has been proposed by various authors (Deary, 
Chalder & Sharpe, 2007; Harvey & Wessely, 2009). This model proposes that illness 
onset and maintenance is the result of the interaction of multiple factors in different 
domains, as described in the following section. 
 
1.4 A Biopsychosocial Model  
Part of the confusion with CFS is due to competing models of the condition. A general 
biopsychosocial model has been applied to explain CFS from a multi-factorial 
perspective. It is one which incorporates predisposing, precipitating and perpetuating 
factors that ultimately seeks to explain the phenomenology of the condition as arising 
through the interaction of biological, affective, behavioural and cognitive factors 
(Deary, Chalder & Sharpe, 2007; Moss-Morris, Deary & Castell, 2013). In a recent 
review of explanatory models of functional somatic symptoms (Van Ravenzwaaij et 
al., 2010), this multi-factorial model was distinguished from other single modality 
models (which propose that symptoms are the result of one pathogenic mechanism), as 
being a meta-model that provides a coherent theoretical framework for describing how 
the interaction of such physiological, behavioural, cognitive and affective factors can 
9 
cause and/or exacerbate physical symptoms. The categories of this model will be used 
to describe what is known in terms of predisposing, precipitating and perpetuating 
biopsychosocial factors in CFS (a 3-P Model).  
 
1.4.1 Predisposing Factors 
Who is affected, what makes the person vulnerable to these symptoms? 
There have been some prospective studies investigating vulnerability to developing 
CFS. Longitudinally, experience of distress, anxiety and depression makes people 
more likely to subsequently develop CFS (Moss-Morris & Spence, 2006; Wessely et 
al., 1995; White et al., 2001). This may be partly genetically mediated with there being 
evidence from a large prospective twin study (Kato et al., 2006) that there appears to 
be a genetic vulnerability to both emotional and physical markers of distress (such as 
fatigue). That said, retrospective studies highlight the importance of early life 
experiences, with people suffering from CFS being more likely to report histories of 
abuse than normal or illness controls (Borsini et al., 2014). Increased physiological 
arousal in individuals, perhaps associated with stress could therefore be contributing 
early on in this condition, to predispose the individual to illness onset. Other 
predisposing factors, although largely from cross sectional and retrospective studies, 
include being physically active, persisting with physical activity when ill and the self-
critical aspects of perfectionism (Deary & Chalder, 2010; Moss-Morris et al., 2011).  
 
1.4.2 Precipitating Factors 
Viral infections (White et al., 1998) and stress (Kato, et al., 2006) are the most 
frequently self-identified triggers for fatigue onset. One prospective study has shown 
that the combination of these factors may be important; people who had glandular 
fever were more likely to go on to develop CFS if they had experienced more stressful 
life events prior to the onset of their glandular fever (Buchwald et al., 2000). These 
findings have been confirmed in both cross sectional and retrospective studies 
(Chalder, 1998; Salit, 1997).  
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1.4.3 Perpetuating Factors 
The multi-factorial model proposes that the interaction of physical processes, illness 
behaviours and illness related cognitions and social factors can serve to perpetuate 
physical symptoms (Deary, Chalder & Sharpe, 2007; Moss-Morris, Deary & Castell, 
2013) (Figure 1.1). This has been demonstrated in two prospective studies (Candy et 
al., 2004; Moss-Morris, et al., 2011). Individuals with more generalised and more 
negative illness and symptom attributions, and those who responded to symptoms with 
more ‘all-or-nothing’ behavioural patterns, were more likely to develop CFS six 
months after a glandular fever infection.   
 
1.4.3.1 Perpetuating Factors – Physical 
The hypothalamic-pituitary-adrenal (HPA) axis serves to regulate the body’s response 
to acute and chronic stress. It has effects on energy metabolism and mood, and also 
influences immune functioning. Biological research has focussed on the HPA axis and 
its dysfunction in patients with CFS (Tomas, Newton and Watson, 2013). In particular, 
there is evidence for a reduced cortisol output in patients (Roberts et al., 2004; Cleare, 
2003), which may be a result of prolonged stress leading to a down-regulation of the 
HPA axis; hypocortisolism is a marker of symptoms such as pain, fatigue and 
enhanced stress sensitivity as observed in CFS.  
 
Research by Heim et al (2009) has also highlighted the role of cortisol in CFS. Their 
study found that low levels of cortisol, a hallmark biological feature of CFS, are 
associated with early life stress such as childhood trauma. The study indicates that low 
cortisol levels may actually reflect a marker for the risk of developing CFS rather than 
being a sign of the syndrome itself. Such findings indicate that neuroendocrine 
dysfunction in patients may reflect a biological correlate of vulnerability. 
 
Further, lowered levels of cortisol may also lead to the increased release of 
inflammatory cytokines and that are important determinants of the “illness response” 
marked by non-specific symptoms such as fatigue, increased pain sensitivity, 
depressed activity and concentration difficulties that accompany the response to 
infection (Fries et al., 2005). Hypocortisolism is also considered an adaptive response 
by the body, characterised by a decrease in energy consumption during periods of 
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sickness or injury (i.e. a state of chronic fatigue) to promote subsequent recuperation 
(Van Hoof et al., 2003).  
 
Issues with existing cortisol studies 
Although this mild hypocortisolism has been shown in CFS patients, other work has 
been unable to replicate these low baseline cortisol levels, finding no links between 
reduced secretion of cortisol and the symptom of fatigue (Wood et al., 1998). The 
variability between studies may be a result of the differential methods of assessment 
method used for sampling cortisol, and also the heterogeneity of patient samples (Nijof 
et al., 2014; Papadopoulos & Cleare, 2012; Cleare, 2003). Ideally, sampling of cortisol 
should occur over a several consecutive days, and at several time points per day to 
overcome the potential for state influences upon levels of cortisol. This affords the 
opportunity to obtain a more stable variable (Hellhammer et al., 2007).  
 
It is also possible (and beneficial) to obtain a number of indices of HPA function in 
patients;  The cortisol awakening response (CAR), describes a surge in cortisol levels 
upon awakening and has two components; the total cortisol output within this period 
and; the dynamic response, usually referring to the change in cortisol output from 
waking to peak levels. Total cortisol output is estimated by computing the area under 
the curve from baseline (AUCG), and the dynamic response by the area under the curve 
from a baseline defined as cortisol level at waking (AUCI) (Pruessner et al., 2003). The 
diurnal cortisol slope can also be calculated, this models the declining pattern of 
cortisol secretory activity throughout the rest of the day, following the CAR. Also an 
estimation of total cortisol output may also be calculated for the complete circadian 
rhythm (or profile) using AUCG or mean cortisol levels. These indices afford more 
robust cortisol assessment in patients, yet a recent review of cortisol studies in CFS 
highlights how existing protocols have been limited in the number of indices obtained, 
and often utilise 1-2 day sampling protocols (Powell et al., 2013). 
 
HPA axis function is also affected by inactivity, sleep disturbance, medication, 
ongoing stress and psychiatric comorbidity, all frequently experienced by CFS 
patients.  Deterioration in the patients’ physical condition (a result of decreased 
activity due to fatigue and pain that in turn results in loss of muscle strength) 
perpetuates symptoms, making daily functioning even more problematic (Van 
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Houdenhove et al., 2007). Persistent sleep problems also serve to worsen symptoms 
and functional limitations in CFS patients as they mimic the body’s neuroendocrine 
response to stressful circumstances. The neuroendocrine-mediated disturbances that 
have been identified in the sleep-wake cycle of CFS patients (i.e. altered temperature 
and melatonin circadian rhythms) (Fossey et al, 2004), have reciprocal effects on the 
release of the stress hormone cortisol (i.e. concentration and timing of cortisol released 
does not follow a circadian pattern), that in turn produces symptoms of daytime 
fatigue, nonrestorative sleep, depression, anxiety and memory and concentration 
problems, such as are seen in CFS (Fossey et al, 2004). Despite the undeniable effects 
of desynchronisation in these cycles, the precise role of disturbed sleep in the 
perpetuation of CFS remains unclear (Armitage et al., 2007; Majer et al., 2007). There 
are also suggestions that such endocrine changes may be secondary to the CFS; given 
the dysregulation is more pronounced in patients who have had the illness for a longer 
period (Cleare, 2004). Nevertheless, these endocrine disturbances are likely to 
perpetuate existing symptoms in patients (Van Houdenhove & Luyten, 2008). 
 
1.4.3.2 Perpetuating Factors – Illness Behaviours & Cognitions  
Patient’s illness beliefs and coping strategies are key (unintentional) perpetuating 
factors in CFS. For instance, symptom-focus and perceived loss of control over 
symptoms has been associated with fatigue severity (Vercoulen et al., 1998). Further, 
patients who have difficulty in making sense of the situation, or a lack of acceptance 
for their CFS diagnosis has been linked to lower quality of life and more associated 
psychiatric symptoms (Van Damme et al., 2006). Patients with CFS are also more 
likely to make fixed physical attributions for their physical symptoms (Moss-Morris, et 
al., 2012), and a common response to physical illness is rest; patients may exacerbate 
their illness by putting their already disturbed stress mechanisms under pressure by 
trying to press on and keep going (Moss-Morris, Deary & Castell, 2013). Those with a 
history of a particularly overactive lifestyle are prone to this “boom-and-bust” activity 
pattern (Van Houdenhove et al., 2001), and these periodic bursts of activity in an 
attempt to meet expectations, inevitably amplify symptoms (particularly disability and 
fatigue severity (Harvey et al., 2009)), resulting in beliefs in failure. 
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There is consistent evidence for complaints about disturbed sleep in CFS. As with 
reduced activity and excessive rest, sleep disturbance may be both a cause and a 
consequence of the fatigue and other physical symptoms associated with CFS 
(Morriss, Wearden & Battersby, 1997).  Sleep dysfunction is considered a hallmark 
symptom of CFS, and features as a key component of the criteria outlined above. This 
disturbance can take various presentations, from problems initiating sleep, waking 
frequently and for long periods during the sleep cycle, through to early awakenings, 
and prolonged sleep duration. However, the specific role of sleep in this condition is 
not fully understood. Given the importance of sleep to human health and wellbeing is 
undeniable (i.e. recuperative, restorative and learning properties (Van Cauter et al., 
2000; Stickgold, 2005), there is a need to broaden our understanding of its precise role 
in CFS. Chapter 2 will examine and review the current literature regarding sleep and 
its implication in CFS in further detail. 
 
1.4.3.4 Perpetuating Factors - Social 
Social and environmental factors in CFS cannot be overestimated. A lack of 
recognition, stigma and disbelief from both family members and healthcare 
professionals, are reactions that create extra stress for the patient and thus negatively 
impact on their quality of life, also encouraging illness behaviour (in the words of 
Hadler (1996): “when you have to prove you are ill, you cannot get well”). With a lack 
of explanation for symptoms and conflicting advice, paired with a dissatisfaction with 
healthcare professionals, there is the suggestion that such lifestyle factors (adjunct with 
worry and rumination) can contribute to a prolonged activation of the stress response 
over time (Brosschot, Pieper & Thayer, 2005), which leads to physiological changes 
(described earlier), that in turn maintain CFS and its symptoms. 
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Figure 1.1: Explanatory model for CFS; a focus on the perpetuating factors and 
maintenance of the condition (adapted from Deary, Chalder & Sharpe, 2007) 
 
 
 
 
In summary, the multifactorial biopsychosocial model of CFS proposes that 
susceptible individuals, for example those prone to distress, high achievers, and 
overactive individuals, experience an onset of symptoms precipitated by a viral illness 
and/or stressful life event(s). Symptoms may then become maintained through 
interactions between several processes. For instance reduced and inconsistent physical 
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activity may lead to physiological changes, such as deconditioning and increased 
physical symptoms of fatigue. Management of these factors may be further impeded by 
medical uncertainty and unhelpful illness beliefs and behaviours. There is indirect 
evidence for this model through treatment trials for CFS. Cognitive Behavioural 
Therapy (CBT) is currently the evidence based treatment for CFS, and is based on 
tackling the interaction between the aforementioned factors. Studies have shown, for 
instance, that improvement in CFS, following CBT, is partly mediated by changes in 
symptom focus (Deale et al., 1997).  
 
1.5 From perpetuating factors to therapy: current CFS treatment practices  
Diagnosis of CFS depends upon self-reported symptoms, and its clinical management 
is therefore challenging for the physician but equally so for the patient. There is no 
“cure” for CFS, rather the best evidence is for symptom management, however there 
remains disagreement with regards to treatment options and their efficacy. That said a 
combination of graded exercise and cognitive behavioural therapy (CBT) is considered 
the best evidence therapeutic approach (White et al., 2011). The rationale for these 
interventions stems from tackling illness-perpetuating factors. It should be noted 
however, that the use of pharmacological therapies (e.g. antidepressants, analgesics 
and other medications with a CNS site of action) alongside these approaches is 
common, however, currently there is little evidence for these, including treatments 
targeting the proposed underlying pathophysiology of CFS, such as hypocortisolism 
(Van Houdenhove & Luyten, 2008).  
 
The cognitive changes that occur during CBT for CFS are important; increased 
perceived activity, physical functioning and sense of control over fatigue, together with 
a decrease in focusing on symptoms does appear to result in lower levels of fatigue in 
patients (Heins et al., 2013). Burgess, Andiappan & Chalder (2012) even demonstrate 
mild to moderate improvements in physical functioning and fatigue following 
treatment utilising telephone-based CBT.  
 
Interventions that gradually increase physical activity (i.e. Graded Exercise Therapy 
(GET) and pacing) and CBT may work not only in the reversal of deconditioning, but 
also in working towards  desensitising the fear of activity in patients, fear that may 
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have derived from their experience of avoiding exposure to sensations (i.e. pain and 
fatigue) (Deary, 2008). Further, Deary (2008) emphasises how a self-regulating cycle 
of ‘unhelpful’ illness cognitions and behaviours serves to maintain medically 
unexplained conditions such as CFS. By incorporating treatment approaches that 
address this self-dysregulation (i.e. ‘third wave’ behavioural therapies such as 
acceptance and commitment therapies), may help individuals switch from avoidance to 
mindfulness and acceptance of symptoms and distress, however, as yet there is no 
evidence for 3
rd
 wave therapies in CFS.  
 
CBT and graded exercise approaches to treatment offer an opportunity to shift patient 
perceptions from symptom avoidance to general wellbeing, or life enhancement 
(Deary, 2008). They work by encouraging patients, despite their symptoms, to switch 
their focus of themselves and the progress being made during treatment, to what they 
feel and are able to do. Further, CBT studies have also demonstrated efficacy in 
increasing cortisol levels (Papadopoulos & Cleare, 2012; Roberts et al., 2004); the 
therapy works to reverse the effects brought on by reduced activity levels, stress and 
depression. In addition to CBT, graded exercise also works to modify patient’s illness 
perception, which in turn encourages patients to make adjustments that optimise their 
energy expenditure (Van Houdenhove & Luyten, 2008; Moss-Morris et al., 2005). 
Further there is evidence for the favourable therapeutic effects of CBT and exercise on 
increasing the resilience of the HPA axis (Gaab et al., 2006).  Such studies highlight 
the multidirectional relationship between cognitive, behavioural and biological 
processes in CFS (Tomas, Newton and Watson, 2013). 
 
1.5.1 Management of sleep disturbance 
Part of the perpetuating cycle concerns disturbed sleep as a maintaining factor in CFS. 
Likewise, one therapeutic goal in CFS management is to improve sleep in patients. 
The current best evidence treatments (GET and CBT) all involve a sleep management 
component (i.e., establishment of a regular sleep pattern, cessation of daytime 
sleeping, establishing a set wake-up time every morning, and a general reduction of 
total time spent in bed), and these evidence-based treatments have observed 
improvements in patients’ sleep disturbances (White et al., 2011) and reductions in 
severity ratings for unrefreshing sleep (Jason et al., 2007), at both post-treatment and 
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follow-up, however it is not yet clear how significant the sleep component may be on 
its own i.e. how the treating sleep alone contributes to the efficacy of the overall 
treatment. Improved sleep would serve to affect the perception of other symptoms and 
the ability of individuals with CFS to carry out daytime activities. On the other hand, 
pharmacological therapies are often prescribed alongside other therapies to manage 
disturbed sleep; low dose antidepressants (i.e. selective serotonin reuptake inhibitors) 
are often prescribed to patients with CFS to be taken at bedtime for enhancing sleep. 
This is despite the adverse effects of such pharmacological treatments on sleep 
documented in non-CFS populations (Menefee, at al., 2000). Given that disturbed 
sleep is a common symptom of CFS, careful assessment is necessary, to distinguish a 
primary sleep disorder (PSD) from a potential comorbid condition than may require 
specific treatment (i.e. hypothyroidism, psychiatric disorder, or other PSD). 
 
Disturbed sleep is likely to be an important factor in CFS. It is unquestionable that 
sleep is vital for human health, and the implication of poor sleep in the perpetuating 
cycle of CFS has been shown (described in section 1.4.3). This, together with sleep 
management being a component of evidence based CFS therapies, highlights the 
importance of more thorough exploration of the nature and extent of the role of sleep 
in CFS. However, the current evidence-base for sleep and its specific role in CFS is 
fragmented. The next chapter will therefore examine the existing research and 
techniques that have attempted to explain these connections. 
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CHAPTER TWO                                                                                           
LITERATURE REVIEW: SLEEP IN CHRONIC FATIGUE SYNDROME 
 
 
2.1 Introduction 
2.1.1 The regulation and structure of normal adult sleep 
Sleep is an anabolic state which means it is a time when most rejuvenation, repair and 
growth occur. Specifically, it is during sleep that the immune system becomes fully 
active and where we fight off disease, counteract allergies and build up new 
resistances. First of all, it is important to understand the ‘normal’ characteristics of 
human sleep, as it provides a context for understanding the role of sleep in CFS, in 
which ‘normal characteristics may be altered.  
 
The sleep-wake cycle is controlled by two separate but interacting processes (Borbély, 
1982); the circadian process and the homeostatic or recovery process. The circadian 
process is that which regulates the daily rhythms of the body and brain. This main 
circadian pace-maker is found in a group of cells in the suprachiasmatic nucleus (SCN) 
of the hypothalamus, providing a pattern of activity that drives all bodily rhythms 
including sleep-wake activity, hormone release and liver function. The biological 
phase markers responsible for measuring the timing of an individual’s circadian 
rhythm are melatonin, cortisol and temperature. The drive to sleep from the circadian 
clock starts slowly around 11pm, increases to peak around 4am and tails of during the 
morning. The clock provides a sleep-promoting process which continues into mid-
morning and then provides a wakefulness-promoting process during the day. 
 
The homeostatic or recovery drive to sleep (process S) is wake-dependent; increasing 
in proportion to the amount of time a person has been awake since their last sleep. 
Process S reaches a maximum after around 16 hours of being awake and rapidly 
declines during sleep. When sleep has been shorter than usual, there is a ‘sleep debt’ 
which leads to an increase in this process, working to ensure the debt is made up at the 
next sleep period. These two processes interact to promote the onset of sleep when 
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both are high (at the usual bedtime), and maintain sleep when the circadian process is 
high and the S process in declining. 
 
Sleep comprises two states; rapid eye movement (REM) and non–REM (NREM) sleep 
that alternate cyclically across a sleep episode. The natural pattern of sleep in adults 
begins in non-REM (stage 1) and progresses through deeper non-REM stages (2 & 3), 
before the first episode of REM that occurs 90-110 minutes later. (Carskadon & 
Dement, 2011) Stage 1 (N1) is the light stage of sleep, occurring at the beginning of 
the sleep cycle and considered a transition period between wakefulness. In Stage 1 
(N1), the brain produces high amplitude theta waves, which are very slow brain waves. 
Stage 2 (N2) sleep is a light stage of sleep, characterised by increasingly slower brain 
wave activity with occasional spikes (sleep spindles), which are thought to be part of 
the sensory-gating system (reducing our responsiveness to external noise or internal 
sensations). Stage 3 (N3) was previously divided into stages 3 and 4 (Rechtschaffen & 
Kales, 1968) which have since been combined to form stage 3 (N3) (Iber, et al., 2007). 
Progressing from light sleep to deeper or slow wave (stage 3 (N3) sleep, brain waves 
become even slower and this is when the body begins the repair and rejuvenation 
process.  
 
After slow wave sleep the brain enters a shorter period of lighter sleep before starting 
the first rapid eye movement (REM) sleep. Here brainwaves resemble those of being 
awake but there is no muscle tension. Heart rate and breathing increase and this is 
when the majority of dreams occur. This is also the time that it is believed that learning 
and memory consolidation occur (Stickgold, 2005). Just as slow wave sleep 
replenishes the body, REM replenishes the mind. A night of normal adult sleep usually 
consists of four to six sleep cycles lasting approximately 90 to 110 minutes, (Edinger 
et al., 2004). As the night progresses, the amounts of deep non-REM sleep decreases 
and the amount of REM sleep increases (See Table 2.1 for a summary of the sleep 
stages and normal architectural parameters). 
 
Recording the Electroencephalogram (EEG) and other physiological variables such as 
muscle activity and eye movements during sleep (a technique called 
Polysomnography, PSG) can provide information about the different stages of sleep 
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and their pattern of occurrence (also considered the ‘macrostructure’ of sleep), and the 
presence of EEG phenomena during sleep (i.e. arousals, k-complexes, sleep spindles,  
also known as sleep ‘microstructure’) (see Table 2.3 for a summary of sleep stages and 
patterns of the EEG). Likewise, other PSG-derived sleep variables offer a basis for 
clinical decision-making and research analyses. Quantitative criteria for ‘normal’ 
sleep, set out by Edinger et al (2004) suggests sleep onset (SOL) should occur within 
30 minutes, and the amount of time spent awake during the sleep period should not 
exceed 30 minutes, beyond which is considered problematic. Furthermore, a total sleep 
time of less than 6 hours and sleep efficiency (SE) less than 85% are also considered 
problematic (See table 2.2 for a description of these sleep variables). 
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Notes: NREM, non-rapid eye movement; REM, rapid eye movement; N1, stage 1; N2, stage 2; N3, stage 3; SWS, 
slow wave sleep. 
 
Table 2.1: Summary of sleep stages and normal architectural parameters (Carskadon 
& Dement, 2011). 
 
Sleep Stage 
 
Activity 
 
  
Normal Architectural Parameters 
 
       Wake 
 
 
Eyes open, responsive to external stimuli, 
can hold intelligible conversation 
 
  
ޒ5% 
N
R
E
M
 
S
le
ep
 
 
N1 
 
Transition between wakefulness and sleep. 
Eyes closed, breathing slows, muscles relax, 
brain starts to produce alpha waves. Many 
people notice the falling sensation during 
this stage of sleep, which may cause a 
sudden muscle contraction (called 
hypnagogic Jerk). 
  
2-5% 
 
N2 
 
Onset of sleep, heart rate slows and the body 
temperature drops. The brain produces 
bursts of rapid, rhythmic brain wave activity 
known as sleep spindles. 
  
45-55% 
 
 
 
 
N3 
(SWS) 
 
 
Deep sleep or Slow-wave sleep (SWS), delta 
brain waves occur. Deepest most restorative 
sleep, muscles relaxed, blood pressure 
drops, breathing slows. Blood supply to 
muscles increases, tissue growth & repair 
occurs. 
 
  
13-23% 
R
E
M
 
S
le
ep
 
 
 
REM 
 
 
Body becomes immobile, muscles relax. 
Energy provided to brain and body. Heart 
rate & breathing become more variable. 
Rapid eye movement & dreaming (dreaming 
can also occur in other stages of sleep). 
 
  
 
20-25% 
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As mentioned previously, poor sleep is a consistent complaint of those suffering from 
CFS. 87-95% of CFS patients identified in community-based surveys report 
awakening unrefreshed, (Hamaguchi et al., 2011; Jason et al., 1999; Nisenbaum, et al., 
2003; Nisenbaum et al., 2004), making it one of the most commonly reported of the 
Fukuda symptom criteria. Patients also commonly report disrupted and fragmented 
sleep and difficulties in getting to sleep or staying asleep, despite feeling tired 
(Anderson & Ferrans, 1997), which may, in some part explain the overall reports of 
unrefreshing sleep. Given the implication of disturbed sleep in the maintenance of CFS 
considered above, and sleep management being componential to CBT and GET 
approaches, it is clearly an important element of CFS. Despite this, the understanding 
of sleep and its role in this condition is limited. Similarly, the reported results from 
studies of sleep in CFS have been fragmented and tenuous (Mariman et al., 2013; 
Jackson & Bruck, 2012; Spitzer & Broadman, 2010). 
 
The following narrative review will examine the current evidence from subjective- and 
objectively-based studies of sleep in CFS. It will also consider the difficulties that exist 
in establishing the relationship between sleep, behaviour, cognition, physiology and 
the physical symptoms of CFS. Searches were made of Medline from 1960 to the 
present, for the terms “CFS”, “chronic fatigue syndrome” AND “sleep” to identify 
articles concerning sleep and CFS. We then cross-referenced the above terms with 
qualitative; self-report and objective assessment. Abstracts identified from the searches 
were reviewed and this material was used to conduct the narrative review. 
 
  
2.2 Sleep Assessment in CFS 
2.2.1 Subjective assessment 
2.2.1.1 Qualitative findings  
The qualitative literature in CFS typically describes themes from both patients and 
physicians outlining their perspectives of the illness and identifying the struggle to 
understand and manage CFS (Anderson & Ferrans, 1997; Clarke, 1999; Lovell, 1999; 
Schoofs et al., 2004; Soderlund et al., 2000). These studies utilise interview-based 
techniques with relatively small samples of patients (See Appendix A for summary of 
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study characteristics), and differ in their use of case definitions of CFS (i.e. Fukuda, 
Oxford, Holmes – see Appendix A). Although they discuss quality of life and social 
factors in CFS - with extreme fatigue, pain, cognitive dysfunction and unrefreshing 
sleep being described as key patients’ illness experiences - the studies rarely explore 
below the surface of these symptoms (Clarke, 1999; Schoofs, et al., 2004). The main 
focus of these studies is rather on themes of gender differences in the illness 
experience, illness beliefs regarding development and potential causes.  A recent 
comprehensive review of the qualitative literature on CFS highlighted that a large 
proportion of the qualitative studies in CFS and Fibromyalgia describe perspectives 
from healthcare professionals regarding medical practice (Anderson et al., 2012), 
rather than focussing on patients’ experience. As such there is no real in-depth data in 
these qualitative accounts on the role of sleep in CFS. This is an area of research that 
needs to be addressed, as qualitative work can, amongst other things, indicate the 
direction to move forward with hypothesis-driven studies, larger cohort studies, 
objective measures, and intervention development. In sum, a potentially rich source of 
data on sleep, and how sleep related disturbances may play a role in maintaining other 
symptoms experienced in CFS is being overlooked. 
 
2.2.1.2 Self-report diaries and questionnaires 
Self-report techniques have been employed to determine the perceptual role of sleep in 
CFS and include the use of sleep diaries and sleep questionnaires, such as the 
Pittsburgh Sleep Quality Index (PSQI: Buysse et al., 1989) and the Epworth Sleepiness 
Scale (ESS: Johns, 1991). Studies assessing sleep through self-report methods show 
higher than normal ESS scores (Decker et al., 2010; Mariman et al., 2012) and PSQI 
scores (Mariman, et al., 2012). Mariman and colleagues (2012) reported ESS and PSQI 
scores in 415 Fukuda defined CFS patients. Excessive sleepiness was observed in 53% 
(ESS scores greater than 10) and poor sleep quality (global PSQI scores above 5) in 
86% of CFS patients. Further, when patients were divided into groups based on ESS 
results, these scores corresponded to a clinical profile of insomnia (complaints of sleep 
disturbance associated with increased alertness) or hypersomnia (excessive daytime 
sleepiness persists despite normal nocturnal sleep) (Mariman, et al., 2012). This 
provides an indication that sleep problems may be heterogeneous in this population. 
Conversely, in a study of 339 CFS patients from the Wichita population (Unger et al., 
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2004), ESS scores and factors from the Sleep Assessment Questionnaire (SAQ), 
showed that while fatigued, CFS subjects tended not to report excessive sleepiness.  
This study also showed that most (81.4%) CFS patients had an abnormal score in at 
least one of the five possible SAQ sleep factors (sleep apnoea, restlessness, non-
restorative sleep, insomnia, excessive daytime somnolence). Interestingly, those with 
sleep abnormalities also had significantly lower wellness scores but unchanged fatigue 
severity scores compared to those with no abnormalities (Unger et al., 2004).   
 
Morriss et al (1997) included 69 Oxford diagnosed CFS patients without psychiatric 
disorder (Sharpe, 1991), 58 CFS patients with a psychiatric disorder, 45 controls, and 
38 psychiatric out-patients with chronic depressive disorders.  A specially designed 
sleep questionnaire was constructed to measure self-rated sleep complaints according 
to the International Classification of Sleep Disorders (Thorpy, 1990), over four weeks 
(Morriss, et al., 1997). The study found a higher prevalence of sleepiness and daytime 
naps in CFS patients compared to healthy controls and depressed subjects, and CFS 
patients were also significantly more likely to wake up because of temperature 
problems and pain than healthy controls or depressed patients. Further, restless legs 
were more frequently reported by CFS (41%) and depressed patients (40%) than by 
controls (4%). This study suggests that difficulty in maintaining sleep is the principle 
sleep complaint in CFS patients with or without psychiatric disorder, and showed the 
nocturnal waking and restless legs to be significantly associated with global disability 
in CFS patients, as assessed by the Medical Outcomes Survey (MOS: Stewart et al., 
1988).  
 
Krupp et al (1993) assessed 68 CFS patients diagnosed according to Holmes criteria 
and 20 non-illness controls, using a modified version of the St. Mary’s Sleep 
Questionnaire (Ellis et al., 1981). They showed patient’s sleep to be more disrupted 
than healthy controls; 37% CFS patients reported sleeping lightly compared to 20% of 
controls, and upon awakening, 76% of CFS patients reported feeling drowsy compared 
to 48% of controls (Krupp et al., 1993). Additionally, patient sleep diaries have shown 
that compared to controls, those with CFS report a significantly longer time in bed at 
night, take longer to fall asleep and wake more frequently during the night, whilst also 
feeling less refreshed on waking (Fossey et al., 2004; Morriss et al., 1993). 
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There are methodological issues with these studies. There is a lack of standardized 
assessment for sleep disorders and subjective self-report is not corroborated by any 
objective indicators such as actigraphy or polysomnographic assessment. In addition 
there are a range of self-report scales utilised to assess the degree to which sleep 
disturbances occur in this patient group. This lack of consistency is further 
compounded by inconsistent criteria for patient selection and atypical CFS patient 
groups (Krupp, et al., 1993; Vercoulen et al., 1994), small patient samples (Krupp, et 
al., 1993; Moldofsky, 1989; Morriss, et al., 1993) and the examination of only a 
limited number of sleep complaints (Krupp, et al., 1993; Morriss, et al., 1993; 
Vercoulen, et al., 1994). Given these caveats probably the most robust conclusion that 
can be drawn from the self-report data is that sleep disturbances are commonly 
reported and they appear analagous to a range of sleep disorders including 
hypersomnia, and both sleep onset and sleep maintenance insomnia; in short, we can 
say that despite methodological issues, sleep problems are variable but significant in 
this population. There are also indications of how this might fit into the multi-factorial 
model outlined above. Duncan (1993) highlighted the possible interaction of daytime 
behavioural and lifestyle factors driving the sleep disturbance in CFS. He has 
suggested that a sedentary lifestyle and daytime sleep (napping) may serve to maintain 
disturbed night time sleep, thus establishing a vicious circle of poor night time sleep 
and compensatory day time sleep.  
 
2.2.2 Objective Assessment 
2.2.2.1 Actigraphy 
Actigraphy offers a method of characterising gross objective measures of sleep 
continuity (the quantity and timing of sleep episodes), without interfering with sleep or 
daytime functioning. Actigraphy is usually measured by an unobtrusive device on the 
subjects body (often placed like a wrist-watch), and allows for 24-hour recording of 
wake and sleep activity in a person’s natural environment.  A combination of 
actigraphy and symptom measurement offers real-time prospective activity-symptom 
relationships to be examined (Yoshiuchi et al., 2007).  
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Actigraphy studies in CFS differ in sample selection and their reporting practices. One 
assessment was carried out with children (Ohinata et al., 2008), another with a small 
group of CFS patients (Rahman, 2011) and a third study with no comparative control 
group (Creti et al., 2010). With regard to the findings, an assessment of 12 children 
with CFS showed longer sleep durations and lower levels of daytime physical activity 
compared to age-matched controls. The actigraph also identified an interaction 
between disrupted sleep-wake and daytime napping (Ohinata, et al., 2008). 
Conversely, a more recent sleep study of 15 CFS patients and 15 controls found no 
significant actigraphy differences between CFS patients and healthy controls in 
daytime activity levels, fragmentation during sleep, sleep efficiency or duration of 
sleep, or duration of napping. Interestingly in this study CFS patients still reported 
poorer sleep quality than healthy control subjects (Rahman, 2011). The Rahman 
(2011) sample, however, is particularly small and perhaps unrepresentative of the 
general CFS population, given these were patients undergoing an intervention program 
of graded-activity oriented cognitive-behavioural therapy at a tertiary referral clinic. 
As such they were treatment motivated patients who were also likely to be well-
informed in terms of behavioural strategies for sleep and symptom management. Of 
note, Creti et al. (2010) identified difficulties with actigraphy as an objective 
measurement modality in this population, showing that it underestimated sleep onset 
latency (SOL: how long it took to get to sleep following retiring to bed) in patients, 
and was also not able to accurately or consistently identify nocturnal wakefulness.  
 
Further, it is difficult to elucidate actual sleep versus inactivity (lying still in bed, but 
awake) in actigraphy and the actigraph alone cannot provide specific information on 
sleep architecture (i.e. the progression and timing of sleep/wake stage transitions). As a 
sole method for examining sleep actigraphy is considered problematic (Sadeh, 2011). 
Creti (2010) concludes however, that when combined with other objective 
measurement modalities, actigraphy can help differentiate CFS individuals who have 
chronic insomnia from those without insomnia.  
 
2.2.2.2 Multiple Sleep Latency (MSLT) Tests  
CFS patients often use the terms tired, sleepy and fatigued interchangeably, which is 
why it is important, albeit difficult, to separate the symptoms of fatigue and daytime 
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sleepiness (Neu et al., 2008). It is also important as the two complaints have different 
implications for diagnosis and treatment. Whereas fatigue relates to lack of available 
energy and loss of ability to exert mental and physical effort, sleepiness is a tendency 
to fall asleep, and only becomes problematic if it occurs at an inappropriate time or 
situation (Shen et al., 2006). The Multiple Sleep Latency Test (MSLT; Carskadon & 
Dement, 1977) objectively measures daytime sleepiness, by measuring the amount of 
time it takes people to fall asleep during the day, given the opportunity. In the case of 
an MSLT four daytime sleep opportunities are offered, separated by 2 hours each time. 
The results from MSLTs carried out in CFS have generally been inconsistent. Several 
studies show CFS patients do not differ from healthy controls on MSLT values (Bailes 
et al., 2006; Buchwald et al., 1994; Majer et al., 2007; Reeves et al., 2006). A twin 
study has shown that CFS twins, despite reporting significantly more subjective 
sleepiness than their healthy co-twins, did not differ in their mean sleep latencies 
(Watson et al., 2004). This indicates that CFS and biological sleepiness is not 
associated, and also points towards a heightened sense of sleepiness among CFS twins. 
 
Where clinically significant MSLT latencies (ޒ10 min) have been identified in CFS 
patients, these again are not consistent; one study revealed 41% of CFS patients had an 
abnormal MSLT yet scores did not differ significantly from those of non-fatigued 
controls (Buchwald, et al., 1994). Another study showed a quarter of their CFS sample 
had an abnormal MSLT (Krupp, et al., 1993). In a recent study of CFS patients from 
the Wichita population (n=225), 59.5% of patients had an abnormal MSLT. 
Interestingly in the same sample 61.7% had an Epworth Sleepiness Score (ESS) within 
the normal range (Decker, et al., 2010). Moreover, in a study assessing CFS patients, 
apnoea patients, and healthy controls, the CFS group showed significantly smaller 
MSLT scores than controls during 2 of the 4 sleep opportunities provided, however 
these still fell within a normal range. Overall comparisons of scores on the MSLT 
showed CFS patients presented with intermediate values between apnoea patients 
(demonstrating the most excessive sleepiness) and healthy controls (Neu et al., 2008). 
 
The key shortcoming of the reported results of MSLTs carried out with CFS patients is 
that they are based on tests usually following a single night of Polysomnography (PSG, 
see section 2.2.2.3 for a description). As such, MSLTs after a single night of PSG, may 
not be an accurate indication of a patient’s daytime somnolence, given that the first 
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night of PSG (usually conducted in an unfamiliar environment) is commonly 
associated with a phenomenon known as the “first-night effect”. The first-night effect 
is the set of differences in sleep parameters observed on the first night of recording in 
comparison to consecutive ones. The main characteristics of the first-night effect 
include; a reduction in sleep time, more time awake during the night and reduced sleep 
efficiency (SE) parameters (Agnew et al., 1966; Rechtschaffen & Verdone, 1964). 
Moreover, polysomnography studies are often criticised for their artificial sleep 
laboratory conditions that do not reflect normal sleep at home and do not allow for 
habituation to cumbersome equipment (Newell et al., 2012). As such, patients are 
likely to be sleepy the next day. The functional impact of the PSG study night may 
also explain the lack of relationship between MSLT scores, sleepiness scores and 
fatigue scales. 
 
Examinations of individuals deprived of or restricted from sleep consistently 
demonstrate deteriorations in mood, cognition and performance (Turner et al., 2007). 
The purpose of each different sleep stage is also unclear, although it is generally 
agreed that the lighter stages of sleep (stage 1 sleep and stage 2 sleep) afford 
transitions between wakefulness and sleep and then between slow wave sleep (SWS) 
and Rapid Eye Movement sleep (REM). SWS and REM are believed to confer 
recuperative, restorative and learning properties for the individual (e.g. the secretion of 
growth hormone, consolidation of memory) (Van Cauter, Leproult & Plat, 2000). 
Therefore, the proportion of each sleep stage and timing of entry into each sleep stage, 
SWS and REM in particular, are important for the long-term maintenance of human 
physical and mental health. PSG studies allow us to measure these sleep parameters, 
and the next section will review the PSG studies that have been carried out in CFS.  
 
2.2.2.3 Polysomnography (PSG) studies 
Overnight Polysomnography (PSG) is an all-night recording of sleep physiology, 
including both sleep continuity and sleep architecture (the progression and timing of 
sleep/wake stage transitions) and involves attaching electrodes to the scalp, forehead, 
and chin to record electroencephalogram (EEG) eye movements or electro-oculogram 
(EOG) and muscle activity from the submental muscle (electromyogram, EMG). In 
addition, variables such as electrocardiogram (ECG), EMG from leg muscles, a range 
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of respiratory variables and body movements may be measured at the same time. 
Overall, PSG sleep findings have not shown any clear pattern of sleep abnormality in 
this population. One characteristic of the PSG research in CFS may account for this: 
there is a high degree of variability in terms of the sleep continuity and sleep 
architecture features that are reported in research studies (see Appendix A).  This 
makes comparisons between PSG studies of sleep in CFS difficult, and meta-analyses 
virtually impossible. There is also a fair degree of variability in the protocols, adding 
to the complexity.  PSG Studies have mostly been carried out over one night 
(Buchwald, et al., 1994; Creti, et al., 2010; Fossey, et al., 2004; Guilleminault et al., 
2006; Kishi et al., 2008; Krupp, et al., 1993; Morriss, et al., 1993; Sharpley et al., 
1997; Stores et al., 1998; Togo et al., 2008) or two (Ball et al., 2004; Decker et al., 
2009; Fischler et al., 1997; Le Bon et al., 2003; Le Bon, Majer, et al., 2007; Neu et al., 
2009; Neu, et al., 2008; Neu et al., 2007; Reeves, et al., 2006; Van Hoof et al., 2007; 
Watson, et al., 2004), which may present with potential ‘first night effect’.  
 
Does the ‘first-night effect’ exist in CFS?  
A great deal of the assumptions regarding the variability and lack of consistency in the 
objective sleep patterns of patients with CFS rests on the idea that people with CFS 
experience a first-night-effect. In a seminal study (Le Bon, et al., 2003) this 
phenomenon was studied in 83 CFS patients without an objectively verifiable sleep 
disorder. Le Bon and colleagues observed clear differences between the first and 
second night sleep parameters. On night one there was less Total Sleep Time and REM 
sleep, a longer REM latency, more intermittent Wake Time and a reduced number of 
sleep cycles (Le Bon, et al., 2003), all indicating poorer first night sleep, in comparison 
to night two. That said, and rather complicating the issue, a quarter of Le Bon at al’s 
(2003) sample demonstrated an ‘inverse first-night-effect’ with patients experiencing 
better sleep on night one than night two. These issues may highlight the need for at 
least a 3-night assessment for PSG research. 
 
Continuity 
There is large variation between PSG studies on reported sleep continuity variables 
(See Table 2.2 for descriptors of sleep variables), for example, in one single-night PSG 
assessment study, Sharpley and colleagues showed a mean Sleep Onset Latency (SOL) 
of 69 minutes (Sharpley, et al., 1997), whereas Togo and colleagues showed a SOL of 
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31 minutes (Togo, et al., 2008). Further, Morris et al (1993) report mean SOL of 12.2 
minutes in their CFS patient cohort. Given that a SOL longer than 30 minutes is 
considered as a presence of potential “sleep initiation difficulty” (Edinger et al., 2004), 
these findings are highly variable and relate to both problematic and non-problematic 
sleep values. A two-night PSG assessment, arguably a more representative indication 
of ‘typical’ sleep, identified a significantly longer SOL (39.9 minutes) on night two in 
CFS patients compared to healthy controls (21.5 minutes) (Fischler, et al., 1997).  
 
Notes: Arousal defined as an abrupt shift in EEG frequency (alpha, theta waves and/or frequencies greater than 16 
Hz, but not sleep spindles), lasting at least 3s, after at least 10 continuous seconds of sleep, and is associated with 
sleep fragmentation (Iber et al., 2007). REM, rapid eye movement; TSP, total sleep period; TST, total sleep time. 
 
Table 2.2:  Description of sleep variables  
Abbreviated 
Variable 
Sleep Variable (measure) Description 
AHI Apnea /Hypopnea Index Number of Apnea or Hypopnea events during 
sleep 
TST Total Sleep Time (minutes) 
 
Amount of time asleep 
SOL Sleep Onset Latency (minutes) Length of time from lights out to first episode of 
stage 2 sleep 
 
WASO Wake After Sleep Onset (minutes) Number of minutes of recorded wake following 
first episode of stage 2 sleep 
 
NWAK Number of Awakenings (over TSP) Number of wake bouts following first episode 
of stage 2 sleep 
 
NoA Number of Arousals Number of arousals over the entire sleep period 
 
REML REM Latency 
 
Length of time to first REM stage 
 
 
SE (%) Sleep Efficiency Percentage of time spent asleep from the 
amount of time spent in bed (TST/TIB*100) 
 
%N1 Percentage of Stage 1 (of TST) Percentage of recorded stage 1 sleep over the 
total time asleep 
 
%N2 Percentage of  Stage 2 (of TST) Percentage of recorded stage 2 sleep over the 
total time asleep 
 
%SWS Percentage of SWS (of TST) Percentage of recorded slow wave sleep over 
the total time asleep 
 
%REM Percentage of REM (of TST) Percentage of recorded Rapid Eye Movement 
sleep over the total time asleep 
 
%WAKE Percentage of  WAKE (of TSP) Percentage of recorded wake over the whole 
sleep period (from lights out to lights on) 
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Further single-night PSG assessments have shown other types of sleep disruption in 
CFS.  After exclusion for medical illness, psychiatric disorders, apnoea, hypersomnia 
and Periodic Limb Movement Disorder, 26 CFS patients - with co-existing 
fibromyalgia - had significantly reduced total sleep time and reduced sleep efficiency 
than controls (Togo, et al., 2008). Home-based PSG studies have also shown CFS 
patients to sleep less efficiently than controls, with patients spending more time in bed 
and significantly more time awake during the night (Morriss, et al., 1993; Sharpley, et 
al., 1997).  However, results of percentage time awake during the night are also highly 
variable between studies, with ranges from 11.7% (Majer, et al., 2007; Reeves, et al., 
2006) to 31.9% (Morriss, et al., 1993) and even as much as 46.28% (Van Hoof, et al., 
2007). 
 
 
Architecture 
Architectural findings of PSG studies in CFS are equally equivocal. Discrepancies 
between studies in their reporting of sleep stages and abbreviations used, may account 
for this, based on the advancements that have been made in the visual scoring of sleep 
stages. Since 2007, the AASM manual (Iber, et al., 2007), replaced Rechtschaffen and 
Kales’ (R&K; 1968) rules that had originally divided the sleep stages into; 
wakefulness, stage 1-4 (non-REM), or REM. Sleep stages were now defined as, N1-N3 
(non-REM) and stage R (REM), the key difference being stage 3 and stage 4 in the old 
R&K rules being abbreviated to stage N3 (SWS) in the new rules (Iber, et al., 2007) as 
it is considered that no physiological basis exists for a difference between stages 3 and 
4. This creates discrepancies with regard to some studies reporting stage 3 and 4 with 
others referring to SWS. Adding to this, few studies report a full characterization of 
sleep architectural variables (amount of each sleep or wake stage and the timing of 
transitions to each sleep stage), making any conclusive statements about sleep 
abnormalities in this patient population difficult. (See table 2.1 for a summary of sleep 
stages). The first report, from a group of 49 CFS patients compared to 20 matched 
healthy controls, found a significantly lower percentage of NREM N3 (formerly 
considered S3 & S4 sleep) in CFS (Fischler, et al., 1997). Conversely, Le Bon (2007) 
showed significantly increased NREM N3 in the sleep of CFS patients (free of medical 
illness, psychiatric or primary sleep disorders),, compared to apnoea patients and 
healthy controls, thus drawing the conclusion that there is an increase in the amount of 
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deep sleep over light sleep in CFS. This latter finding was corroborated in 2009 by 
Neu and colleagues, who reported architectural differences from the second night of  
 PSG assessment with CFS patients exhibiting less light (N1 and N2) sleep and more 
deep (Slow Wave) sleep than healthy controls or apnea patients (Neu, et al., 2009).   
 
 
 
 
 
Notes: NREM, non-rapid eye movement; REM, rapid eye movement; N1, stage 1; N2, stage 2; N3, stage 3; SWS, 
slow wave sleep; Spindles, short bursts of rhythmic activity (occur during light and deep non-REM sleep) to keep 
the cortex from processing during sleep; K complexes, manifestations of a downward signal (from cortex to 
thalamus and brain stem) to stay asleep (evoked readily in light sleep by auditory stimulation); SWA, slow wave 
activity. 
 
 
 
Table 2.3: Sleep stages and patterns of the EEG (Carskadon & Dement, 2011). 
 
 
 
 
 
Sleep Stage 
 
EEG Features 
 
Waveform Type 
 
EEG Size (Amplitude) 
        
Awake 
 
Low-amplitude, mixed, and 
sometimes alpha rhythm. 
 
Alpha 8-13 Hz; 
Beta ޓ13 Hz 
 
Low 
N
R
E
M
 
S
le
ep
 
 
N1 
 
Low amplitude, mainly irregular 
theta activity, and triangular 
vertex waves. 
 
Theta 4-7Hz 
 
Low 
 
 
N2 
 
Sleep spindles, K complexes, 
some low amplitude theta and 
delta activity. 
 
Spindles 12-15Hz 
 
Medium 
 
N3 
(SWS) 
 
 
High-amplitude delta activity, 
spindles less prominent, K 
complexes longer, and less 
discrete. 
 
Delta or SWA ޒ4.5 Hz 
 
 
High 
 
 
REM 
 
Low-amplitude, frequency EEG, 
and sometimes saw-toothed 
waves. 
 
Theta 4-7 Hz 
 
Low 
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Large variations also exist between studies in terms of reported percentage of REM 
sleep in CFS cohorts. Normal adults spend approximately 20-25% of their total sleep 
time in REM (Kryger, Roth & Dement, 2011). Some CFS studies have shown reduced 
REM; 7.6% (Kishi, et al., 2008), normal range; 22.3% (Reeves, et al., 2006) and others 
have observed increased REM; 27.7% (Ball, et al., 2004). Moreover, reported REM 
latencies (length of time to the first REM cycle), which in normal adult sleep is around 
90 minutes (Kryger, Roth & Dement, 2011), are equally varied in individuals with 
CFS. Some report latencies as short as 63.5 minutes (Ball, et al., 2004) and others 
much longer, for example 149 minutes, (Togo, et al., 2008).  
 
These results relating to the proportion of REM are based on either a single night 
(Kishi, et al., 2008; Togo, et al., 2008) or a second night (Ball, et al., 2004; Reeves, et 
al., 2006) of recording, so perhaps, again, the first-night effect explains this variance. 
Indeed, much of the variance in the reported structural and architectural sleep variables 
in these studies of CFS patient’s sleep may well be explained by the number of study 
assessment nights. Very few studies have conducted a three-night protocol of PSG 
assessment (Armitage et al., 2007; Fischler, et al., 1997; Whelton et al., 1992). This 
protocol inconsistency is further complicated by the fact that reporting practices differ, 
making interpretation and comparisons difficult. Some studies report the percentage of 
each sleep and wake stage as an index of Sleep Period Time (amount of the whole 
sleep period), Total Sleep Time (amount of time once sleep has been initiated) or even 
amount of Time in Bed (Armitage et al., 2007; Ball et al., 2004; Fischler et al., 1997; 
Majer et al., 2007; Manu, et al., 1994; Reeves et al., 2006; Stores et al., 1998; Van 
Hoof et al., 2007; Watson et al., 2003; Whelton, et al., 1992), whilst others report 
minutes of each stage (Le Bon et al., 2003; Le Bon, et al., 2007; Morriss et al., 1993; 
Sharpley et al., 1997; Togo et al., 2008). However, collectively these studies do not 
demonstrate any consistent architectural differences in sleep of patients and healthy 
controls/co-twins. Consequently, results should be treated carefully. The variability in 
measures of sleep parameters could be the result of either the heterogeneity of sleep 
problems within the CFS populations, a variability in measurement protocols, and/or 
the result of still often neglected primary sleep disorders (PSD) in these studies (i.e. 
mild OSAS or PLM). 
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There have also been indications of alteration in the transition pattern of sleep stages in 
CFS - particularly, significantly fewer transitions from REM to non-REM sleep over 
the night in CFS patients than in controls (Kishi, et al., 2011; Kishi, et al., 2008). This 
suggests a potential disruption in the normal circadian regulation of sleep-wake 
patterns, abnormalities that could lead to unrefreshing sleep. 
 
 
Power Spectral Analysis (PSA)  
EEG brain wave activity can be categorised in frequency bands and they can to some 
extent provide a gross indication of a particular sleep/wake state. For example, alpha 
activity (8 to 12 Hz) is the dominant rhythm in relaxed wake state (eyes closed) in 
posterior regions of the scalp. That said, alpha waves can also be observed (although 
they do not predominate) during the various stages of sleep. When these alpha waves 
intrude into deep sleep it is suggested the brain is not resting like it should (also known 
as alpha-delta intrusion), indicating a wakeful period during sleep and high levels of 
alpha-intrusion into sleep is often associated with complaints of non-refreshing sleep. 
PSA deconstructs the amount, and density, of each frequency band over each phase of 
wake and sleep. PSA integrates the amount of energy (power) and respective density in 
each frequency band and potential overlap or ‘intrusion’. In some cases, these 
intrusions can result in a change of stage shift (e.g. going from one sleep stage to 
another, including wake). In terms of the PSA evidence, Armitage and colleagues 
(Armitage et al, 2007) assessed 13 twin-pairs (from the University of Washington CFS 
Twin Registry) of the 22 who originally underwent PSG assessments. Having applied 
PSA, using Fast Fourier Transformation (FFT: a widely applied linear modelling 
method to obtain EEG power spectra), delta power was observed to be slightly 
elevated overall in the CFS-twins, although this was not enough to significantly 
differentiate them from their healthy co-twins (Armitage, et al., 2009). Moreover, there 
have been new perspectives in what the homeostatic impairment in slow wave sleep 
(SWS) in CFS might be. Le Bon and colleagues looked at delta activity in the very 
slow end of the frequency band, which had mainly been overlooked in studies. They 
showed lower ultra-slow delta power in the sleep of 10 young females with CFS in 
comparison with healthy controls (Le Bon et al., 2012). This underlines the importance 
of looking beyond the conventional gross EEG.   
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Decker and colleagues (Decker, et al., 2009), also used FFT, and analysed the PSG 
recordings of 35 CFS patients from the Wichita population study, comparing these to 
40 non-fatigued controls. Overall there was significantly reduced spectral power of 
alpha activity in CFS subjects during stage 2 sleep, SWS, and with the greatest 
reduction observed during REM sleep.  CFS patients also showed significantly reduced 
delta power activity in SWS, which would concur with the common symptoms found 
in CFS, as reduced delta power is associated with reported fatigue and the perception 
of pain (Lentz et al., 1999). However, this delta power was increased during stage 1 
and REM sleep. This latter finding has been corroborated elsewhere (Guilleminault, et 
al., 2006; Neu, et al., 2009). This rebound might reflect an impairment of sleep related 
homeostatic functions in CFS. 
 
However, alpha-delta sleep, or alpha intrusions are not entirely specific to CFS. Other 
disorders, such as rheumatoid arthritis, fibromyalgia and lupus erythematosus also 
feature differences in alpha range EEG frequencies compared to control subjects 
(Macfarlane & Moldofsky, 2011). Additionally, there are reports of this alpha-delta 
sleep in stages 2, 3 and non-REM sleep in fibromyalgia patients who present with 
excessive daytime somnolence and chronic fatigue (Branco et al., 1994; Drewes et al., 
1995; Moldofsky et al., 1975; Roizenblatt et al., 2001). Furthermore, changes in alpha 
can also be found in several primary sleep disorders (PLMD, sleep apnoea, and 
narcolepsy) and occasionally in patients with no complaints of fatigue (MacFarlane et 
al., 1996).  The role of alpha-delta sleep in the development of CFS remains 
questionable, with some studies of CFS patients observing alpha intrusions in SWS 
(Manu et al., 1994; Whelton, et al., 1992) and others failing to support this (Armitage 
et al., 2009; Flanigan et al., 1995; Mariman et al., 2012).  
 
 
Co-twin control methodology 
Despite offering a powerful method by which to control for genetic factors (Hrubec & 
Robinette, 1984), PSG twin studies have not provided strong evidence for sleep 
abnormalities in CFS. In one 2-night PSG assessment study, and following exclusion 
of psychiatric and medical disorders, CFS twins did not appear to differ from their 
healthy co-twin on any sleep parameter (Armitage, et al., 2009; Ball, et al., 2004; 
Watson, et al., 2004). However, delaying sleep onset by 4-hours resulted in CFS twins 
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showing less slow wave activity than their healthy co-twins (Armitage, et al., 2007). 
This finding may be indicative of a potential impairment in homeostatic sleep pressure 
in CFS and supports that the daytime complaints observed in people with CFS may be 
associated to potential issues in sleep regulation.  
 
Summary of PSG 
Overall, the PSG studies report that CFS patients have abnormal sleep, however such 
disturbances are variable and not found across all patients. There is also no 
standardisation in protocol, selection criteria, or reporting practices, making 
interpretation and comparisons between studies difficult. Moreover, different studies 
exclude different groups, and, whilst most exclude medical illness, psychiatric 
disorders, and some sleep disorders (primary hypersomnias, sleep aponea and PLMD), 
they tend not to exclude insomnia (Creti, et al., 2010; Le Bon, et al., 2003; Sharpley, et 
al., 1997). This is highly problematic in terms of reporting sleep findings in CFS where 
patients are likely to encounter symptoms similar to those experienced in Insomnia 
such as problems getting off to sleep or staying asleep. Further, given the considerable 
overlap in the existing diagnostic criteria (used in the reported studies), between CFS 
and insomnia (namely non-restorative sleep), it is highly important to tease these 
conditions apart to be able to understand CFS exclusively. 
 
2.2.3 A combination of methods 
There have been several studies, mentioned earlier, that have used a combination of 
objective sleep assessment with subjective measures of patient’s sleep (Creti, et al., 
2010; Majer, et al., 2007; Sharpley, et al., 1997; Watson, et al., 2004; Watson et al., 
2003). These triangulation studies demonstrate interesting discrepancies between what 
emerges in subjective and objective measures. Overall, CFS patients report poorer 
sleep quality and more non-restorative sleep than healthy and non-fatigued controls, 
but objectively they appear to have close to normal sleep architecture (structure and 
pattern of sleep) or macrostructure (temporal organisation of sleep). Similarly, CFS 
patients report more subjective sleepiness, yet objective measures (MSLTs) of 
sleepiness do not tend to differ between CFS twins and their healthy co-twins (Watson, 
et al., 2004). These discrepancies between subjective daytime complaints and 
objectively measured sleep are also common in individuals with insomnia, often 
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described as sleep-state misperception (SSM; i.e. perceiving sleep as 
wakefulness/overestimating sleep). Such sleep misperception has been explained by 
the neurocognitive model of insomnia, emphasising that brain cortical arousal is a 
central component whereby both physiological and cognitive arousal arises from 
increased cortical arousal around the sleep onset period (Perlis et al., 1997).  
 
Neu et al (2007) specifically demonstrated this difference between subjective and 
objective sleep. After exclusion of psychiatric disorders and certain sleep disorders 
(aponea, PLMD and hypersomnia), their 28 ‘pure’ CFS patients reported significantly 
poorer subjective sleep quality - as demonstrated by PSQI scores - compared to healthy 
age and gender matched controls but there was no evidence of structural PSG 
abnormalities. This might suggest that CFS patients negatively perceive their sleep 
quality even though they may sleep well. One suggestion is that they may over-
monitor their sleep and this perhaps contributes to perceived sleep problems, a 
phenomenon which has also been observed in insomnia (Harvey & Payne, 2002). 
Also, in CFS, the lack of explanation and guidance surrounding the condition may 
increase patient anxiety, symptom experience and consequently, symptom focus 
(Deary, Chalder & Sharpe, 2007). This in turn could cause an increased monitoring of 
sleep duration and quality.  Again this emphasises the importance of considering the 
interaction between cognitions, behaviours, physiology and symptoms in this condition 
and also the importance of combining assessment techniques.  
 
2.3 Issues, conclusions and recommendations. 
2.3.1 Minor case definition criteria – the pitfalls 
The lack of regularity in working case definitions and guidelines for CFS creates 
uncertainty regarding the role of sleep in CFS. Specifically, complication exists as to 
where sleep complaints fit within the available case definitions of CFS. For example 
the Holmes (CDC) definition includes sleep disturbances such as hypersomnia or 
insomnia in its minor criteria (Holmes et al., 1988), whereas the Fukuda (CDC) 
definition considers sleep disorders such as sleep apnea and narcolepsy as exclusionary 
and regards unrefreshing sleep as minor criteria (Fukuda, et al., 1994). Given that some 
available criteria regard sleep problems as minor - whilst sleep complaints are 
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consistently reported in CFS - together with the considerable variation in the use of 
terminology, there is scope to investigate sleep disturbances in CFS in much more 
detail, and certainly, the need to establish more definitive criteria with regard to sleep. 
This raises the issue of the overlap/confusion between sleep disorders and CFS. 
 
2.3.2 Sleep disorders  
The presence of sleep disorders has been highlighted in sleep studies with CFS 
patients. In a single night PSG and self-report observational study (Fossey, et al., 
2004), it was found, that of the 37 CFS patients, 58% fulfilled the criteria for a 
diagnosable sleep disorder (Diagnostic Classification Steering Committee, 1990); 11 
(42%) had apnea and 4 (16%) had restless legs syndrome/ periodic limb movement 
disorder (RLS/PLMD). High rates of self-reported insomnia (86%) were also evident 
in the CFS group. In another study that combined PSG, actigraphy and self-reports, 42 
(86%) of the 49 CFS patients had a diagnosable sleep disorder, with 32 (65%) meeting 
DSM-IV criteria for chronic insomnia and 10 (20%) with aponea (Creti, et al., 2010). 
In a recent large-scale study of 205 patients (n=410, combined data over 2 recorded 
nights), one third of the sample had suspected apnoea, based on their respiratory 
disturbance index (RDI: average number of episodes of apnoea, hypopnea, and 
respiratory event-related arousal per hour of sleep) (Decker, et al., 2010). In a recent 
survey of a specialist CFS service in London, (Devasahayam et al., 2012) it was 
reported that  of the 377 patients referred to the CFS service – almost half (49%) had 
alternative diagnoses made, based on an assessment that included a detailed history, 
physical and mental state examination. Of those assessed (n = 250), a sleep disorder 
was the most common (28%), which suggests an alternative diagnosis may be 
warranted.  
 
These findings highlight the fact that sleep disorders (i.e. insomnia, apnea, RLS, 
PLMD) may well be comorbid, overlooked or misdiagnosed in CFS. Further some 
authors have suggested that CFS is a primary sleep disorder in itself. However this 
questions the nature of causal relationships between physiology, symptoms, and 
behaviour in this population (indeed in any chronic condition) and how the appellation 
“primary” must be used with caution. Hypersomnia and insomnia are common features 
of CFS and are as likely to be effects as they are causes of fatigue. To date no 
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treatment studies have sought to exclusively target sleep to ascertain how this impacts 
on other symptoms. Only experimental designs would afford causality. Given the lack 
of consistency in findings from studies of sleep architecture and multiple sleep latency 
times, it could also be considered that symptoms such as unrefreshing sleep and 
unremitting fatigue may not reflect a sleep disorder per se but rather an impaired sleep 
homeostasis (Armitage, et al., 2007; Le Bon et al., 2012), the body’s natural ability to 
regulate the sleep/wake cycle (Borbely & Achermann, 1999), but again this would 
have to be experimentally tested.  Practically, what this work highlights is the 
necessity to perform thorough sleep assessments in this population.  
 
2.3.3 Future research 
Sleep studies in CFS have shown very mixed results, particularly with regard to 
polysomnography. Not only do these studies significantly differ in their results, but 
their protocol and exclusion criteria are equally inconsistent. As a result no consistent 
picture of sleep disturbance emerges from the data. The most consistent findings are in 
the subjective reports of sleep quantity and quality. However, rather than dismissing 
this inconsistency as an artefact of inconsistent methodologies, we would suggest that 
a more plausible conclusion is that there is significant heterogeneity of sleep 
phenotypes in the CFS population. This needs to be further investigated. 
 
There is a need for more qualitative accounts from patients about their experience of 
sleep. This could highlight the proposed heterogeneity and also guide or complement 
subsequent objective studies to further investigate which specific components of sleep 
are disturbed, and how they might play a role in maintaining symptoms such as 
fatigue. There is a need for more mixed method studies, combining and comparing 
objective and subjective data. This would afford an examination of sleep state 
misperception (SSM), as a principle problem in this population. Moreover, it is 
important that research moves forward in measuring sleep according to more stringent 
protocols, avoiding single-night recordings, selecting well-matched control subjects 
and accounting for sleep disorders such as apnoea.  
 
More research is also needed to tease apart the causative and consequential role of 
sleep in CFS and to explore whether the daytime fatigue that is attributed to the CFS is 
40 
related to a sleep disturbance or something else (i.e. autonomic dysregulation, activity 
patterns, homeostatic dysregulation).  Changes have now been made in the DSM-5 and 
International Classification of Sleep Disorders - Third Edition, where non-restorative 
sleep is removed from the criteria for Insomnia Disorder and may afford a greater 
differentiation between CFS and Insomnia. In clinical practice, it is important that CFS 
patients are screened for the presence of a sleep disorder to identify any incorrect or 
co-morbid diagnoses, as currently, complete sleep testing is not part of routine CFS 
evaluation (Carruthers et al., 2011; Fukuda, et al., 1994; Holmes, et al., 1988). 
 
Ultimately, sleep comprises specific brain activities and physiological systemic 
adaptations, which are implicated in various functions of brain and body restoration, 
learning processes, memory consolidation and mood regulation (Kryger et al., 2011). 
Investigating sleep is thus highly relevant to this population given the overlap of these 
features with symptom presentation in CFS patients (loss of physical functioning, 
impairments in memory, attention and concentration) (Afari & Buchwald, 2003). 
Currently though there is no standardised method to measure sleep in this patient 
cohort. Practically there is a need to address and standardise the technical aspects of 
assessing sleep efficiently by employing a standardised 3-night protocol to observe 
sleep continuity, architecture and microstructure in CFS patients. This would help to 
determine 1) sleep disorders in this patient group, 2) the overlap between sleep 
disorders and CFS and 3) the distinct sleep characteristics of CFS patients. It may then 
be possible to clarify the precise relationship between sleep, behaviour, cognition, 
physiology and the physical symptoms of CFS. 
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2.4 Summary of thesis aims 
 
This thesis intends to examine the specific role of sleep in CFS from a number of 
perspectives; from the personal through to the biological, using a range of sleep 
assessment methods. This biopsychosocial research programme aims to;  
  Explore CFS patients’ lived experience of sleep, through qualitative interviews;  Evaluate subjective sleep quality in CFS patients and its association with key 
dimensions of the illness experience;  Examine sleep objectively via a single-night of PSG and explore the possibility 
of heterogeneity of sleep problems in patients with CFS;  Determine the feasibility of a comprehensive (mixed-methods) protocol for the 
assessment of sleep and cortisol, in an ambulatory setting, with CFS patients.   
 
 
More far-reaching aims;  Focussing in depth on one aspect of this condition, sleep, will lead to a greater 
understanding of CFS; helping to characterise CFS at every level from the 
biological through to the social and understand how these mechanisms interact.   
  Establishing a feasible protocol for standardised assessment of sleep and 
cortisol in CFS, will inform future research practice and also lead to enhanced 
therapeutic delivery with more focus on the central role of sleep in CFS.  
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CHAPTER THREE                                                                                           
THE EXPERIENCE OF SLEEP IN CHRONIC FATIGUE SYNDROME: A 
QUALITATIVE INTERVIEW STUDY  (STUDY 1) 
 
 
3.1 Introduction  
CFS affects between 0.23% and 2.6% of the adult population (Wessely et al., 1997; 
Jason et al., 1999; Reyes et al., 2003) and previous research has shown that there is a 
relationship between disrupted sleep patterns and CFS (Morriss, Wearden et al. 1997; 
Boneva, Decker et al. 2007; Togo, Natelson et al. 2008). Sleep is a consistent 
complaint of those suffering from CFS, with 87-95% of CFS patients report awakening 
unrefreshed following sleep (Jason, Richman et al. 1999; Nisenbaum, Jones et al. 
2003; Nisenbaum, Reyes et al. 2004; Hamaguchi, Kawahito et al. 2011). Patients also 
report experiencing disrupted and fragmented sleep and difficulties in getting to sleep 
despite feeling tired (Anderson and Ferrans 1997). The effect of sleep is important to 
consider in CFS because disrupted sleep can cause fatigue, myalgia and poor 
concentration in healthy volunteers and therefore sleep disruption may result in a 
worsening of the effects of fatigue and other symptoms (Morriss, Sharpe et al. 1993). 
 
Qualitative studies provide a potential for a richer understanding of the specific 
experiences patients have of their condition. A review by Anderson et al (2012) 
summarised thirty five qualitative studies in CFS. The key areas and themes they 
identified related to patient’s experiences of living with the condition and physician 
understanding of the condition. However as yet, no qualitative studies in CFS have 
looked specifically at the sleep experience of patients in depth. Instead they have 
explored coping experiences, illness identity, social impact and physician-specific 
perspectives (Hart & Grace, 2000; Larun & Malterud, 2007; Whitehead, 2006).  
 
The aim of the present study then was to explore the experience of sleep in CFS from 
the patients’ perspective. This qualitative work will inform the systematic development 
of a sleep characterisation and intervention development programme. However what is 
missing from this and from the existing literature on sleep is the person with CFS's 
perspective and voice. This is a voice that is often obscured in the ideological battles 
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which occur in the definition and aetiology of CFS. It is an illness which is often 
poorly understood, where a crude dualism pits biological against psychological models 
and the complex experience of living with it is often lost. By utilising qualitative 
methods, particularly a critical realist approach, there is the potential to short circuit 
this debate by making the patients’ lived experience of the condition, and their own 
understanding of it, the focus of research.  
 
This method potentially offers a deeper understanding of the processes that may be 
involved in maintaining this chronic condition. Given the lack of extant qualitative 
accounts of sleep then, this study seeks to elicit in detail CFS patient’s accounts of this 
key aspect of their illness experience. It will seek to build a picture of their complete 
sleep experience over a typical 24-hour period, from their own individual point of 
view. Further, we will attempt to see how sleep has an impact on patient’s daytime 
functioning and quality of life in a way that could have implications for clinical 
practice.  
 
3.2 Methods 
3.2.1 Participants  
A consecutive sample of participants were recruited and considered eligible if they 
fulfilled the Fukuda diagnostic criteria for CFS (Fukuda et al., 1994), and referred to 
the Newcastle-upon-Tyne Royal Victoria Infirmary. Patients were excluded if they met 
caseness on the Hospital Anxiety and Depression Scale (HADS), or were taking 
Thyroxine or sleep medications. Eleven patients (2 male and 9 female) participated in 
the research in response to an invitation letter, with ages ranging from 22-68 (mean = 
48.2 years), and length of illness ranging from 4-33 years, (mean =10.2 years). 
 
The research was given approval by the Newcastle and North Tyneside Local Research 
Ethics Committee, all subjects provided written informed consent and the Newcastle 
Hospitals NHS Foundation Trust sponsored the study. 
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3.2.2 Procedures and Data Collection 
Data was collected through individual semi-structured interviews. All interviews were 
conducted privately, by the same researcher and participants had the option of being 
interviewed at home or in the University. Two participants chose to be interviewed at 
home, one via telephone, one via Skype video call and seven at the Northumbria 
Centre for Sleep Research (NCSR). Interview length ranged from 0.5-1.5 hours and all 
sessions (including the telephone and Skype interview) were audio-recorded. To 
maintain the anonymity of the participants, transcripts were labelled simply as the 
Participant numbered 1 to 11 (e.g. P1). All participants were asked “Can you please 
tell me a bit about your experience of having CFS” from the outset, and further 
interview prompts were used to follow up responses as necessary. Nevertheless, all 
interviews followed the same interview schedule (see Appendix C). The interview 
typically elicited a narrative of the patients’ experience of their condition, with 
particular attention to their sleep and any particular disturbances. They were able to 
describe a ‘typical’ 24 hour period, including any symptoms, what made these better or 
worse, and their impact on daily functioning. Interviews were carried out until a point 
of data saturation. It was following the 11
th
 patient interview, that it was considered 
saturation had been reached; at this stage in the study, no new themes were emerging 
in the data.  
 
3.2.2.1 Data Analysis 
A critical realist approach was taken to data analysis, making the patients’ lived 
experience of the condition, and their own understanding of it, the focus of research. 
This is particularly important for this population, given that in the medical field the 
ontology of CFS is a matter of dispute. Braun and Clarke’s (2006) thematic approach 
was chosen to address the focus of this research because as a realist methodology, it 
explores individual experiences and the meanings they attach to them without looking 
for hidden connotations or imposing the researcher’s biases.  
 
We transcribed the digital recordings verbatim, and analysed the transcripts 
thematically. During the analytical process initial thoughts and ideas were noted down, 
this is considered an essential stage in analysis (Riessman, 1993). The transcribed data 
were then read several times, and the recordings were also listened to several times to 
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ensure the accuracy of the transcription. This process of ‘repeated reading’ (Braun & 
Clarke, 2006) and the use of the recordings to listen to the data, results in "data 
immersion", a sense of closeness with the data. Following on from this initial stage and 
having become immersed in the data, we next developed codes which identified key 
features, for instance “broken”, “pain” and “temperature”. The codes identified 
features of the data that were considered pertinent to the research, and also ensured the 
whole data set was given equal consideration when repeated patterns in the data were 
seen to emerge.  
 
In the third stage, we searched for themes that were able to explain larger sections of 
the data by combining different codes that were very similar. For example, if a 
participant talked about an aspect of experience, such as utilisation of alternative 
treatment approaches, we then allocated that part of their interview to the broad theme 
‘attempts at coping/sleep management’. We then refined and considered the themes in 
stage four, and this refinement of the themes took place on two levels; firstly ensuring 
the coded data formed a coherent pattern, and next, once a coherent pattern had been 
established, the themes were considered in relation to the data set as a whole, which in 
turn ensured the themes accurately reflected what was evident in the data.  
 
The fifth stage involved defining and naming the themes. In addition, we felt it was 
important to develop short but informative names that conveyed an immediate sense of 
what the theme was concerned with. The final stage involved choosing examples of 
each transcript to illustrate elements of the themes. These extracts were selected on the 
basis that they clearly identified the issues within the theme and presented a clear 
example of the point being made. Such examples, illustrated as patient quotes from the 
transcriptions and the themes they fit into are shown in Table 3.1 
 
3.3 Results 
After characterising a full sleep-wake profile for each patient based on their individual 
narratives, and exploring in detail, their sleep-related experiences and the meanings 
they attach to them, the thematic analysis that was applied to the transcripts elicited 
three overarching themes; 1. Sleep Disturbances; 2. Effect of sleep on daytime 
functioning; and 3. Attempts at coping and sleep management. These are set out in 
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Table 3.1 which displays each main theme with their associated sub-themes and 
illustrative quotes from patients. It is important to note that the integrated sub-themes 
should not be considered mutually exclusive or independent of one another.  For 
example, one patient describes how over the course of the year, her sleep patterns have 
become more irregular, describing how some periods are different to others and the 
unpredictability is a problem for maintaining a schedule. This illustrates the time-
course variability of her sleep (Theme 1 subtheme 2) but also that has an impact upon 
her day-to-day living (Theme 2). Thus one theme may also contribute to others. 
Overall, sleep emerged as a key aspect of the experience of CFS, and its management 
and the effect on daytime functioning was a central preoccupation for all 11 
participants; all of them saw sleep as playing a critical role in either maintaining or 
exacerbating existing symptoms. The themes and incorporated sub-themes are set out 
in the following sections, and a schematic of the cyclic nature of these themes can be 
seen in Figure 3.1. The nature of sleep problems and their frequency in the patient 
group are also illustrated in Table 3.2.   
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Main Theme Associated  
Sub-themes 
Illustrative quotes 
 
Sleep Disturbances 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variation between 
individuals*  
 
*[See Table 3.2 for 
the nature and 
frequency of sleep 
problems across the 
sample] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variability of sleep 
over illness course 
 
      
 
 
 
 
 
 
 
 
 
 
Disturbers of sleep           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 “I have a lot of problems getting to sleep but it comes in phases” (P5) 
“99% of the time I go to bed and I’m out... I’m out like a light” (P8) 
“Being in bed wide awake and there is no chance of going to sleep, it’s 
just awful.  Hours and hours and hours of it... at least one night a week 
I have no sleep at all” (P7) 
“I’m quite good at going to sleep, but I have a lot of other problems..” 
(P1) 
“I feel I’m sleeping quite a lot but it’s not good sleep if that makes 
sense” (P5) 
“It’s not consistent.. feel like I haven’t had enough sleep and broken 
sleep..” (P1) 
 “I can’t get to sleep and I just have to wait until I get tired.. it’s a 
nightmare” (P11) 
“For me, it’s waking up very very early..waking varies, sometimes it 
could be an hour, others it’s a question of waking up stretching and 
going back to sleep again.. it does vary quite a lot” (P2) 
“I tend to wake up and then just keep going back to sleep for an hour or 
so” (P5) 
 “sometimes I will have very distinct, quite vivid dreams” (P11) 
 
 
“It’s just different on different nights… it varies” (P1) 
“for the last months, perhaps a year my sleep patterns have become 
more and more interrupted and irregular” (P2) 
 “When it [CFS] started, I just couldn’t get out of bed any day” (P9) 
“not sleeping when I want to sleep is a thing that’s hit me at the 
moment…I have periods where sleeping is all I can do” (P7) 
“It’s not like in the past. It used to be one night a week that wasn’t 
constantly disturbed, now I’m having only one night a week where I’m 
awake most of the night, I think I’ve improved” (P7) 
“It was very much in the beginning, as though I had gone to sleep and 
my body had forgotten how to wake up, there was one point at that 
time where I slept for 6 days solid” (P8) 
 
 
“…these temperature fluctuations are quite a problem.. hot flushes 
every two hours or so but at night much worse, this is what wakes me 
up” (P1) 
“..my body temperature can change rapidly.  I can be really hot one 
moment, really cold the next..I can’t sleep if I am cold” (P10) 
“I wake up and I realise that I am frozen.. because I’ve thrown the 
bedclothes off so I must be feeling hot and that’s difficult to regulate 
especially in the winter” (P11) 
“I wake up in a lot of pain during the night, in my body and it’s the 
pain that actually wakes me up” (P3) 
 “I’m always in a lot of pain, I get terrible neck and shoulder pain 
which gets worse through the night” (P4) 
“It’s not great, I wake up at like any noise, I’m always waking up... 
like I’ll say  to my fiancé “Did you hear that?” during the night, he’s 
like “Uh?” whereas I seem to wake up at everything” (P9) 
“..my mind’s quite active as well..I can’t get back to sleep ..I never get 
up when I’m awake at night, because there would be no advantage, the 
only thing that seems to be able to help me, to distract me from it, is to 
just read”(P1) 
 
 
Continued on next page 
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Effect of Sleep on 
Daytime 
Functioning 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Attempts at Coping 
and Sleep 
Management 
          
 
 
 
Maintenance/ 
exacerbation of 
Symptoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impact on quality of 
life and living 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beliefs about impact 
on daytime 
functioning 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balancing activity 
 
 
 
 
 
 
“Sleep is such a big part of the effect on me… sleep is a big factor in 
how I am” (P1) 
“If I haven’t slept well I’m aching before I get up..physically it’s more 
difficult for me..I feel unrefreshed.. very tired, my body is very tired if 
I haven’t slept well” (P1) 
“combination of stress and lack of sleep creates an element of stress in 
me that consequently will cause me to become more confused” (P11) 
“I find I can’t pull my thoughts together, my thinking..muddled and my 
thoughts fuzzy” (P3) 
“I get word salad really badly when I’m tired, I use wrong words or 
can’t think of a word to use” (P11) 
“I feel quite unwell when I wake up, extremely...very, very tired on a 
morning even when I’ve slept ok... my body is very painful and I have 
nausea” (P3) 
 
 
“When I was asleep all the time I hardly spent any time with my 
husband and there was no sense of achievement from the day.” (P7) 
“I was spending 2 or 3 months in bed to get myself back on track to be 
able to take on work again” (P7) 
“having patches of sleep, with lots of awake time in between is a 
dominant part of my life, it’s boring” (P7) 
“When it [CFS] started I couldn’t get out of bed, I stopped going to 
school, my brother had to carry me to the bathroom..” (P9) 
“I haven’t got any energy, I can be bed ridden for days” (P8) 
“the unpredictability of the onset of symptoms, I went on holiday and 
then had to spend a considerable percentage of the holiday in bed” 
(P11) 
“ Because there’s no kind of set pattern, some days I’m just so tired, at 
the minute, the last 4 weeks, I haven’t even picked a book up. I can’t 
even function so I am just like a vegetable. I’ll go to the supermarket 
and I don’t even know what I am putting in the…. Just do the shopping 
and come out and talk about rubbish with the school” (P6) 
 
 
“I would say eight hours, it really affects me if I don't…If I’ve had five 
or six, I can definitely feel that.  I probably get between six and seven, 
but it’s the fact that it’s so broken, it’s also a factor. “(P1) 
“In an ideal world I would like to go back to having around 8 hours 
sleep, I functioned well on that, and providing that pattern wasn't 
interrupted. Now, I am not getting as much...Erm, I function now 
within what I do, with the sleep that I get, erm... just spend a lot more 
time feeling very tired.” (P2)  
“I feel like no matter how much sleep... I never function like a normal 
person would..Like I always, I always wake up tired no matter how 
much I sleep I have. Some nights, if I just have 2 or 3 hours obviously I 
will be a lot worse, but there’s no difference between having like 6 
hours and 12 hours sleep, I still feel just as bad.” (P9) 
“For me, I would say I need 8 hours solid sleep… And I haven't had 
that for years. I'm in bed for about 10 hours, erm... but my actual sleep 
is probably about 6 hours.” (P10) 
 
 
 “I wake up at my own rate, very slowly, I could never burst out of bed 
and run round, that couldn’t happen so it’s a very slow pace and it 
dictates to me whether or not I’m going to be able to shower or dress 
myself” (P8) 
“I will nap between lectures because I am just so exhausted from uni” 
(P9)                                                                              Continued on next page 
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Table 3.1: Sleep-related themes (and associated sub-themes), developed from the 
qualitative analysis 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adaptation & 
accepting disturbed 
sleep 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alternative treatment 
approaches 
 
 
 
 “I find the more active I am, the more chance I have of having a better 
sleep, because if I’m not using the energy the mind is not going to 
switch off” (P10) 
“I stringently pace myself. If I eat the right food, get the right amount 
of exercise, get the right amount of sleep and do this to a fairly 
constant regime, it seems to improve my condition. You must not 
flatten the battery, and it took me a long time to learn that” (P11) 
“You can improve and maximise the situation by management, that’s 
what I’ve done and that’s what my life now consists of, it’s an 
optimised condition” (P11) 
“Everyday, as soon as I come home I have a nap, because I am just 
exhausted” (P7) 
“I try to avoid any form of sleep throughout the day to try to keep that 
night time sleep pattern.. if you can call it that” (P10) 
 
 
 “You just don’t get a decent night’s sleep, so I wake up most mornings 
feeling fairly lousy, but I’ve gotten used to it, you adapt.” (P2) 
“I spent 8 months sleeping on the couch, It’s really hard sharing your 
living space with someone who has to get up on a morning, and it’s a 
big factor. I also now have a stair lift, so there’s the practical aspects of 
being able to go to bed” (P7) 
“I’ve adapted my lifestyle and my thinking and I live within my limits” 
(P11) 
“It’s how I cope with the erm... it doesn’t matter what the day before 
was like..you don’t tend to plan things too much or anything you 
just...... kind of go with it” (P8) 
“[as a family] we’ve learned how to handle and cope with the sleeping” 
(P8) 
 “it’s [not sleeping well] always bothered me, but I’ve put up with it for 
8 years so it’s just a part of my life now, I’m not going to sleep” (P9) 
“It’s accepting it and being willing to try” (P10) 
 
 
“I empty my head before going to bed, if I have worries or stress on my 
mind – I tend to write it down” (P10) 
“I have learned some techniques, like to use positive thinking, like my 
bed is really comfortable…” (P1) 
“when I wake up, sometimes if I read it helps” (P1) 
“I’ve got a homeopathic kit.. I use the Bach Flower Olive remedy for 
sleep” (P6) 
“I’ve actually almost been prescribing myself sleep.. feeling recovered 
after sleeping” (P7) 
“I use lavender spray on my wrists and pillows, it works for me. I’ve 
got CD’s with nature sounds and whale sounds, I try counting 
backwards [sighs]. I throw the whole lot at it [sleep]” (P7) 
“I do a lot of meditation, to switch [my] mind off. When lying in bed 
it’s time to switch everything off. I use relaxation exercises and shut 
my body down and relax” (P11) 
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SOL, sleep onset latency; WASO, wake after sleep onset 
 
Table 3.2: Nature and frequency of sleep problems and factors that disturb sleep in the sample of patients (N = 11)
 Frequency in 
group 
N (%) 
 
P1 
 
P2 
 
P3 
 
P4 
 
P5 
 
P6 
 
P7 
 
P8 
 
P9 
 
P10 
 
P11 
 
Sleep Continuity Problems 
 
            
       SOL problem 
 
4 (36.4%)            
       Frequent   
       Awakenings/Broken 
       Sleep 
 
9 (82%)            
       WASO 
       (long duration) 
 
3 (27.3%)            
       Extended sleep  
       duration 
 
3 (27.3%)            
       Short sleep duration 
 
6 (54.5%)            
       Waking too early 
 
6 (54.5%)            
       Napping 
 
6 (54.5%)            
 
Sleep Disturbers 
 
            
       Vivid dreaming 
 
4 (36.4%)            
       Mentally Alert  
       (during sleep) 
 
5 (45.5%)            
       Temperature 
 
5 (45.5%)            
       Pain During Sleep 
 
 
5 (45.5%)            
 
Changes over course of 
illness 
 
10 (90.9%) 
                     
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Theme 1: Sleep Disturbances 
 
“I feel as though I sleep deeply but feel dreadful the next morning, as if I’ve 
never been to bed.” (P3) 
 
A key overarching theme that was developed from the interviews was ‘Sleep 
Disturbances’. This theme has three sub-themes that emerged across the sample of 
patients: 1.Whilst sleep was universally disturbed, for each person the nature of this 
disturbance was different. We have called this theme "variation of sleep between 
individuals". 2. For every patient sleep was not a stable phenomenon, rather the pattern 
of sleep disturbance had changed over the illness time course. We have called this 
theme "variability of sleep over the illness course". 3. Finally, the factors that disturbed 
sleep were a recurring theme - "the disturbers of sleep". These themes are summarised 
in Table 3.2 where we can see the unique "Sleep fingerprint" for each individual, the 
nature and frequency of sleep disturbers by patients, and the number of patients 
reporting change over time. We will now explore these themes in more detail.  
 
 
Variation between individuals 
 
Evident through the differing narratives, each patient had their own unique experience 
of sleep. This emerged through the different kinds of sleep problems being described 
by each patient. Despite this variability between patients in the types of problems 
identified, there were also complaints that were more common than others (see Table 
3.2 for the nature and frequency of sleep complaints experienced by patients). Each 
patient however, considered their sleep-related problems to have a significant bearing 
on their lived experience of CFS and overall quality of life (discussed in a later theme). 
Examples of the nature of sleep continuity problems observed across the patient group 
are described below.  
 
Difficulties getting to sleep (Sleep Onset Latency (SOL) problem) (4/11; 36.4%); 
 
“it usually takes about 1 hour to an hour and a half when I first go to bed” 
(P9) 
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“I have a lot of problems getting to sleep but it comes in phases” (P5) 
 
“Being in bed wide awake and there is no chance of going to sleep, it’s just 
awful.  Hours and hours and hours of it... at least one night a week I have no 
sleep at all” (P7) 
 
For other patients, there were no latency-related issues: 
 
“99% of the time I go to bed and I’m out... I’m out like a light” (P8) 
 
  “I’m quite good at going to sleep, but I have a lot of other problems..” (P1) 
 
 
Frequent awakenings/broken sleep (9/11; 82%); 
Most patients interviewed also regarded their sleep as broken, with the experience of 
frequent awakenings: 
 
“I get it so rarely all in one go.. having broken sleep affects the quality of it, 
you don’t hit the full sleep cycle” (P7) 
 
“I never get through a night without waking up…it’s at least six times.. 
because I don’t get into a deep sleep” (P10) 
 
“It’s not consistent.. feel like I haven’t had enough sleep and broken sleep..” 
(P1) 
 
“A good night - where I have actually been in bed for 10 hours - depends on 
how many times I have been awake in-between those 10 hours” (P10) 
 
“I don’t think I sleep longer than two hours at a time, ever”(P1) 
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Wake after sleep onset (WASO) (3/11; 27.3%) 
A long duration of wake time throughout the sleep period was problematic for three 
patients:  
 
“I can be awake from an hour to up to 4 hours 5 hours” (P4)   
 
“I spend most of the night awake… it does hit me maybe one night a week, one 
night of sleep that wasn’t constantly disturbed through exhaustion and now I’m 
having one night of being wake most of the night” (P7) 
 
 
Short sleep duration (6/11; 54.5%) 
Six patients considered their sleep duration to be too short: 
 
“I think I need about 8-9 hours and I only get probably on average about 5 
hours, so it is quite a bit less than I think I need” (P4) 
 
“I was just sleeping a couple hours here and a couple of hours there.  That’s 
more of the pattern, sleeping for a couple of hours, an hour and a half, two 
hours; awake for a few hours, asleep for a few hours 24 hours a day” (P10) 
 
 
Extended sleep duration (3/11; 27.3%) 
Three patients recounted how their sleep was long or had extended periods of sleep: 
 
“Sleep is a thing that’s hit me at the moment and I tend to have periods when 
sleeping is all I can do.  When I’m sleeping all of the time it doesn’t matter how 
much I sleep, I just want to sleep more” (P7) 
  
“I can continue that for a good 12 -14 hours, that’s the norm.  It has been 
longer and it can go on for days. Erm... when I haven’t got any energy I can be 
bed ridden... like say this week for example, I was in bed on Monday afternoon 
and I got out yesterday [Wednesday] afternoon more or less” (P8) 
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“At the minute I feel like I do need 12 hours a night. I feel I really do, or my 
body will suffer” (P6) 
 
 
Waking too early (6/11; 54.5%) 
More than half of patients considered themselves to be waking up too early: 
 
“For me, it’s waking up very very early..waking varies, sometimes it could be 
an hour, others it’s a question of waking up stretching and going back to sleep 
again.. it does vary quite a lot” (P2) 
 
“…for the past few months it has been the same thing…waking up very early, 
well early for me, so waking up at 5.30 or 4am in the morning, it is rarely that I 
would be asleep after that”. (P2) 
 
“Recently the last like couple of months I’ve been waking up about half an 
hour before my alarm” (P9) 
 
“Wake up time varies, it varies between sometimes I wake up between 4-5am in 
the morning” (P11) 
 
The variability of sleep problems between the patients is significant, In short, it 
highlights the heterogeneous nature of sleep in CFS and how for each patient, there is 
the experience of a different manifestation of sleep-related problems.  What also 
emerged was that the nature of the sleep disturbance pattern changed over time for 
most patients. We explore this theme next.  
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Variability of sleep over the illness course  
 
“It was very much in the beginning, as though I had gone to sleep and my body 
had forgotten how to wake up, there was one point at that time where I slept for 
6 days solid” (P8) 
 
This was the single most consistent theme across the data, the fact that sleep changed 
over the illness course. ‘Time course changes’ was identified by all but one patient in 
this sample (10/11; 90.9%).  
 
For each individual patient, they felt that throughout the entire course of their illness 
(i.e. prior to CFS, illness onset, over the illness course, up to the present time point), 
their experience of sleep-related problems, including the severity and the extent to 
which they impact upon other symptoms, has been highly variable and unpredictable. 
Many patients reflected upon “the beginning” or the early stages of their illness, a 
point at which they felt their sleep was highly disturbed. Patients on the whole 
considered their sleep to be different to how it had been before their CFS: 
 
“It’s [sleep] totally different.  Before this started every morning I was up at 5 
o’clock, out into the fields walking my dog. You know prepare for work, go to 
work.  I probably had around 6 hours sleep and felt absolutely fine (P3) 
 
“It used to be [before CFS] 6 hours, 7 hours sleep, no bother...no bother at all. 
Now, I’m in bed 10 hours, erm, but actual sleep is probably about 6 hours 
because of all the disturbances and that’s just my mind and my body. I don’t 
get solid sleep like I used to, I think getting by on such little sleep has had that, 
you know, effect of running on empty and me having no fuel…it’s led to the 
complete mental and physical breakdown of exhaustion” (P10) 
 
“My daughter had a sleep over and I wanted to try to stay awake for the simple 
reason... well... I couldn’t believe it because I even fell asleep within the first 
10 minutes of that going on downstairs.. which you know, wouldn’t happen to 
me.  So there is an abnormality definitely formed in my sleeping, whatever it is, 
I do not know” (P8) 
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Interestingly, the sleep-related problems being experienced by patients were 
changeable across the illness trajectory (longer term), but also highly variable from one 
day to the next: 
 
“It was very much in the beginning, as though I had gone to sleep and my body 
had forgotten how to wake up, there was one point at that time where I slept for 
6 days solid” (P8) 
 
“When it [CFS] started, I just couldn’t get out of bed any day” (P9) 
 
“It’s not like in the past. It used to be one night a week that wasn’t constantly 
disturbed, now I’m having only one night a week where I’m awake most of the 
night, I think I’ve improved” (P7) 
 
“I must be sleeping now, differently if I’m remembering my dreams” (P7) 
 
“it’s just different on different nights.. it varies” (P1) 
 
“waking varies, sometimes it can be an hour, others it’s a question of waking 
up, stretching and going back to sleep” (P11). 
 
 
Disturbers of sleep 
 
Having identified and described the nature of the sleep-related complaints experienced 
by patients, there are specific problems described that patients consider highly 
contributory to the actual disturbance of their sleep.  The key sleep ‘disturbers’ to 
emerge from the interviews were; bodily pain, mental alertness/arousals, vivid 
dreaming and temperature problems: 
 
Bodily pain 
The experience of bodily pain during their sleep was a problem for nearly half of the 
sample (5/11; 45.5%): 
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“I wake up in a lot of pain during the night, in my body and it’s the pain that 
actually wakes me up again…I feel very very uncomfortable with the pain in 
my body” (P3) 
 
“Pain…yes, because if I am in one position for more than an hour that’s what 
wakes me up.  I do take er... 60 mg of codeine at night; not for the sleep but to 
try to stay on top of the pain.  Erm, to see if that can get me into a more settled 
sleep, just to take the edge off the pain or the discomfort in order to be able to 
settle” (P10) 
 
“Sleep is a nightmare; I am in so much pain during the night. I sleep, I feel as 
if I sleep in a little ball, tensed up, I don’t relax when I’m asleep and I don’t 
sleep... I go to sleep easily but I wake frequently” (P4) 
 
“I’ll wake up... “Oh God, that really hurts!” I’ve got to move, find a different 
position. Every time I change position I wake up” (P10) 
 
 
Mental alertness/arousals 
Arousability during the sleep period was a factor recounted by many patients  (5/11; 
45.5%). They described that during sleep, they experienced mental alertness, and this 
contributed to a sense of light and unrefreshing sleep: 
 
“It’s like my brain won’t stop.  So whether it’s been hungry or being awake or 
erm, yeah it just seems “Right, that’s what I’m doing right now” it doesn’t 
know what the off switch is” (P7) 
 
“.. You feel as though you’ve been awake which you haven’t ... it’s just the 
sleep is probably not as deep as I would normally have” (P3) 
 
“I would say I wake at least every two hours, but sometimes for a long time can 
be for an hour, or even up to two hours, and then my minds quite active as well, 
I can’t get back to sleep so I might read.  I never get up, I never get up when 
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I’m awake at night, because there would be no advantage, the only thing that 
seems to be able to help me, to distract me from it, is to just read” (P1) 
 
“I wake up at like any noise, I’m always waking up... like I’ll say  to my fiancé 
“Did you hear that?” during the night, he’s like “Uh?” whereas I seem to 
wake up at everything” (P9). 
 
“I’m disturbed, easily woken, like noise, So I must sleep fairly lightly” (P4) 
 
“Every time I change position I wake up, unfortunately I don’t seem to be... you 
know... one of those who can have a restless sleep but not even seem to be 
aware of it. I am!” (P10) 
 
 
Vivid dreaming  
Although fewer patients (4/11; 36.4%) reported experiencing vivid dreaming as part of 
their CFS, they emerged as being a significant problem for these particular patients; 
they regarded them as “horrendous” and “disturbing” (P4) with “difficulty 
distinguishing dream from reality” (P5) and highly significant to their negative sleep 
experience: 
 
“I have horrendously vivid dreams.. the more I sleep, the more it happens, 
troublesome, vivid dreams...the doctor put me on medication to try and get rid 
of these quite disturbing nightmares” (P4)  
 
“Sometimes I have very distinct dreams and what was worrying me about this 
episode … I was getting dreams because I had slept in the afternoon and I was 
getting my dream mixed up with reality” (P11) 
 
“When I wake up it is really hard to distinguish the dream from reality, it 
actually feels as if it has really happened and I can feel the emotions from it” 
(P4) 
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“I get a lot of really messed up dreams that I can’t really remember, but I get 
a lot of weird dreams, you know, when they are with you when you first wake 
up and you get a bit groggy, I have trouble when waking up constantly like 
every few minutes whatever it is telling the difference between what has 
happened when I’m asleep and when I’m awake” (P5) 
 
 
Temperature problems 
Nearly half of patients (5/11; 45.5%) highlighted temperature problems, typical of 
autonomic dysfunction, as a key contributor to their disturbed sleep: 
 
“I wake up and I realise that I am frozen.. because I’ve thrown the bedclothes 
off so I must be feeling hot and that’s difficult to regulate especially in the 
winter” (P11) 
 
“I think what wake me up is the temperature, the heat, and the sweating; I 
wear a cotton nightdress which I try to mop myself with… these temperature 
fluctuations are quite a problem, hot flushes every two hours or so but at night 
much worse, this is what wakes me up” (P1) 
 
“Temperature is another factor...my body temperature can change rapidly.  I 
can be really hot one moment, really cold the next. During the night I am 
exactly the same.  Again, I can’t get to sleep if I am cold” (P10) 
 
 
Daytime Sleep (napping) 
Patients who avoided sleeping during the day described how they were aware of the 
impact such napping on their night-time experience of sleep, and thus considered it to 
be a ‘disturber’ (5/11; 45.45%). This is also discussed as part of Theme 3, under sleep 
management strategies.  
 
“Whenever I have done [nap], because I have been particularly tired, which is 
a rare occurrence.. I always feel dreadful when I wake up” (P2) 
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“My priority is sleeping at night.. so I never nap during the day… it doesn’t 
help what is already a problem for me [sleep].” (P3) 
 
“If I sleep at all during the day…my [sleep] pattern gets worse” (P10) 
 
 
Theme 2: Effect of sleep on daytime functioning 
 
Maintenance/Exacerbation of Symptoms 
 
Patients expressed how the poor quality of their sleep had a significant bearing on their 
daytime symptoms the following day. Bodily pain, confusion and concentration 
problems were shown to be the key symptoms exacerbated by poor sleep. It is clear 
from these patient narratives that sleep quality, symptoms and daytime functioning are 
highly inter-related.   
 
Confusion/concentration problems 
Most patients (73%; 8/11) considered the consequences of their disturbed sleep as 
impacting upon their memory, creating feelings of confusion and affecting their ability 
to concentrate during the day; 
  
“I find depending on how tired I am.. I get word salad really badly when I’m 
tired. I use wrong words or I can’t think of a word to use… I just don’t have the 
energy, the focus and the concentration to you know..” (P11) 
 
“The combination of stress and lack of sleep creates an element of stress in me 
that consequently will cause me to become more confused” (P11) 
 
“Sometimes I get quite tired and for the last few weeks, I might have been 
eating dinner or watching the television and I actually go blank for a few 
moments which is quite an odd experience. I really need to go and get that 
checked out, but sort of blank or dizzy for a few seconds, just a short while” 
(P2) 
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“With exhaustion all of the time, I have with it like this mental fuzziness, this is 
quite difficult because my brain doesn’t work very well so it is quite hard just 
to get my brain to work properly” (P4) 
 
“I find I can’t pull my thoughts together, my thinking...muddled and my 
thoughts fuzzy” (P3) 
  
“...there's a difference in the fatigue of the syndrome and to feeling very tired 
due to a lack of sleep, there is a subtle difference between the two I think. You 
know when you're tired and you know when you're deeply fatigued.  When you 
are deeply fatigued everything is a big effort and when you are tired you are a 
bit dozy obviously and it is a bit harder to concentrate on doing things or 
reading a book or whatever, that's quite hard work.  Concentrating on a book 
for example, or listening to someone talking, trying to explain something to 
you” (P2) 
 
 
Bodily pain/discomfort 
Nearly half of patients (5/11; 45.5%) considered their poor quality sleep to have an 
impact physically in the form of bodily pain: 
 
“If I haven’t slept well I’m aching before I get up...physically it’s more difficult 
for me…I feel unrefreshed… very tired, my body is very tired if I haven’t slept 
well” (P1) 
 
“I wouldn't say that I have any good days... but at the moment on my better 
days when I can get out, I still don't feel well, I don't wake up and think, oh, 
you know ‘I feel fine this morning’, I feel quite unwell when I wake up, 
extremely... very, very tired on a morning even when I’ve slept ok... my body is 
very painful and I have nausea” (P3) 
 
“If I do sleep... it’s not... I don’t ever feel rested from it.  I always just feel in so 
much pain when I wake up, so I don’t know what it would be like to have a 
restful night’s sleep [laughs] I can’t remember what that’s like”(P4) 
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Impact on Quality of Life and Living 
 
“When I was asleep all the time I hardly spent any time with my husband and 
there was no sense of achievement from the day.” (P7) 
 
All patients interviewed emphasised the negative impact of sleep-related complaints on 
their lived experience of CFS, which ultimately affected their quality of life. Patients 
found that their irregular sleep schedules affected their capacity to socialise with 
friends, and by spending long periods of time in bed, not necessarily asleep, this took 
away time spent with family members and the ability to maintain employment status or 
school attendance. These consequences in turn impact upon the illness, with patients 
struggling to address and overcome the social consequences of their condition when 
they barely have the energy to function. 
 
“When sleeping all of the time, it’s as if those days and weeks and months 
never happened.  And sometimes I can’t remember what year it is or how old I 
am because I just feel like I’ve lost so much time, you know?” (P7) 
 
“I was spending 2 or 3 months in bed to get myself back on track to be able to 
take on work again” (P7) 
 
“ ..because there’s no kind of set pattern, some days I’m just so tired, at the 
minute, the last 4 weeks, I haven’t even picked a book up. I can’t even function 
so I am just like a vegetable. I’ll go to the supermarket and I don’t even know 
what I am putting in the…. Just do the shopping and come out and then go and 
talk about rubbish with the school” (P6) 
 
 
Beliefs about impact on daytime functioning 
 
Patients also held beliefs about their sleep and the impact it had on their daytime 
functioning. They highlighted that in order to ‘function’ the following day they 
required a certain amount of sleep; the consensus across this patient group was for 8 or 
more hours. However, it is important to note that patients did not feel they obtained 
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this amount each night, and that it was highly disturbed. They also emphasised how 
their sleep amount varied and was inconsistent and even if they did reach this level of 
sleep duration, they still felt as though they had not slept. It did not matter how much 
sleep was being obtained, the quality was not there and that it was the quality of the 
sleep that affected their functioning capacity the following day: 
 
“There’s no difference between having 6 hours and 12 hours of sleep, I still 
just feel as bad, I never function like a normal person would” (P9). 
 
“I feel I’m sleeping quite a lot but it’s not good sleep if that makes sense” (P5) 
 
“I don’t feel like the length of sleep makes much difference makes any 
difference, it doesn’t matter how much sleep I have time wise, because it 
doesn’t mean the quality is there” (P5) 
 
“In an ideal world I would like to go back to having around 8 hours sleep, I 
functioned well on that, having more sleep would make life better, more 
enjoyable... tolerable, and probably easier to cope with this underlying fatigue 
problem because it must compound upon itself” (P2) 
 
 
Theme 3: Attempts at coping and sleep management 
 
“You can improve and maximise the situation by management, that’s what I’ve 
done and that’s what my life now consists of, it’s an optimised condition” (P11) 
 
 
Balancing Activity 
 
All patients (11/11) described the need to balance their activity as a means of 
managing their energy levels. This formed an integral part of their day-to-day lives, 
and was the focus for all patients. The key to maintaining some quality of life for 
patients was being able to integrate some form of activity or social interaction into 
each day, albeit different levels for different individuals.  
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Over half of patients in the sample described that they also slept during the daytime 
(Napping) (6/11; 54.5%). Patients found by utilising frequent naps during the day, they 
were able to better cope with the demands of that day in terms of physical activities 
and mental demands. Others also felt improvements in mental symptoms such as 
confusion in thoughts and concentration difficulties: 
 
“I will nap between lectures because I am just so exhausted from uni” (P9) 
 
“I sleep during the day, whereas the majority of people I would imagine if they 
had slept that bit during the day, it would keep them awake during the night.  It 
doesn’t happen like that with me it is a constant sleeping.. I just need to do it.. 
to cope.. and do a little more in the day.” (P8) 
 
“I sleep in the afternoon, usually my sleep varies between 20 minutes and 2 
hours and I don’t have a cut off on it…it helps me in my thinking in general…” 
(P11) 
 
“Every day as soon as I come home.. I have a nap, because I am just 
exhausted” (P7) 
 
On the other hand, five patients were very aware that daytime napping was a disturber 
of their sleep at night (described previously under Theme 1) and made a conscious 
effort to avoid doing it, a strategy for sleep management. These differences between 
patients demonstrate the heterogeneity in the group; some using the napping as a 
strategy to help with their energy levels, whilst others avoiding doing so – aware that it 
was a key disturber of their sleep at night: 
  
“I do not nap during the day, I've always hated that... that may well be because 
whenever I have done, because I have been particularly tired, which is a rare 
occurrence.. I always feel dreadful when I wake up” (P2) 
  
“I try to avoid any form of sleep throughout the day to try to keep that night 
time sleep pattern... if you can call it that” (P10) 
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“I never want to get into a habit where I nap during the day I would rather... 
my priority is sleeping at night really” (P3) 
 
 
One patient considered their night-time sleep to be improved if they increased the 
activity levels in the day, stating “if I am not using the energy then the mind is not 
going to switch off” (P10). Patients also described the need for a “dozing” period after 
waking, and once awake the slow and paced routine that would help them to get 
through the day ahead. Through attempts at coping and overall lifestyle management, 
patients describe how “you can improve and maximise the situation by management: 
 
“I stringently pace myself. If I eat the right food, get the right amount of 
exercise, get the right amount of sleep and do this to a fairly constant regime, it 
seems to improve my condition. You must not flatten the battery, and it took me 
a long time to learn that” (P11) 
 
“I know I’ve got to find a balance again and get the juicing back… 3 times a 
week and the food right, that keeps my health right and my brain works better” 
(P6).  
 
“I wake up at my own rate, very slowly, I could never burst out of bed and run 
round, that couldn’t happen so it’s a very slow pace and it dictates to me 
whether or not I’m going to be able to shower or dress myself” (P8) 
 
These examples demonstrate how patients consider the balance of activity for 
regulation of both physical and mental energy as vital in their day-to-day living, with 
the utilisation of sleep-specific means to deal with anticipated lifestyle demands. 
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Adaptation & Accepting Disturbed Sleep 
 
“You just don’t get a decent night’s sleep, so I wake up most mornings feeling 
lousy, but I’ve gotten used to it, you adapt” (P2). 
 
A key element to emerge from the interviews with patients was that over the course of 
their illness they had learned, to varying extents, to adapt their lifestyle and accept 
their limitations, and this acceptance and adaptation also occurred around sleep 
problems.  
 
Patients described how they “live within [my] limits” and “have adapted [my] 
thinking” (P11), as a way of coping with the condition. Others have adapted their 
homes, for example one patient described how she “spent 8 months sleeping on the 
couch and now has a stair lift, so there are the practical aspects of being able to get to 
bed”(P7). Patients also made attempts at modifying their diet, for example P6 
expressed how she had cut dairy from her diet completely, which had beneficial effects 
on energy levels and also resulted in helping sleep initiation difficulties she was 
experiencing.  
 
As a means of coping, an integrative theme that was evident across the patient group 
was a sense of acceptance, and this was particularly true with regard to the sleep 
problems they were experiencing as part of their CFS. “I’ve put up with it [not 
sleeping well] for 8 years, so it’s just part of my life now, I’m not going to sleep” (P9). 
Acceptance was even expressed on a family level “[as a family] we’ve learned how to 
handle and cope with the [problems] sleeping” (P8). This depicts how perhaps over 
time, patients adjust to the symptoms they experience, sleep problems being the 
example here, and as a consequence, accept that they play a part of their illness 
experience, so learn to live with it. 
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Alternative Treatment Approaches 
 
“I’ve actually almost been prescribing myself sleep… feeling recovered after 
sleeping. I use lavender spray on my wrists and pillows, I’ve got CD’s with 
whale and nature sounds and I try counting backwards – I throw the whole lot 
at it [sleep]” (P7) 
 
The use of alternative treatments was a common integral theme for sleep-management 
strategies utilised among many participants in the study. Patients identified how they 
resort to approaches such as homeopathic remedies (e.g. “I’ve got a homeopathic kit.. I 
use the Bach Flower Olive remedy for sleep” (P6)), methods of relaxation (e.g. “I do a 
lot of meditation and use relaxation exercises to shut my body down and relax” (P11)), 
and practice general sleep hygiene, techniques to promote better sleep (e.g. “I empty 
my head before going to bed, if I have worries or stress on my mind – I write it down” 
[P10]). It is evident from the interviews that patients have a good awareness of sleep 
hygiene and many put into practice the appropriate measures to maximise the potential 
for good sleep opportunity.  
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Figure 3.1: Cycle of themes and associated sub-themes, developed from the qualitative analysis
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3.4 Discussion 
The study aimed to understand the nature and severity of sleep disturbances 
experienced by patients with CFS by examining a sample of patients with the 
condition using qualitative methods, in particular a critical realist approach which 
ensured that patients experience and understanding was at the centre of the results 
rather than pre-existing coding frames or any analytic preconceptions. 
 
Overall, there were three key findings. Whilst sleep was disturbed in all patients, the 
nature of the disturbance was highly individual, changed over the course of time and 
was caused by a cycle of multiple factors. Secondly, sleep was universally seen as 
impacting on daytime functioning and symptoms. Finally, the attempts to manage 
sleep formed a considerable part of the emotional and physical "work" of coping with 
CFS.  
 
The variability of sleep patterns within and between individuals mirrors a recent 
exploratory study that highlighted the changeable nature and progression of CFS over 
the illness trajectory (Anderson et al., 2012). This provides qualitative corroboration of 
what was observed in the literature review – that sleep problems might be highly 
heterogeneous in CFS. Further qualitative work with CFS patients when focussing on 
their sleep may wish to identify the different sub-groups of sleep-related complaints 
prior to the study. This could offer a deeper and more representative insight into 
specific types of sleep complaints presenting in this population. Future research should 
also consider illness length when examining the role of disturbed sleep in patients, 
particularly in light of the variability in length of illness in the current sample. The 
length of illness may not necessarily reflect illness severity, but it should be 
highlighted nevertheless. We will further explore the heterogeneity of sleep in CFS in 
Chapter 5. 
 
The ‘sleep disturbers’ that emerged from the patient accounts mirror the causes of 
waking (temperature fluctuations, pain and vivid dreams) identified by a study that an 
examined self-reported sleep, fatigue and disability in CFS patients (Morriss, Wearden 
& Battersby, 1997). Interestingly, such disturbances appear related to the 
psychophysiological processes (HPA/physiological arousal, cortical arousal, 
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emotional/autonomic arousal), and the dysregulation of these self-regulatory biological 
systems that has been postulated as being important in the maintenance of CFS (see 
Tomas, Newton & Watson, 2013 for a review). As such temperature dysregulation, 
pain sensitivity and nocturnal mental alertness and vivid dreams may be reflections of 
underlying dysregulation of homeostatic mechanisms. This could be reflecting the 
interaction between the sleep homeostat and circadian phase marker regulation. These 
dysregulations disturb sleep, causing more daytime symptoms and further attempts at 
self-regulation. Such a vicious cycle may be involved in the perpetuation of the 
condition. 
 
The thematic findings build upon previous qualitative work that describe coping 
experiences and the social impact of CFS (Hart & Grace, 2000; Larun & Malterud, 
2007; Whitehead, 2006), and illness course and progression (Anderson et al., 2012). 
However, this study offers a deeper insight into sleep-specific issues faced by patients, 
one of the key symptoms experienced as part of the illness (Anderson et al., 2012), and 
how sleep relates to the overall experience of their condition. Importantly, not only did 
this study highlight that sleep problems were evident in these patients, but more 
precisely that they contributed substantially to the weight of the illness burden. 
Chronic illness can be seen as a biographical disruption and part of that disruption is 
the new workload of managing the illness and the responsibility of being a patient that 
the illness entails (Bury, 1982). Sleep-management was "work" for these patients, part 
of the more general work of energy management and pacing, and formed a central part 
of the daily coping strategies that ultimately helped them live with their condition. 
 
3.4.1 Clinical implications & future directions 
Disturbed sleep is common in CFS and like other symptoms experienced in this 
condition, the way in which the sleep disturbances present and their intensity is highly 
variable between patients, and also within the same patient across their illness path. 
Despite the differing narratives regarding the role of sleep in CFS, all patients held the 
belief that sleep was central to their wellbeing and had a direct bearing on the course 
and progression of their CFS. The sleep-related themes identified above should not be 
viewed as individual categories, but rather as factors that reinforce one another, and 
thus may serve to maintain other symptoms of the condition, even the CFS itself. 
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Working out the “sleep fingerprint” of each patient through detailed assessment can 
then lead to tailored therapies, individualised for each patient. This indicates a 
potential way forward for implementing genuinely stratified medicine, an avenue that 
is becoming increasingly favoured in the CFS research domain.  
 
In terms of research, utilising qualitative methodology in CFS sleep research affords 
the exploration of sleep-specific patient insights and experiences in greater depth. The 
patient insights and experiences that emerged from this study highlight the importance 
of drilling down into parts of the CFS experience, and a similar approach could be 
used around other specific parts of the illness experience. This in turn could help 
inform and guide clinicians and researchers working with CFS patient groups.  
Certainly it seems to be that further investigation, both objective and subjective, of the 
role of sleep disturbances on maintaining and/or exacerbating existing symptoms in 
CFS is warranted.  
 
3.4.2 Conclusion 
All patients in this study made attempts to implement ways of managing their sleep 
problems, yet all patients still regarded their sleep as in some way “broken” and in 
need of management/repair. The impact of broken sleep contributes to the cycle of  
biopsychosocial interaction that may serve to maintain this illness. The study 
highlights a need to go into more depth with the sleep difficulties faced by this patient 
group, and work with patients at an individual level during treatment. In terms of the 
current research programme, this study has informed the systematic development of a 
detailed sleep characterisation and intervention study, and in the coming chapters we 
will describe how we utilised a range of quantitative and self-report assessment 
methods to address the inconsistencies in existing sleep studies with CFS patients, and 
work towards developing a tailored sleep-treatment intervention. However, all of this 
work would not have been possible without first listening to what the patients had to 
say about sleep. 
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CHAPTER FOUR                                                                                                       
AN EXAMINATION OF SELF-REPORTED SLEEP IN CHRONIC FATIGUE 
SYNDROME: THE ASSOCIATION BETWEEN SLEEP QUALITY AND 
DAYTIME PHYSICAL AND MENTAL FUNCTIONING  (STUDY 2) 
 
 
This chapter was presented at the UK Society for Behavioural Medicine (UKSBM) 
Annual Scientific Meeting, 2013, Oxford: 
Gotts, Z. M., Ellis, J. G., Brannan, K., Newton, J. L., & Deary, V. (2013). Daytime Napping 
Impairs Cognitive Functioning in Chronic Fatigue Syndrome (CFS), 76. 
 
 
4.1 Introduction 
CFS, characterised by intense fatigue which affects both physical and cognitive 
functioning (Fernandez, Martin et al. 2009), is also associated with cognitive and 
affective symptoms including: poor memory and concentration, anxiety, depression, 
sleep disturbances and mood swings (Afari and Buchwald 2003).  Whilst fatigue is the 
principal complaint of this complex illness, this is closely followed by sleep 
disturbance which is also a cardinal feature of CFS.  A study by Togo and colleagues 
found that patients with CFS felt more sleepy and fatigued after a night’s sleep 
compared to controls. This was shown to be primarily due to a decrease in the length 
of periods of uninterrupted sleep in patients with CFS compared to healthy controls 
(Togo et al., 2008).  More specifically, patients tend to report fragmented sleep and 
sleep onset difficulties despite feeling tired (Anderson & Ferrans, 1997), and one study 
found that 61% of patients reported sleep continuity complaints which were 
independent of cognitive functioning, fatigue and psychological wellbeing (Vercoulen 
et al., 1994). Disrupted sleep has been shown to cause fatigue, myalgia and poor 
concentration in healthy volunteers and therefore sleep disruption may be not just a 
consequence but also a cause of the other symptoms in patients with CFS (Morriss et 
al., 1993).  
 
Daytime sleep, or napping, has been shown to have a negative impact on nocturnal 
sleep in non CFS populations. For example a long nap or a nap taken later in the day or 
early evening has been shown to have a detrimental effect on the length and quality of 
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sleep during the subsequent night, by decreasing homeostatic pressure (Karacan et al., 
1970; Feinberg et al., 1985; Dijk et al., 1989; Werth et al., 1996).  
 
Disrupted sleep may serve to complicate the course of CFS by worsening existing 
symptoms. Even if sleep complaints are common in CFS, existing studies of self-rated 
sleep and its association with daytime functioning and disability are limited. Findings 
show sleep complaints are associated with greater global disability and that sleep 
continuity complaints become worse when the underlying condition and fatigue 
worsen (Morin & Barlow, 1993). Sleep disturbances form a key dimension of CFS 
(alongside others such as social functioning, psychological wellbeing and functional 
impairment) (Vercoulen et al., 1994), and CFS patients report more naps and restless 
legs than healthy controls (Morin & Barlow, 1993). However, studies have not directly 
examined self-reported sleep and its impact on daytime physical and mental 
functioning in CFS, nor have they looked at the impact of daytime napping in this 
population.  
 
Importantly, there are methodological limitations in existing studies. These include 
taking measures of sleep disturbance based on self-rated presence or absence of sleep 
problems (Morin & Barlow, 1993); not defining the duration of sleep complaints 
(Vercoulen et al., 1994); having a limited range of complaints (Vercoulen et al., 1994; 
Morriss, Wearden & Battersby, 1997); or examining sleep related complaints lasting 
only one night (Morriss, Wearden & Battersby, 1997). These limitations make the 
generalizability of this research problematic, and none of these studies meet the 
standard for sleep assessment - 14-day consecutive sleep diaries – which is needed to 
afford appropriate characterisation of patient’s sleep patterns. The present study 
therefore aims to utilise this standard sleep assessment to examine self-reported sleep 
in CFS, and to establish whether disrupted sleep continuity and daytime napping 
predict markers of daytime functioning, specifically fatigue severity, sleepiness and 
cognitive dysfunction.  
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4.2 Methods 
4.2.1 Subjects  
A power calculation (significance level of 0.05 and statistical power of 80%) was 
performed to estimate participant numbers. In order to detect the smallest change of 
clinical relevance, a sample size of 87 subjects was required. A consecutive sample of 
one hundred and eighteen patients (allowed for a 10% drop out rate), referred to the 
Newcastle-upon-Tyne Royal Victoria Infirmary who fulfilled the Fukuda diagnostic 
criteria for CFS (Fukuda et al, 1994), and had been screened by a specialist physician 
for any medical and mental illness which could explain their fatigue, as per the UK 
NICE (British National Institute for Health and Clinical Excellence) Guidelines for 
CFS (NICE, 2007). The study was approved by the Newcastle and North Tyneside 
Local Research Ethics Committee, all subjects provided written informed consent and 
the Newcastle Hospitals NHS Foundation Trust sponsored the study.  
 
4.2.2 Procedure 
Subjective assessments 
Subjective sleep was assessed using a 14-day sleep diary (Krupp et al., 1991) 
(Appendix D). Patients were required to complete the diary on waking each morning. 
Patients recorded the times at which they retired to bed, identified time of lights out, 
the number of nocturnal awakenings, time of morning awakening, the number, 
duration and timing of daytime naps, alcohol and caffeine consumption, and 
medication use. Patients returned the completed diaries and data were averaged across 
the number of days completed (Mean completion 14 ± 0 days) for each participant. 
The following sleep continuity variables were calculated; Time in Bed (TIB), Total 
Sleep Time (TST), Sleep Onset Latency (SOL), Wake After Sleep Onset (WASO), 
Number of Awakenings (NWAK), and Sleep Efficiency (SE). To characterise patient’s 
napping behaviour, an overall duration of daytime napping was calculated in minutes, 
including duration of napping that occurred in the morning (AM napping) and 
afternoon-evening (PM napping) period, on average across the 14 days. (Descriptions 
of sleep variables are detailed in table 4.1). 
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Functional and symptom assessment tools 
On commencing the study, patients completed a series of assessments, each of these 
were completed once. Levels of daytime sleepiness were determined by the Epworth 
Sleepiness Scale (ESS) (Appendix E). Patients self-report their chance of dozing or 
sleeping based on 8 given situations. The responses are made on a Likert-type scale 
ranging from 0 (would never doze/sleep) to 3 (high chance of dozing/sleeping) Total 
possible scores derived from the 8 questions range from 0-24, with a score of 10 or 
more being indicative of significant daytime sleepiness (Johns, 1991). 
 
The 11-item Chalder Fatigue Questionnaire (CFQ) evaluated fatigue severity. It is one 
of the most widely used measures for assessing physical and mental symptomatic 
fatigue experienced by CFS/ME patients. Four response options are available, ranging 
from ‘‘less than usual’’ to ‘‘much more than usual’ The Likert system for scoring was 
used (0, 1, 2, 3), with a total possible score ranging from 0-33. A higher score indicates 
more fatigue.  The test has been shown by its authors to have good reliability (r =.86 
for physical fatigue, and r =.85 for mental fatigue) and has high internal consistency as 
measured by Cronbach’s alpha (.89) (Chalder et al., 1993) (Appendix F).  
 
Cognitive functioning was assessed using the Trail Making Test (TMT) (Appendix G). 
The TMT is a task designed to measure visual attention and task switching and 
requires participants to connect-the-dots between 25 consecutive targets on a sheet of 
paper. In version A of the test all of the targets are numbers. In version B, targets 
alternate between numbers and letters (1, A, 2, B). The time it takes to complete the 
task is the measure of performance, with longer time indicating poorer cognitive 
performance (Reitan, 1958). 
 
Patients completed the 25-item Cognitive Failures Questionnaire (CFQ) (Appendix H, 
a tool developed by Broadbent (Broadbent et al, 1982) to assess self-reported deficits 
in attention, perception, memory and motor functioning. The questionnaire measures 
the frequency of everyday cognitive failures or lapses by asking participants to rate 
how often they make mistakes on a 5-point Likert scale, from 0 (never) to 4 (very 
often). The total possible CFQ score ranges from 0-100, with higher scores indicating 
more cognitive failures. 
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To control for the impact of anxiety and depression on daytime functioning, patients 
completed the 14-item Hospital Anxiety and Depression Scale (HADS) (Appendix I), 
7 items provide a measure of anxiety and 7 a measure of depression (Zigmund & 
Snaith, 1983). For both Anxiety and Depression scales, raw scores between 8 and 10 
identify mild cases, 11-15 moderate cases and 16 or above, severe cases. 
4.2.3 Statistical analysis 
The data were analysed with SPSS (IBM 19.0). First, descriptive statistics for CFS 
patients’ self-reported sleep variables and napping were calculated. HADS variables 
were also compared with published data of a reference sample (Crawford et al., 2001). 
Second, Multiple Regression analyses examined the extent to which self-reported sleep 
and napping predicted patient’s daytime physical and mental functioning, fatigue 
severity and sleepiness. Step one of each model incorporated patient characteristics 
(age, gender, length of disease), step two consisted of the mood variables of anxiety 
and depression (from HADS), and step three contained the subjective sleep parameters 
(SE, NWAK, WASO, SOL, napping duration), TIB and TST were not included in the 
models as together these variables make up SE. Daytime symptoms measured by 
fatigue severity (Chalder Fatigue Scale), daytime sleepiness (ESS) and objective and 
subjective cognitive functioning (Trail Making Test, Cognitive Failures Questionnaire) 
were included as dependent variables in each analysis, respectively, and checks for 
multicollinearity were carried out.   
Notes: REM, rapid eye movement; TSP, total sleep period; TST, total sleep time 
 
Table 4.1: Description of sleep variables included in study 2 
Abbreviated 
Variable 
Sleep Variable  
(measure) 
Description 
 
TST 
 
Total Sleep Time 
(minutes) 
 
 
Amount of time asleep 
 
SOL Sleep Onset Latency 
(minutes) 
Length of time from lights out to first onset of sleep 
 
WASO Wake After Sleep Onset 
(minutes) 
Number of minutes of recorded wake following first onset 
of sleep 
 
NWAK Number of Awakenings 
(over TSP) 
Number of wake bouts following first onset of sleep 
 
SE (%) Sleep Efficiency Percentage of time spent asleep from the amount of time 
spent in bed (TST/TIB*100) 
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4.3 Results 
Of the 118 diaries returned by patients, 17 had missing data so 101 were used in the 
analysis. The final sample therefore consisted of 101 patients with an average length 
since diagnosis of 7.8 years (±7.34). The mean age of the sample was 42.05 (±12.99), 
range 16 - 68 years, and 81.2% were female.  
 
21 (20.8%) patients in the sample did not report any daytime napping throughout the 
14-day period. Of the 80 (79.2%) that did nap, on average napping duration was 39.55 
(±55.35) minutes. Patients spent on average 7.80 (±16.03) minutes napping in the 
morning period (AM), and 31.74 (±43.94) minutes napping in the afternoon-evening 
period (PM). (The mean values for all sleep and functioning variables of the study, 
including demographic characteristics are shown in Table 4.2). 
 
The sleep diary data show patients had on average TST of 426.69 (±80.30) minutes, 
SOL of 37.60 (±41.67) minutes, WASO of 50.81 (±43.75) minutes and sleep 
efficiency at 75.74 (±13.64) %, demonstrating values in the abnormal range (Edinger 
et al., 2004).  
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      Notes: N differs on different measures. Data presented as means and standard deviations (SD). 
      HADS, hospital anxiety and depression scale 
 
 
 
Table 4.2: Self-reported sleep, functional & symptom assessment data for CFS patients 
 
 
 
 
 
 N Mean (SD) 
Patient Characteristics   
            Gender M, F [N (%)] 101 M: 19 (18.8%), F: 82 (81.2%)  
            Age 101 42.05 (12.99) 
            Length of Illness [Months] 
 
101 93.69 (88.12) 
Sleep Continuity Parameters   
            Sleep Onset Latency (SOL)  [Minutes] 101 37.60 (41.67) 
            Time In Bed (TIB) Sleep Period [Minutes] 101  569.50 (83.18) 
            Total Sleep Time (TST) Sleep Period [Minutes] 101 426.69 (80.30) 
            Number of Awakenings (NWAK)  101 1.48 (1.14) 
            Wake After Sleep Onset (WASO)[Minutes]  101 50.81 (43.75) 
            Sleep Efficiency (%) 
 
101 75.74 (13.64) 
Daytime Sleep (napping)   
           Total Napping Duration [Minutes] 80 39.55 (55.35) 
           Duration AM Napping [Minutes] 80 7.80 (16.03) 
           Duration PM Napping [Minutes] 80 31.74 (43.94) 
Functional and Symptom Measures   
            HADS Anxiety 101 8.31 (4.62) 
            HADS Depression 101 8.42 (4.10) 
            Chalder Fatigue Questionnaire  101 25.19 (6.31) 
            Epworth Sleepiness Scale 101 9.87 (5.07) 
            TRAIL Making Test [Minutes] 96 135.31 (74.03) 
            Cognitive Failures Questionnaire 89 58.45 (21.14) 
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4.3.1 Fatigue Severity 
For fatigue severity (based on Chalder Fatigue Questionnaire scores), three predictors 
(length of disease, depression, WASO) accounted for 23.7% of the variance. 
Examination of the beta weights in the third model showed that length of disease 
significantly predicted Chalder Fatigue scores, with people who had been diagnosed 
for less time being more fatigued. Having higher depression scores and more WASO 
were the other significant factors (see Table 4.3). 
 
4.3.2 Daytime Sleepiness  
Anxiety was the single determinant of daytime sleepiness and explained 14% of the 
variance in scores on the Epworth Sleepiness Scale. Higher anxiety significantly 
predicted higher scores on the ESS, based on the third model (see Table 4.3).  
 
4.3.3 Cognitive Functioning 
With regards to subjective cognitive functioning, three predictors (gender, anxiety and 
depression) explained 30% of the variance in scores on the Cognitive Failures 
Questionnaire (CFQ). Examination of the beta weights in the third model showed that 
gender significantly predicted subjective cognitive dysfunction, with women reporting 
more cognitive failures than men. Higher scores on anxiety and depression were also 
significant predictors (see table 4.3).  
 
Patients’ Trail Making Test performance (objective cognitive functioning) was within 
the normal range for both TMT part A (mean = 43.79 ± 30.02 seconds) and part B 
(mean 92.83 ± 49.85 seconds) (completion time >78 seconds (TMT A) and > 273 
seconds (TMT B) are indicative of cognitive impairment [Reitan, 1958]). For the 
regression, Total Trail time was used. Two predictors (depression scores and napping 
duration) explained 14% of the variance on TMT performance, based on the third 
model that incorporated the self-reported sleep variables. Examination of the beta 
weights in the third model showed that having a higher depression score and a longer 
duration of overall daytime napping significantly predicted poorer TMT performance 
(longer completion time on the test) (see Table 4.3). 
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Notes: *p < .05, **p < .01, ***p < .001; Entries represent standardized beta coefficients. 
SE, sleep efficiency; NWAK, number of awakenings; WASO, wake after sleep onset; SOL, sleep onset latency 
 
Table 4.3: Hierarchical regressions for the dependent variables; Chalder Fatigue 
Scale, Cognitive Failures Questionnaire, Trail Making Task and Epworth Sleepiness 
Scale. 
 
 
To explore the specific time of day at which napping occurred and determine whether 
this made a difference to performance on the TMT task, a further Multiple Regression 
analysis was carried out. Step three of the model which incorporated the subjective 
sleep parameters was modified to include total AM (morning) napping duration and 
total PM (afternoon-evening) napping duration, in place of total napping duration. 
 Dependent Variable 
 Chalder Fatigue 
Scale  
(N=101) 
Epworth 
Sleepiness Scale 
(N=101) 
Cognitive Failures 
Questionnaire 
(N=89) 
Trail Making 
 Task 
(N=96) 
Variables in the model β t β t β t β t 
         
Step 1         
            Constant  10.11  3.54  5.07  5.03 
            Length of Disease -0.41
**
 -3.27 0.00 0.01 0.13 1.17 -0.03 -0.28 
            Age 0.23
*
 2.22 0.15 1.36 0.08 0.75 0.11 0.99 
            Gender -0.09 -0.96 0.03 0.33 0.09 0.82 -0.24
*
 -2.36 
            Adj. R
2
 0.08  -0.01  0.00  0.03  
            F 4.05
**
  0.75  1.05  2.12  
Step 2         
            Constant  8.04  1.68  2.90  3.32 
            Length of Disease -0.31
**
 -3.20 0.00 0.03 0.12 1.30 -0.01 -0.05 
            Age 0.11 1.06 0.10 0.93 -0.08 -0.84 0.01 0.10 
            Gender -0.00 -0.04 0.09 0.89 0.24
*
 2.48 -0.17 -1.67 
            Anxiety -0.02 -0.17 0.27
*
 2.41 0.33
**
 3.10 0.04 0.31 
            Depression 0.42
***
 3.77 0.11 2.41 0.34
**
 3.02 0.33
**
 2.70 
            Adj. R
2
 0.22  0.09 0.96 0.30  0.13  
            F 6.61
***
  3.05
*
  8.41
***
  3.73
**
  
Step 3         
           Constant  3.38  -0.79  2.40  2.24 
           Length of Disease -0.41
***
 -3.94 0.07 0.59 0.10 0.96 -0.02 -0.20 
           Age 0.07 0.62 0.11 1.03 -0.12 -1.17 -0.03 -0.31 
           Gender -0.01 -0.09 0.11 1.16 0.23
*
 2.37 -0.16 -1.64 
           Anxiety -0.08 -0.68 0.29
*
 2.48 0.32
**
 2.86 -0.02 -0.20 
           Depression 0.45
***
 4.02 0.12 1.04 0.30
*
 2.55 0.35
**
 2.81 
           SE (%) 0.05 0.39 0.20 1.66 -0.17 -1.43 -0.10 -0.80 
           NWAK  -0.18 -1.52 0.07 0.54 0.11 0.88 -0.11 -0.85 
           WASO (min) 0.34
**
 2.47 -0.09 -0.58 -0.02 -0.11 0.01 0.08 
           SOL (min) -0.03 -0.28 0.02 0.18 0.01 0.08 -0.05 -0.46 
           Total Napping (min) -0.05 -0.55 0.17 1.76 0.06 0.62 0.22
*
 2.19 
           Adj. R
2
 0.24  0.14  0.30  0.14  
           F 4.10
***
  2.57
**
  4.76
***
  2.49
*
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Three predictors (depression scores, AM napping duration and PM napping duration) 
explained 19% of the variance in time taken to complete the TMT. Examination of the 
beta weights in this revised third model indicated that having a higher depression 
score, a longer duration of afternoon napping (β = .49) and less morning napping (β = -
.30) were determinates of poorer objective cognitive functioning (see table 4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: N = 96 *p < .05, **p < .01, ***p < .001; Entries represent standardized beta coefficients 
SE, sleep efficiency; NWAK, number of awakenings; WASO, wake after sleep onset; SOL, sleep onset latency 
 
 
Table 4.4: Hierarchical regression for the dependent variable; Trail Making Task 
(replacing total napping duration with AM and PM napping duration in the model). 
 Trail Making Task 
Variables in the model β t 
 
Step 1 
  
            Constant  5.03 
            Length of Disease -0.03 -0.28 
            Age 0.11 0.99 
            Gender -0.24
*
 -2.36 
            Adj. R
2
 0.03  
            F 2.12  
Step 2   
            Constant  3.32 
            Length of Disease -0.01 -0.05 
            Age 0.01 0.10 
            Gender -0.17 -1.67 
            Anxiety 0.04 0.31 
            Depression 0.33
**
 2.70 
            Adj. R
2
 0.13  
            F 3.73
**
  
Step 3   
           Constant  2.30 
           Length of Disease -0.02 -0.17 
           Age -0.06 -0.54 
           Gender -0.14 -1.39 
           Anxiety 0.00 0.03 
           Depression 0.29
* 
2.36 
           SE (%) -0.11 -0.89 
           NWAK  -0.13 -1.01 
           WASO (min) 0.13 0.81 
           SOL (min) -0.07 -0.63 
           Napping AM (min) -0.30
*
 -2.15 
           Napping PM (min) 0.49
**
 3.41 
           Adj. R
2
 0.19  
           F 3.03
**
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4.4 Discussion 
This study sought to characterize the sleep and daytime napping of patients presenting 
with CFS and the extent to which their self-reported sleep and napping behaviour 
impacted upon the daytime symptoms.  The major findings of this study are: (i) CFS 
patient’s self-reported WASO, SOL and Sleep Efficiency are in the abnormal range, 
but also highly variable, (ii) higher self-reported depression, more WASO and a 
shorter time since diagnosis together explained 24% of patient variance in fatigue 
severity on the Chalder Fatigue Scale, (iii) scoring more highly on depression and 
longer duration of PM napping, with shorter amounts of AM napping explained  14% 
of variance on objectively assessed cognitive functioning (TMT). Being female and 
scoring more highly on anxiety and depression predicted 30% of the variance in self-
reported daily cognitive failures (CFQ); (iv) Patients with higher scores of self-rated 
sleepiness (ESS) were characterised by those who self-reported higher levels of 
anxiety on the HADS, explaining 14% of the variance on the ESS.   
 
4.4.1 The role of sleep in daytime functioning 
The variability in reported sleep may be a reflection of sleep phenotypes in CFS. For 
instance, the mean sleep onset latency was 37.6 minutes but the standard deviation was 
41.67 minutes. As such, whilst the present results are suggestive of the role of 
disturbed sleep in the CFS population as a whole, future work should be mindful that 
the nature of CFS patients’ sleep problems may differ but may fit the characteristics 
for a sleep-specific phenotype. 
 
Given this caveat, sleep still emerges as a significant predictor of impaired daytime 
functioning. Disturbed sleep at night, specifically longer amounts of wake time during 
the sleep period, is significantly associated with daytime fatigue, and longer duration 
of napping during the afternoon-evening period is associated with objective measures 
of daytime cognitive impairment. This would suggest that rather than being “primary 
symptoms” of CFS, daytime fatigue and cognitive dysfunction may in part be 
mediated by disturbed sleep and daytime napping. This in turn would suggest that 
interventions, such as the sleep management strategies that form part of cognitive 
behavioural therapy for CFS, may impact on these symptoms by way of improving 
sleep. Daytime napping is a common target of CFS management interventions. In 
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particular, Cognitive Behavioural Therapy for Insomnia (CBT-I) discourages napping 
during the course of treatment; excessive napping and extended time in bed are 
considered factors that can amplify existing disturbances in night-time sleep by 
weakening the homeostatic sleep drive (Manber et al., 2012). The present study would 
add that daytime napping impairs cognitive function and may lead to a vicious circle 
where such napping causes daytime sleepiness which in turn leads to daytime napping. 
 
4.4.2 The role of other factors 
Overall this study suggests that sleep is only one of the factors that affects daytime 
functioning in CFS as WASO was the only sleep parameter to influence fatigue. The 
other key predictors were scoring higher on the depression scale of the HADS and 
having a more recent diagnosis. The latter is interesting in that it would suggest that 
there is an “acute” phase to CFS, whereby fatigue is higher. This would fit with the 
qualitative study described in the previous chapter, and reports of patients in clinic, 
who frequently mention having learned to adjust to the disease and to pace themselves 
the longer they have it. This has particular implications for early stage treatment 
strategies, which should involve helping people adjust to and manage their condition. 
The depression finding is less easy to interpret. Patients are rightly wary of being 
diagnosed as depressed and the overall means of this group are at the very low end of 
caseness. Overall the most parsimonious interpretation of these results would be that 
fatigue is influenced by multiple factors, and that this study has highlighted that sleep, 
adjustment to illness, and mood may be pieces in the complex biopsychosocial fatigue 
jigsaw.  Again this would also suggest that helping people to adjust and adapt to 
illness, sleep management strategies, and mood management may impact positively on 
daytime fatigue.  
 
Scores on the depression scale, and scores on the anxiety scale, also emerged, along 
with daytime napping, as significant contributors to objective and subjective measures 
of cognitive functioning. Anxiety also emerged as a single predictor of levels of 
daytime sleepiness. Any explanation of this is speculative, but it could be that higher 
anxiety, marked by higher autonomic arousal, may produce more sleepiness.  
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Overall these results suggest the determinates of daytime fatigue severity, sleepiness 
and cognitive functioning in CFS are multi-factorial. Whilst sleep is an important 
determinant, particularly disturbed sleep and daytime napping, other factors are also 
important. As such, any intervention probably needs to consider each factor on an 
individual basis. Whilst one person may benefit from straight forward sleep 
management, another person relatively early post-diagnosis may also need help 
adjusting to the illness, whilst others still may need help with the emotional impact of 
being ill.  As there is no one sleep phenotype, there is no one typical CFS patient. It is 
therefore recommended that at the minimum patients receive an individualised sleep 
assessment by an experienced clinician and a sleep and napping diary. 
 
There are several limitations to this study. The main methodological problems were 
that we largely relied on self-report data. Further, the time of day at which functional 
measures are taken should be considered for future studies, particularly where daytime 
napping occurs, as sleep inertia following a nap may have implications for cognitive 
performance (Groeger et al., 2011). As for objective measures, there was no clinical 
screening, by way of standardised interview for sleep disorders, no multiple sleep 
latency testing (MSLT) to objectively measure daytime sleepiness, and no 
polysomnography (PSG) to objectively measure sleep parameters. Nevertheless, 
subjective reports are a good way to identify the parameters of interest for future 
studies, and they are also what is routinely used in the clinic with CFS patients to 
assess treatment outcomes. Future work should consider a triangulation of subjective 
and objective reports of sleep, fatigue, sleepiness, and daytime functioning, both in the 
lab and in intervention studies. In terms of the latter, the present works suggests that 
sleep interventions merit further study in this population.  
 
In conclusion, disturbances in sleep continuity may serve as a mediator of daytime 
mental and physical dysfunction in CFS. Whilst they need to be considered in the 
context of other factors, it would seem that targeting disturbed sleep and napping may 
improve daytime fatigue and cognitive functioning. Most current interventions in CFS 
are multi-factorial, and so involve sleep management strategies. However to date there 
has been no trial of sleep interventions on their own. The present study would suggest 
that this is an avenue worth exploring.    
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CHAPTER FIVE                                                                                                           
A CROSS-SECTIONAL POLYSOMNOGRAPHY ANALYSIS TO 
DETERMINE SLEEP-SPECIFIC PHENOTYPES IN A SAMPLE OF CFS 
PATIENTS  (STUDY 3) 
 
 
An extended version of this chapter has been published as: 
Gotts, Z. M., Deary, V., Newton, J., Van der Dussen, D., De Roy, P., & Ellis, J. G. 
(2013). Are there sleep-specific phenotypes in patients with chronic fatigue syndrome?  
A cross-sectional polysomnography analysis. BMJ open, 3(6). 
(For the full manuscript see Appendix CC) 
 
5.1 Introduction 
Despite 87–95% of CFS patients reporting sleep difficulties (Hamaguchi et al., 2011; 
Jason et al., 1999; Nisenbaum, et al., 2003; Nisenbaum et al., 2004), previous research 
has been unable to reliably identify specific irregularities in objectively measured 
sleep. Over 30 PSG studies on individuals with CFS exist, however, conclusive 
statements about the type of sleep abnormalities in this population are difficult. Few 
studies report a full characterisation of both sleep continuity (the timing, efficiency and 
amount of sleep obtained) and sleep architecture (amount of each sleep or wake stage 
and the timing of transitions to each sleep stage), with some studies providing no PSG 
data at all (Buchwald, et al., 1994; Creti, et al., 2010; Decker et al., 2009; Fossey et al., 
2004; Kishi et al., 2010; Watson, et al., 2004). Moreover, reporting practices differ 
widely, making interpretation and comparisons difficult (e.g. studies report the 
percentage of each sleep and wake stage as an  index of Sleep Period Time, Total 
Sleep Time (TST) or even Time in Bed) (Manu et al., 1994; Whelton, Salit & 
Moldofsky, 1992; Armitage et al., 2007; Ball et al., 2004; Fischler et al., 1997; Majer 
et al., 2007; Reeves, et al., 2006; Stores, Fry & Crawford, 1998; Van Hoof et al., 2007; 
Watson et al., 2003), while others report the number of minutes spent in each stage (Le 
Bon et al., 2003; Le Bon et al., 2007; Morriss et al., 1993; Sharpley et al., 1997; Togo, 
et al., 2008). 
 
What can be concluded from previous PSG studies is that, in each study, deviations 
from ‘normal sleep’ exist, but there is no consistent pattern. For example, where two 
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studies (Le Bon et al., 2003; Le Bon et al., 2007) report poor sleep efficiencies and 
‘normal range’ REM latencies, others (Armitage et al., 2007; Ball, et al., 2004; Le Bon 
et al., 2007) found ‘normal range’ sleep efficiencies and short REM latencies and yet 
others still report a normal sleep efficiency and a long-REM latency (REML) (Stores, 
Fry & Crawford, 1998) or poor sleep efficiency and long-REM latencies (Togo, et al., 
2008). Moreover, the picture remains unclear after controlling for the severity of 
patients’ self-reported sleep complaints (Guilleminault et al., 2006; Rahman et al., 
2011). Although differences in protocol, definitional criteria and reporting criteria 
may, to some extent, explain these differences, an alternative explanation is that sleep 
difficulties in individuals with CFS are not homogeneous and various sleep phenotypes 
exist in this population.  
 
Symptoms such as unrefreshing sleep may not only be markers of CFS; they may also 
serve to maintain it. For instance, there may be reciprocal links between sleep quality, 
sleep-wake regulation and fatigue. There is evidence of this. For instance, studies have 
shown that adopting activity and sleep management strategies improves HPA axis 
functioning as measured by cortisol levels (Roberts et al., 2004). This suggests that 
further investigation of sleep disturbance of CFS is of more than academic importance 
but may highlight new avenues for intervention. From a clinical perspective, it is also 
important to study sleep more thoroughly in CFS as it may highlight some areas of 
diagnostic ambiguity. For instance, previous studies have shown that sleep disorders 
(notably obstructive-sleep apnoea) are occasionally identified during 
polysomnographic (PSG) assessments with CFS patient cohorts (Buchwald, et al., 
1994; Krupp, et al., 1993; Manu, et al., 1994; Whelton, Salit & Moldofsky, 1992).  
 
To explore the possibility that sleep problems in this population are not homogeneous 
and clarify the specific characterisation of sleep in CFS objectively, the current study 
examined PSG data for a single night of sleep in a large group of CFS patients. The 
aim was to determine whether specific sleep disturbances exist in this group, and if so, 
whether they are consistent across all patients.  
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5.2 Method 
A cross-sectional, single-site observational study was undertaken on a consecutive 
series of 343 patients (mean age 37.21±12.42 years; 72 men and 271 women) referred 
for a single-night PSG study at a fatigue clinic in the Netherlands. The referral criteria 
for PSG investigation were that the patient (1) met diagnostic criteria for CFS 
according to the Fukuda definition, (2) they were drug-free for at least 2 weeks prior to 
the overnight study and (3) their symptoms could not be explained by a physical or 
psychological illness (e.g. anxiety or depression). Patients were interviewed and 
medically screened for the referral criteria by a registered physician and a registered 
psychiatrist. The collection of the PSG data was part of patients’ routine clinical care 
under the management of Pierre de Roy (director, Vermoeidheidcentrum, NL). The 
Ethics Committee for the School of Life Sciences at Northumbria University approved 
the secondary data analyses. 
 
Patients arrived at the clinic 2 hours before normal bedtime for electrode placement 
and biocalibration. The PSG montage comprised a standard 10/20 (i.e. F4-M1, C4-M1, 
O2-M1 and Cz with backups at F3-M2, C3-M2, O1-M2 and Fpz). Additional channels 
were used for electro-oculography (EOG; E1 and E2 referenced to M2), 
electromyography (chin and anterior tibialis placements), ECG, and airflow, effort, 
body position and oximetry (via a pulse oximeter). Filter settings were set to the 
American Academy of Sleep Medicine (AASM, 2007) guidelines (e.g. low 0.3 
Hz/high 35 Hz for EEG and EOG) with a sampling rate of 500 Hz. Impedances were 
maintained below 5 kΩ. Participants slept in the laboratory overnight and were 
allowed to retire to bed when they wished and left to naturally wake in the morning. 
Scoring was conducted manually by a registered BRPT-certified technician at 30 s 
epochs, according to the AASM guidelines. The scorer was blind to the aims of the 
study. The mean recording period was just over 8 h (508.5±63.11 min). Descriptions of 
all sleep variables are detailed in table 5.1. 
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Notes: REM, rapid eye movement; TSP, total sleep period; TST, total sleep time. 
 
Table 5.1: Description of sleep variables included in study 3 
 
5.2.1 Analytic strategy 
A hierarchical cluster analysis was used to determine the number of phenotypes within 
the present sample after excluding those with Sleep Apnoea or Periodic Limb 
Movement (PLM) Disorder. Cluster analysis is a data-reduction technique that 
examines patterns among a set of variables to form homogeneous groups. The 
Euclidean squared distance measure of similarity method was chosen for the cluster 
analysis as it uses the progressive distance between variables to form the 
groups and does not rely upon standardised data. As cluster analysis can be affected by 
multicollinearity, a correlation matrix was used to exclude variables that were highly 
correlated with one another. A one-way analysis of variance (ANOVA) was used to 
examine which of the sleep variables differentiated the phenotypes. 
 
Sleep Variable 
 
Description 
 
Total Sleep Time (min) 
 
Amount of time asleep 
 
Sleep Onset Latency (min) Length of time from lights out to first episode of stage 2 sleep 
 
Wake After Sleep Onset (min) Number of minutes of recorded wake following first episode of stage 2 sleep 
 
Number of Awakenings  
(over TSP) 
 
Number of wake bouts following first episode of stage 2 sleep 
 
Number of Arousals Number of arousals over the entire sleep period 
 
REM Latency Length of time to first REM stage 
 
AHI Index Number of apnea or hypopnea events per hour of sleep 
 
% N1 (of TST) Percentage of recorded stage 1 sleep over the total time asleep 
 
% N2 (of TST) Percentage of recorded stage 2 sleep over the total time asleep 
 
% N3 (of TST) Percentage of recorded slow wave sleep over the total time asleep 
 
% REM (of TST) Percentage of recorded Rapid Eye Movement sleep over the total time asleep 
 
% WAKE (of TSP) Percentage of recorded wake over the whole sleep period (from lights out to 
lights on) 
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BMI, body mass index; AHI, apnoea/hypopnea index; TST, total sleep time; SL, sleep latency; WASO, wake after 
sleep onset; SEI, sleep efficiency index; %N1, percentage of stage 1 sleep; %N2, percentage of stage 2 sleep; %N3, 
percentage of slow wave sleep; %REM, percentage of rapid eye movement sleep. 
 
 
 
Figure 5.1 Study Overview. 
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5.3 Results 
An initial examination of the Apnoea Hypopnoea Index (AHI) and PLM indices 
indicated that 104 (43 men and 61 women) of the original 343 referrals (30.3%) met 
the AASM criteria for either sleep apnoea (AHI≥15; n = 101) or a PLM disorder (PLM 
≥5; n = 17) (14 participants met the criteria for both disorders). The overall sleep 
profile of the remaining 239 patients (mean age 34.4±11.84; 210 women and 29 men) 
was highly variable, indicating the presence of phenotypes (Figure 5.1).  
 
A hierarchical cluster analysis, using Ward’s method, was undertaken to determine the 
number of groups (clusters) within the remaining 239 patients. Prior to the cluster 
analysis, a correlation matrix was examined to avoid multicollinearity influencing the 
cluster model. On this basis, four variables were excluded (height, weight, sleep 
efficiency and number of spontaneous arousals per hour) for having correlation 
coefficients with one or more variables above r = 0.8. The final grouping variables 
included in the cluster analysis were: age, sex, body mass index (BMI), AHI’s, PLM 
index, Number of Awakenings, Number of Arousals per hour, TST, Sleep Latency 
(SL), Wake After Sleep Onset (WASO), percentage of %N1 (stage 1 sleep) of TST, 
%N2 (stage 2 sleep) of TST, %N3 (SWS) of TST, %WAKE of TST, %REM of TST 
and REML. The Euclidean squared distance measure of similarity was used to group 
patients according to the included variables.  
 
There were six clustering iterations overall (going from 8 to 2 clusters). The fourth 
iteration was chosen as the saturation point as it was the point where the agglomeration 
schedule and dendrogram had the highest reduction in the number of groupings (from 
six groups to four groups) while retaining at least 5% of the total sample size in each 
group (i.e. n ≥11). This latter rule was chosen to afford sufficient power for inferential 
data analysis to occur. A one-way ANOVA was undertaken on the four groups to 
determine which sleep variables significantly differentiated the groups. There were no 
overall differences between the groups on age (p = 0.12) or BMI (p = 0.48). On 
inspection of the sex frequencies in each group, there was a higher ratio of men to 
women in the first group compared with the other three groups. However, as two 
groups contained less than five men, this could not be tested statistically. In relation to 
the polysomnography variables, there were no group differences in the number of 
91 
arousals per hour or AHI index scores (PLMs were not included as less than 10% of 
the total sample had a PLM index), but significant differences were observed on all the 
other sleep variables (table 5.1). 
 
5.3.1 First phenotype 
The first phenotype comprised 14 patients with the longest Sleep Onset and REMLs 
and the highest percentage of SWS. Moreover, this group had the lowest percentages 
of both stage 2 sleep and REM sleep. Statistically; this phenotype differed from the 
other three groups in terms of longer Sleep Onset and REMLs and a lower percentage 
of REM. 
5.3.2 Second phenotype 
The second phenotype comprised 55 patients with the highest percentage of stage 2 
sleep and the highest number of arousals per hour, although neither of these variables 
statistically separated them from the other three phenotypes. 
5.3.3 Third phenotype 
The third phenotype comprised 146 patients with the highest TST and percentage of 
REM. Additionally, this group demonstrated the shortest Sleep Onset and REMLs, 
lowest WASO and percentages of wake time and stage 1 sleep, and the lowest number 
of awakenings. Statistically, TST, percentage wake and WASO differentiated 
this phenotype from each of the others. 
5.3.4 Fourth phenotype 
The fourth phenotype comprised 24 patients who demonstrated the highest WASO, 
percentages of wake and stage 1 sleep, and the highest number of awakenings. This 
group was also the lowest in terms of TST, number of arousals per hour and 
percentage of SWS. Statistically, only WASO and percentage of wake differentiated 
this group from each of the other groups. 
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Notes: Letters sharing the same subscript are significantly different. 
*Statistical tests of between-group sex differences could not be performed due to the small number of men in each group. 
AHI, Apnoea Hypopnoea Index; BMI, body mass index; CFS, chronic fatigue syndrome; TSP, total sleep period; TST, total sleep time; REM, rapid eye movement. 
 
 
Table 5.2: Characteristics of sample of individuals with CFS 
 
 
Grouped Variable Clusters Group 1 (N = 14) Group 2 (N = 55) Group 3 (N = 146) Group 4 (N = 24) F P Value 
Demographics             
    Age 35.79 (12.39) 37.29 (12.72) 32.99 (10.82) 35.54 (14.49) 1.95 n.s. 
    Sex 5 Males (35.71%) 10 Males (17.65%) 14 Males (9.59%) 1 Male (4.17%) * * 
    BMI 24.86 (5.68) 23.85 (4.63) 23.41 (4.03) 22.81 (3.86) 0.82 n.s. 
Sleep Variables            
    Total Sleep Time (min) 270.95 (41.85)ab 387.03 (46.1)acd 473.21 (45.82)bce 264.15 (74.43)de 188.07 p<.001 
    Sleep Onset Latency (min) 107.79 (42.09)abc 30.97 (29.13)ad 19.17 (14.71)bd 28.94 (27.54)c 67.26 p<.001 
    Wake After Sleep Onset (min) 75.79 (39.35)ab 82.12 (45.25)cd 35.45 (25.39)ace 180.2 (58.48)bde 119.74 p<.001 
    Number of Awakenings (over TSP) 15.21 (8.06) 14.75 (11.62)ab 9.54 (5.85)a 16.96 (9.26)b 10.52 p<.001 
    Number of Arousals 3.57 (9.21) 10.91 (23.01) 6.2 (15.26) 1.38 (4.13) 2.24 n.s. 
    REM Latency 173.22 (55.03)abc 57.71 (34.31)ad 47.01 (28.22)be 84.46 (48.21)cde  63 p<.001 
    AHI Index 3.43 (3.46) 4.58 (4.39) 4.73 (4.04) 3.54 (4.19) 0.92 n.s. 
    % N1 (of TST) 21.84 (13.36)a 14.35 (9.14)b 12.55 (7.37)ac 24.22 (14.82)bc 14.15 p<.001 
    % N2 (of TST) 27.57 (13.15)ab 38.82 (12.36)a 38.44 (12.14)b 36.95 (13.66) 3.46 p<.02 
    % N3 (of TST) 44.46 (20.45)abc 31.07 (11.05)a 31.78 (12.41)b 29.28 (16.42)c 4.64 p<.004 
    % REM (of TST) 6.11 (4.58)abc 15.16 (5.47)ad 17.19 (5.57)be 9.65 (6.35)cde 26.46 p<.001 
    % WAKE (of TSP) 60.32 (21.09)abc 25.75 (11.61)ade 11.03 (6.16)bdf 75.26 (22.92)cef 271.62 p<.001 
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5.4 Discussion 
The aim of the study was to determine whether specific sleep phenotypes existed in 
patients with CFS. A large consecutive series of patients, meeting the criteria for CFS, 
underwent a single night of polysomnography to determine the presence or absence of 
distinct sleep phenotypes. The first finding, over 30% of individuals meeting 
diagnostic criteria for CFS, also demonstrated that a Primary Sleep Disorder (PSD; 
sleep apnoea or PLMD) is important and underscores the need to assess for PSDs in 
CFS populations. As the recommended treatment strategies for some PSDs differ 
considerably from those for CFS (e.g. Continuous Positive Airway Pressure for apnoea 
vs sleep management strategies in CFS), it is important to direct the individual to, or 
adjunct, appropriate care pathways as soon as possible. This finding also questions the 
ability to differentiate fatigue associated with sleep apnoea or PLMD from that 
associated with CFS. Here, family members and/or carers may be helpful for diagnosis 
sensitivity as they are likely to be aware of nocturnal breathing disturbances (i.e. heavy 
snoring, gasping or pauses in breathing).  
 
The overall PSG results (after excluding sleep apnoea and PLMD) confirm objective 
sleep difficulties in patients with CFS. When the percentages of each sleep stage in 
‘normal’ adult sleepers (i.e. <5% wake, between 2% and 5% stage 1, between 45% and 
55% stage 2, between 13% and 23% SWS and between 20% and 25% REM 
(Carskadon & Dement, 2011) are compared with those in the present sample, it is seen 
that this group falls outside the range for all these variables. The present sample is 
spending more time awake and in the lighter stages of sleep (stages 1 and 2 sleep), and 
less time in the deeper sleep stages of sleep (i.e. stage 2 sleep and SWS) and in REM. 
Further, using the quantitative benchmarks of sleep disturbance outlined by Edinger et 
al. (2004), it can be seen that where sleep efficiency and SLs appear to be on the cusp 
of ‘normal’ sleep in the present sample (85% sleep efficiency is considered normal and 
SL of >30 denotes a sleep problem), WASO appears to be almost twice as long as is 
considered problematic (>30 min tends to denote a sleep problem). Together, these 
findings indicate that sleep is an objectively verifiable problem for patients with CFS 
that should be addressed clinically.  
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The cluster analysis identified, at saturation, four sleep phenotypes. The dendrogram 
identified two groups partially related (i.e. groups 1 and 4) and two that were largely 
independent (i.e. groups 2 and 3). This configuration was confirmed by ANOVA 
showing statistically significant differences in sleep continuity and architecture 
variables between the groups. That said, where statistical significance and relative 
characterisation (e.g. group 1 highest in the variables SL and REML and lowest in AHI 
Index) are important in understanding between-group differences, the more salient 
question is whether these four groups are clinically relevant in terms of specific sleep 
treatments in patients with CFS. The use of different pharmacological agents 
(benzodiazepines, z-hypnotics or stimulants) or therapeutic interventions (i.e. 
Cognitive Behavioural Therapy for Insomnia or behavioural modification strategies) 
has been shown to have differential effects on specific aspects of sleep continuity and 
architecture. For example, zolpidem appears to have a better impact on the number of 
awakenings and perceived quality of sleep compared with nitrazepam, and 
lormetazapam appears to be better in reducing SLs than zoplicone (Dündar et al., 
2004). As such, tailoring treatment options to the sleep problems presenting in this 
population is likely to be more effective (table 5.3). 
Notes: CFS, chronic fatigue syndrome; REM, rapid eye movement 
Table 5.3: Characteristics (statistical and phenomenological) of patients with CFS 
Sleep 
Phenotype  
 
Central Differential 
Features 
Associated Diagnostic 
Features 
How this may present subjectively 
1 Long Sleep Onset Latency         
Long REM Latency                   
High amounts of Slow 
Wave Sleep                                      
Low amounts of REM 
Low amounts of Stage 2 Sleep Problems in getting off to sleep but 
when asleep few awakenings. The 
Sleep that is obtained is of normal 
quality. 
 
 
2 
   
High number of arousals per 
hour                                            
High amounts of Stage 2 
Sleep 
 
 
No difficulties in getting off to sleep 
and few awakenings but feelings or 
evidence of a 'restless' night sleep. 
 
3 High Total Sleep Time              
Low amounts of time 
awake during the night               
Low number of wake 
periods during the night 
High amounts of REM Sleep          
Short Sleep Onset Latency              
Low number of Awakenings           
Short REM Latencies                      
Low amounts of Stage 1 Sleep 
 
No difficulties in getting off to sleep 
and few awakenings but feelings of 
being unrefreshed on waking despite a 
significant amount of time in bed 
asleep. 
  
4 Highest number of wake 
periods during the night           
Highest amounts of time 
awake during the night 
Low Total Sleep Time                     
Low number of arousals per 
hour during the night                       
Low amounts of Slow Wave 
Sleep 
Short sleep duration and although no 
difficulties getting off to sleep lots of 
awakenings for significant periods of 
time. Also increased feelings of 
daytime sleepiness. 
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Another consideration, albeit related, is the presence within the final sample of PSDs 
for which PSG is either not routinely recommended or where, as stand-alone, it is 
insufficient for a definitive diagnosis (AASM, 2007). Most relevant to the present 
sample are insomnia disorder and hypersomnolence disorders. Interestingly, groups 1 
and 4 appear to be characterised by insomnia-like symptoms (i.e. difficulties initiating 
sleep or maintaining sleep), whereas groups 2 and 3 appear to share overlapping 
characteristics with disorders characterised by poor sleep quality (table 5.1). In relation 
to group 3, there is some overlap with hypersomnolence disorders (the term 
hypersomnolence will replace hypersomnia under the DSM-5) as 14 patients (9.59%) 
slept for 9 hours or longer and eight patients (5.48%) demonstrated the main 
polysomnographically defined symptom of narcolepsy (i.e. an REML of less than 15 
min). For group 2, there is no obvious overlap with a specific DSM-5-defined sleep 
disorder, although as stage 2 sleep has been associated with hormonal and autonomic 
regulation (Brandenberger et al., 2005), increased amounts are likely to relate to both 
higher levels of autonomic and cortical arousal inhibiting deep sleep. As such, a PSG 
study with adjunct sleep history interviews, sleep diaries, actigraphy and/or a Multiple 
Sleep Latency Test or Maintenance of Wakefulness test would be valuable tools in 
determining whether these groups share all the diagnostic features of each PSD.  
 
The findings from the present study should be viewed with the limitations in mind. 
There was no control group to determine the extent to which the four phenotypes exist 
in the general population. That said, with 6–10% of the population meeting the 
diagnostic criteria for insomnia (Dauvilliers, 2006) and 5% meeting the diagnostic 
criteria for hypersomnia (Ohayon, 2002), the present data do not reflect this with 213 
of the 239 (89.1%) participants, without apnoea or PLMS, meeting at least one 
quantitative criterion for insomnia or hypersomnia. It could also be argued that a single 
night of polysomnography may not be enough to capture the sleep of patients with 
CFS due to the first-night-effect (Le Bon et al., 2003). The first-night-effect is a 
commonly observed response to the first night of sleeping in an unusual environment, 
such as a sleep laboratory, whereby aspects of sleep can be affected. That said, where 
Le Bon and colleagues demonstrated significant differences between nights 1 and 2 in 
a cohort of individuals with CFS, these differences were not largely evident in the 
sleep architecture and many differences in the sleep continuity variables disappeared 
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after those with psychiatric illnesses were excluded from the analysis. Interestingly, 
over 25% of Le Bon et al’s (2003) sample also demonstrated an ‘inverse first-night-
effect’ whereby they slept better on the first night compared with the second night. 
This issue of the first-night-effect in CFS is further complicated by other studies which 
have shown no such effect in this population (Whelton, Salit & Moldofsky, 1992). It is 
very likely that inconsistencies in the first-night-effect reflect typical night-to-night 
variability (Buysse et al., 2010; Perlis et al., 2010; Vallieres et al., 2011) in addition to 
situation-specific factors, such as acclimating to a new environment, relating to PSG 
on the first and second nights. What would be ideal, albeit expensive, is a PSG study 
over several nights (e.g. at least 14 continuous nights are suggested for insomnia 
(Wohlgemuth et al., 1999)) to ensure that these issues are accounted for. That said, 
what may be more practical is to determine how information from the present study 
can inform, in conjunction with other assessments, actual clinical practice. One 
suggestion is that, ideally after ruling out PSDs, individuals should be interviewed 
about their sleep (usually over the last month) and provided a sleep diary. This 
information would provide a subjective account that could be matched to the four 
phenotypes (as in table 5.3) to inform treatment.  
 
Overall, the results suggest a significant overlap between CFS and a variety of 
symptoms of sleep disturbance. One night of PSG is sufficient to tease apart, and 
exclude, those with apnoea and PLM disorders from four other distinct sleep 
phenotypes in patients with CFS. Interestingly, these four phenotypes tend to mirror 
symptoms related to sleep quality and quantity that are amenable to different treatment 
strategies. As such, clinicians tailoring sleep-based interventions for patients with CFS 
should be mindful of these phenotypes. 
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CHAPTER SIX                                                                                                         
THE FEASIBILITY AND ACCEPTABILITY OF A 3-NIGHT AMBULATORY 
PSG SLEEP ASSESSMENT IN PATIENTS WITH CFS  (STUDY 4) 
 
 
 
 
 
 
 
 
 
 
 
6.1 Introduction 
It is clear that sleep needs to be examined in depth in this patient population, given the 
findings from the qualitative interviews, and the subjective (diaries) and objective 
(PSG cluster analysis) exploration of sleep in CFS. These results show that not only 
does disturbed sleep play a critical role in the maintenance and exacerbation of 
symptoms, but that there also appear to be specific sleep phenotypes in CFS patients as 
assessed through nocturnal PSG. Developing a detailed, high quality sleep protocol 
assessment that is acceptable to patients is therefore crucial in order to explore these 
findings further. 
 
As discussed in the introductory chapter, PSG studies on individuals with CFS have 
not been uniform in their data reporting or methodological practices, and so 
determining the nature and extent of sleep difficulties in CFS patients remains 
difficult. It is fundamental that the sleep of patients with CFS should be looked at in as 
much detail as possible, given the probable reciprocal effects of disturbed sleep on 
existing CFS symptoms. Equally, it is important to consider how we measure the 
function of the HPA axis. As discussed earlier hypoactivity in this axis has been 
postulated as one of the underlying pathophysiological processes in CFS (Demitrack et 
al., 1991) and reviews confirm this dysregulation as  indicated by attenuation in 
cortisol levels and Cortisol Awakening Response (CAR), albeit with variable results 
This chapter presents the feasibility and acceptability findings of a comprehensive sleep 
assessment study with a small group of patients with CFS. Whilst presented in accordance 
with CONSORT guidelines, the chapter is expanded upon to emphasise the feasibility 
rather than effectiveness, through assessment of recruitment, attrition, protocol 
acceptability and fidelity. The results are considered with a view to inform the design of 
future sleep studies in CFS, and will help inform practice in a clinical setting when 
applied to the assessment process of this illness. 
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(for recent reviews of this literature see Tomas et al., 2013; Papadopoulos & Cleare, 
2012). However as with the PSG studies, the protocol with respect to HPA axis 
measurement has been highly variable. With respect to saliva sampling for cortisol, 
existing studies have utilised at most a protocol of one to two days of assessment with 
samples ranging from 3-9 time points per day (Powell, 2013). It is recommended that 
to obtain a stable variable for the CAR and overcome state influences, 4 samples 
should be taken on a given day and over the course of 2/3 days (Hellhammer et al., 
2007). 
 
To redress this, the present study utilised a range of methods, combining sleep and 
comprehensive cortisol assessment over a 3-day period, a protocol that has never been 
endeavoured in this patient population. The cortisol sample collection in this study was 
for the purpose of protocol feasibility. As such, procedural findings are described and 
analysis of cortisol is not included as part of this study. The study combines 3-night 
home-based PSG and a gold-standard protocol for salivary cortisol sampling (7 
assessments per day), alongside self-reported sleep diaries, functional and symptom 
assessment questionnaires and Actigraphy. Given this is the most comprehensive 
assessment of sleep and cortisol ever attempted in a CFS population, the primary aim 
of the study was to establish its feasibility in a small group of CFS patients, with 
particular emphasis on the extent to which patients were able to adhere to this 
comprehensive protocol. The demands of such protocol for a CFS patient group, 
already experiencing a host of debilitating symptoms had the potential to impact on 
their sleeping patterns, consequently affecting the assessed sleep parameters of 
interest. Continuous monitoring throughout the study was therefore of utmost 
importance.  The outcome of this study will then inform whether it is possible to move 
forward and utilise this protocol, or a modified version (based on how well tolerated it 
is found to be) in larger more definitive sleep and cortisol studies (and in clinical 
screening), thus affording a more definitive answer to the question of the role of sleep 
and cortisol in CFS.  
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6.2 Methods  
6.2.1 Design 
The study was a cross-sectional feasibility study of sleep and cortisol assessment in 
CFS patients. The objectives of this study were as follows: 
6.2.1.1 Acceptability and feasibility objectives  To assess the feasibility and acceptability of the methods and procedures of a 3-
night ambulatory sleep assessment, and 3-day gold-standard saliva sampling 
protocol for cortisol in CFS patients;  To take measures of compliance to the protocol, and the assessment of barriers 
and facilitators to participation with the full protocol. 
 
The objectives were measured through patient retention to the study and completion 
rates (acceptability of the procedures and assessment methods included in the 
protocol), and through monitoring patients’ experience of the protocol via an 
observational process made by the researcher taking field notes throughout the entire 
study process. 
 
6.2.1.2 Outcomes 
The primary outcomes for the study were the estimates of feasibility and acceptability 
in CFS patients, assessed as described above, through retention to the study process 
and by participant adherence to protocol. Participant adherence was assessed through 
both the sleep and cortisol components of the assessment via completion of specific 
measures (sleep diary completion, saliva sampling correctly wearing monitoring 
equipment) and fidelity to timing protocol (sample time-log completion, marker press 
for lights out/lights on during PSG). 
 
Given the small sample size, and the primary feasibility aims of this study, definitive 
comments on the nature of sleep and cortisol would not be appropriate. We will 
however attempt a preliminary, primarily descriptive characterisation of this study 
sample based on the measures deployed in the feasibility study. These symptom and 
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functional assessments, subjective and objectively-derived sleep variables and the 
preliminary characterisation of sleep can be found in Chapter 7. 
 
6.2.1.3 Sample size 
A pragmatic approach was used to determine the sample size. The primary determinant 
was the number of patients to be assessed through the study period whilst also 
factoring in estimates of patient ineligibility, rescheduling and attrition. It was 
anticipated to be approximately 25 patients (and 25 normal sleepers) entered into the 
study over 12 months. 
 
6.2.2 Participants and setting 
6.2.2.1 Inclusion 
Study participants were CFS patients recruited from the local CFS clinical service 
based at the Newcastle upon Tyne Hospitals NHS Foundation Trust. All participants 
fulfilled the CDC 1994 (Fukuda) diagnostic criteria for CFS (Fukuda et al., 1994), they 
shared the same referral and assessment path and were identified and approached by 
their clinician (who was seeing patients as part of routine clinical practice). Potentially 
eligible patients were identified on the basis of their age and clinical demographics, 
and participants who expressed an interest were subsequently contacted regarding their 
participation in the study. Non-illness control participants were recruited from a bank 
of participants held by the Northumbria Centre for Sleep Research (NCSR) and 
consented using the same process as indicated for patient participants.  
 
Participants were considered eligible for the study if they were between 18-65 years of 
age, and met the criteria for CFS, according to the Fukuda definition (patients). 
Participants were excluded from the study if they were taking sleep medication, seeing 
a sleep medicine specialist, had travelled beyond one time zone within three months of 
study participation, and if they had a diagnosis of Obstructive Sleep Apnoea (OSA). 
 
Ethical approval was sought and approved by the Newcastle and North Tyneside Local 
Ethics Committee, the sponsor was Newcastle upon Tyne Hospitals NHS Foundation 
Trust, and the study was registered with the UKCRN Portfolio database, under the 
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title: A case controlled study exploring the roles of sleep architecture, and diurnal 
patterns of salivary cortisol in CFS/ME (Short title: CFS Sleep), Identifier: 12889. All 
participants provided written informed consent prior to the study. 
6.2.2.2 Assessment 
The study was carried out at participant’s homes. Prior to the 3-day assessment, 
participants were required to wear an Actiwatch and complete a sleep diary over a 14-
day pre-assessment period. During this time, participants were also required to 
complete a series of functional and symptom assessment questionnaires. The following 
section will detail the included measures that were used to measure sleep, cortisol and 
assess functioning and symptoms in participants. 
 
6.2.3 Measures 
6.2.3.1 Functional and symptom measures 
A range of measures were incorporated into a questionnaire booklet that patients were 
required to complete during their 14-day pre-assessment period which was considered 
to represent less burden than all at once in one session. 
 
DePaul Symptom Questionnaire (DSQ: Jason et al., 2010) 
The DePaul Symptom Questionnaire (DSQ: Appendix N), is a self-report measure that 
assesses the presence of core CFS symptoms, originally developed to provide a 
structured way to gather standardized information that can be used to aid in the 
diagnosis of CFS. It is important to consider the contentious nature in attempting to 
operationalize the assessment criteria in CFS, as currently, the Fukuda and the 
Canadian criteria have yet to be formally operationalized. This issue creates 
methodological problems where studies in different settings recruit samples of patients 
with different amounts of each of the core symptoms. It is evident there is need for a 
new approach, and Jason et al. (2010) suggests the DSQ assesses the core symptoms of 
CFS in a consistent way across settings, affording investigators in different settings to 
identify more homogenous samples of patients, and this more standardized approach to 
patient identification will increase the likelihood of reliable detection of biomarkers 
across samples, that will ultimately aid diagnosis. Using the DSQ in this study will add 
to such developments and it is the first use of it in the United Kingdom. The format of 
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the DSQ integrates scores of symptoms and functional health status data (see below for 
SF-36 and symptom measures), through which an algorithm produces a “diagnosis” 
based on several of the more common definitions of ME and CFS. If found to be 
sufficiently sensitive, the instrument could aid patient diagnosis, saving time through 
home/clinic completion, and improving overall confidence in the diagnosis process. 
 
The DSQ captures critical symptoms and their frequency/severity. The 54-item scale 
of symptoms loads onto 3 factors; 1) Neuroendocrine, Autonomic and Immune 
Dysfunction; 2) Neurological/Cognitive Dysfunction; and 3) Post-Exertional Malaise 
(PEM). A ‘total’ score can be obtained to represent overall illness burden. Participants 
are required to rate on a Likert scale (0-4) as to how often they have experienced each 
symptom and how much each symptom has bothered them over the last 6 months. 
Brown and Jason (under review) demonstrate that the threshold criteria that seems the 
most able to differentiate CFS patients from controls is a score of 2 or more on 
Frequency of symptoms (2 = about half the time) and Severity of symptoms (2 = 
moderate). 
   
Integrated into the DSQ is the Short Form-36 Health Survey (SF-36: Appendix O), a 
36-item questionnaire constructed to collect data on health status, functioning, and 
well-being for the Medical Outcomes Study (Ware & Sharebourne, 1992). It measures 
Quality of Life (QoL) across eight domains, which are both physically and emotionally 
based. The multi-item scales assess functional impairment in eight areas: limits in 
physical activities (physical functioning), limits in one’s usual role activities due to 
physical health (role physical), limits in one’s usual role activities due to emotional 
health (role emotional), bodily pain (pain), general health perceptions (general health), 
vitality (energy and fatigue), social functioning (social), and general mental health 
(Ware et al., 2000). Scores in each area reflect ability to function and higher values 
indicate better functioning (QoL). Reliability and validity studies have demonstrated 
high reliability and validity in a wide variety of patient populations for this instrument 
(Stewart et al., 1989). Based on the CDC empiric case definition (Reeves et al., 2005), 
the SF-36 was used to assess disability. Significant reductions in occupational, 
educational, social, or recreational activities have been defined as scores lower than the 
25
th
 percentile on physical functioning (≤70), or role physical functioning (≤50), or 
social functioning (≤75), or role emotional (≤66.7). A person would meet the disability 
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criterion for the empiric CFS case definition by only showing impairment in one or 
more of these four areas (Reeves et al., 2005). Measures of caffeine consumption, 
alcohol intake, smoking status and amount of exercise per week were also taken 
(Appendix P). 
 
General Health Questionnaire (GHQ-28; Goldberg, 1978) 
The 28-item General Health Questionnaire (Appendix Q) is an assessment comprising 
four 7-item subscales: somatic symptoms (items 1-7), anxiety/insomnia (items 8-14), 
social dysfunction (items 15-21) and severe depression (items 22-28). Patients are 
asked to assess changes in their mood, feelings and behaviours based on the previous 
four weeks, evaluating their occurrence on a 4-point response scale (“less than usual”, 
“no more than usual”, “rather more than usual”, “much more than usual”).The total 
possible score on the GHQ-28 ranges from 0 to 84. 
 
Chalder Fatigue Questionnaire (CFQ; Chalder et al., 1993) 
One of the most widely used measures for assessing fatigue in research with CFS 
patients, the Chalder Fatigue Questionnaire (Appendix R) was used as a measure of 
symptomatic fatigue experienced by patients. The Likert system for scoring was used 
(0, 1, 2, 3), with a total possible score ranging from 0-33. A higher score indicates 
more fatigue.  A score of 18 or less (based on Likert system) out of a total 33 is 
considered as within the normal range of fatigue (White et al., 2013).  
 
Hospital Anxiety and Depression Scale (HADS; Zigmond and Snaith, 1983) 
The Hospital Anxiety and Depression Scale (Appendix S) measured symptoms of 
depression and anxiety in patients. Its seven depression items and seven anxiety items 
were rated on a four-point Likert scale (0-3), with scores ranging from 0-21 on each 
subscale. Scores of 11 or more are indicative of a ‘case’ of depression and/or anxiety 
in a general population sample. 
 
Work and Social Adjustment Scale (WSAS Mundt et al., 2002) 
The Work and Social Adjustment Scale (Appendix T) is a simple, valid and reliable 5-
item patient self-report measure of impairment in functioning. It assesses the impact of 
the patient’s illness on their ability to function in terms of work, home management, 
social leisure, private leisure and personal and family relationships. Scale responses for 
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each item range from 0-8 and the maximum total score on the WSAS is 40, higher 
scores indicate worse functional impairment. 
 
Perceived Stress Scale (PSS; Cohen et al., 1983) 
The Perceived Stress Scale (Appendix U) is a 14-item measure of individuals’ 
appraisal of levels of stress over the past month. Evaluating the degree to which 
individuals believe their life has been unpredictable, uncontrollable and overloaded 
during that time. Responses to each item are scored on a five-point Likert scale (0-4) 
and total scores range between 0-56 with higher scores indicating higher levels of 
perceived stress.  
 
Illness Perception Questionnaire (IPQ; Broadbent, et al., 2006) 
The brief Illness Perception Questionnaire (Appendix V) was used to assess patient’s 
cognitive representation of their illness. With an overall possible score ranging from 0 
to 80, higher scores reflect a more severe illness perception. 
 
6.2.3.2 Self-report measures of sleep 
A standard sleep diary was used to derive core measures of subjective sleep continuity 
(Time in Bed [TIB], Sleep Onset Latency [SOL], Wake After Sleep Onset [WASO], 
Number of Awakenings [NWAK], Total Sleep Time [TST], and to calculate Sleep 
Efficiency [SE] (TST/TIBx100)) over a period of 14 continuous days, during the 
baseline pre-assessment period. A 3-day version of the sleep diary was used in the 
sleep assessment stage of the study. Participants were required to complete the diary 
upon waking each day. Mean values were derived for each variable based on the 
number of nights completed. The pre-assessment phase of the study was an 
opportunity for the participant to become familiarised with the format of the diary and 
address any uncertainty with regard to completion prior to the 3-night assessment. 
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Incorporated into the Questionnaire booklet were a range of retrospective sleep 
measures; 
 
The Pittsburgh Sleep Quality Index (PSQI: Buysse et al., 1989) 
The Pittsburgh Sleep Quality Index (Appendix W) is a 19-item questionnaire 
evaluating sleep quality and disturbances over the previous month. The 19 self-rated 
items (5 questions rated by the bed partner or roommate (if available)) are combined to 
form 7 component scores (subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sleep disturbances, use of sleeping medication, daytime 
dysfunction), responses are rated on 4-point Likert scale (0=no difficulty, 3=severe 
difficulty). The PSQI has good internal consistency and a reliability coefficient 
(Cronbach α) of 0.83 for its seven components (Buysse et al., 1989). The seven 
component scores are then added to yield one global score that has a possible range of 
0-21 (0=no difficulty, 21=severe difficulties in all areas). A global PSQI score ޓ5 
suggests poor quality sleep.  
 
The Insomnia Severity Index (ISI: Morin et al., 2011) 
The Insomnia Severity Index (Appendix X) is a reliable and valid tool for detecting 
cases of insomnia in a population. It’s’ 7-items evaluate the severity of sleep onset, 
sleep maintenance, and early morning awakening problems, sleep dissatisfaction, 
interference of sleep difficulties with daytime functioning, noticeability of sleep 
problems by others, and distress caused by the sleep difficulties, over the previous 
month. Each item is rated on a 5-point Likert scale (0 = no problem; 4 = very severe 
problem) that yields a total score ranging from 0 to 28.  It has good internal 
consistency (Cronbach’s α of 0.90), and convergent validity is supported by high ISI 
scores being significantly correlated with QoL and fatigue. Interpretation of total ISI 
scores are able to determine; an absence of insomnia (0-7), subthreshold insomnia (8-
14) or ‘caseness’ for clinical insomnia (15-21), a cut-off of 10 is considered optimal 
for detecting insomnia cases (Morin et al., 2011). 
 
Ford Insomnia Response to Stress Test (FIRST: Drake et al., 2004) 
The Ford Insomnia Response to Stress Test (Appendix Y) is a measure to identify 
individuals who have an increased risk of developing a sleep difficulty when 
confronted with a stressor. The 9-item questionnaire asks respondents to rate the 
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likelihood that various stressful events would disturb their sleep. Responses are rated 
from 1 (not likely) to 4 (very likely) with a total possible score ranging from 9-36. The 
scale has high reliability (Cronbach's α = .83) and factor analytic techniques identified 
a single 9-item factor that was representative of the construct of "stress-related" 
vulnerability to sleep disturbance. It has also been established that higher scores on the 
FIRST is a significant risk factor for the development of insomnia in normal sleepers 
over 13-month period (Drake et al., 2004
b
). 
 
6.2.3.3 Objective measures of Sleep 
Polysomnography 
Polysomnography (PSG) was carried out over three consecutive nights, in participants’ 
homes. The researcher arrived at the participant’s home 2 hours before normal bedtime 
for electrode placement and biocalibration. The first night of assessment served as a 
screening night and opportunity for participant adaptation. This first night of 
assessment included an extended EEG montage, with placement of electrodes at; FP1, 
FP2, F3, F4, C3, C4, P3, P4, O1, O2, A1, A2 and Cz, in accordance with the 
International 10/20 system (Harner & sannit, 1974), additional channels were used for 
electro-oculography (EOG; left and right eyes), electromyography (EMG; chin and 
anterior tibialis placements), ECG, thermal flow and effort sensor, body position and 
oximetry (via pulse oximeter) and snore microphone. The second and third nights of 
assessment used a reduced montage, but utilised the same EEGs, EMG (chin 
placement only), EOG and heart rate measurements (See Figure 6.1 for a schematic of 
the polysomnogram hook-up). Participants slept in their own home and could retire to 
bed when they wished and left to naturally wake in the morning. The PSG was 
recorded on 33-channel SOMNOscreen plus, using DOMINO software 
(SOMNOmedics GmbH, Randersacker, Germany), at a sampling rate of 128 Hz for 
EEG channels, and 256 Hz for EMG and ECG channels. Impedances were maintained 
below 5kΩ during the recording period. PSG data was scored manually by an 
independent registered technician blind to the aims of the study, at 30s epochs in 
accordance with American Academy of Sleep Medicine criteria (Iber, et al., 2007). 
The mean recording period was 8.5 h (513.5±90 min). Descriptions of all sleep 
variables are detailed earlier in Table 4.1 (chapter four). 
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Notes: EEG, electroencephalography; EOG, electrooculography, EMG, electromyography; 
ECG, electrocardiography PSG, polysomnography 
 
 
Figure 6.1: The Polysomnogram 
 
 
 
Actigraphy 
Actiwatches were worn by patients on their non-dominant wrist during the 14-day pre-
assessment period and also throughout the 3-day sleep assessment, to monitor 
sleep/wake activity. Using a piezo-electric accelerometer, Actiwatches measure and 
record the amount, duration and intensity of movement in all directions, storing this 
activity in the memory of the Actiwatch. Actigraphy was used to complement the sleep 
diary and to aid the researcher in confirming the relative circadian stability of 
participants prior to the start of the study. It was not used in any further analyses. 
Wearing the Actiwatch throughout the entire study period affords the ability to 
determine its feasibility in conjunction with the PSG and saliva sampling procedures 
and equipment. 
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6.2.3.4 Salivary Cortisol Sampling Protocol 
There have been difficulties in the interpretation of previous studies that measure 
levels of cortisol in CFS patients, partly due to the stressful procedures entailed by 
sampling (i.e. hospital admission, cannulation, blood sampling and drug 
administration). Alternatively, markers of basal HPA axis function in a CFS patient 
group, can be assessed through the measurement of cortisol in saliva, across a diurnal 
period in an ambulatory setting (Saxbe, 2008).With this in mind, a comprehensive 
procedure of 7 samples per day allows for a stable assessment of cortisol across the 
diurnal period. If adhered to, the protocol provides the opportunity to characterise 
patients on the basis of a number of indices of HPA function, specifically; a) overall 
cortisol secretion across the entire day, through the calculation of  the area under the 
curve with respect to ground (AUCG
1
) (Pruessner et al., 2003); b) the cortisol 
awakening response (CAR) as measured by taking the individual’s peak cortisol value 
(the highest value of the CAR, observed between the sample taken at 15 minutes post-
wake and the sample obtained at 60 minutes post-wake), and total secretion during the 
CAR period as measured by AUCG
1
. 
 
To overcome the potential for state influences upon levels of cortisol, a 3-day protocol 
for sampling was employed to obtain a more stable variable (Hellhammer et al., 2007). 
The sample timings were immediately at wake, 15, 30, 45 and 60 minutes post-wake, 
for a measure of the CAR, and subsequent samples were at a mid-afternoon point 
(between 2-4pm) and immediately preceding bedtime to provide further measures of 
diurnal secretion and evening nadir.  
 
Participants provided their samples using Salivettes (Sarstedt, Leicester, UK), this 
required chewing on an absorbent piece of cotton until saturated, before depositing into 
a protective plastic storage tube. Samples were then stored in a refrigerator until 
collected by the researcher, and then frozen at -20°C at the earliest opportunity until 
assaying (samples centrifuged at 3000 rpm for 15 minutes and assays performed in-
house using luminescence immunoassay methods in accordance with manufacturer’s 
instructions (Salimetrics, Newmarket, UK).  
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Given this was a home-based protocol, adherence was crucial. Participants were given 
a demonstration of how to use the Salivette device and the importance of the timing of 
samples and avoidance of behaviours known to affect concentrations of saliva 
(Kudielka et al., 2003) were emphasised. Participants were additionally required to 
complete the sample log provided (integrated into 3-day sleep diary: see appendix AA) 
indicating time of waking and specific sample times as well as state mood rating on a 
Likert scale. The log enabled the researcher to undertake a retrospective adherence 
check against the sleep diary (wake timings) for the first sample time. 
 
6.2.4 Data analysis 
Data analysis was carried out via a number of stages; the primary outcomes of 
feasibility and acceptability were assessed by recording a tally of recruitment, attrition 
and exclusion of patients in the study. Monitoring compliance to the procedures and 
fidelity to timing protocols included in the study was determined by making a tally of 
rates of completion and by taking a record of timed activities required by the protocol.  
Finally, to gain a comprehensive account of the study’s acceptability by patients, 
keeping detailed field notes throughout the course of the study made it possible to 
evaluate the entire study process, based on patient’s experiences of the protocol.  
Statistical methods were employed for analysis of secondary outcome measures of the 
study (Chapter 7). 
 
6.3 Results 
6.3.1 Feasibility and acceptability in patients  
As the feasibility of the protocol for normal sleepers was not the focus of this part of 
the study, in the following sections, data are considered from a standpoint of feasibility 
and acceptability to CFS patients. Based on the guidelines set out by Thabane and 
colleagues (2010), the results are reported in line with the CONSORT format, with a 
greater emphasis on the feasibility objectives and outcomes.  
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6.3.2.1 Participant Flow and Recruitment 
30 patients with CFS (Fukuda defined) undergoing routine care at the Newcastle CFS 
clinical service, expressed an interest to participate in the sleep study. Of the 30 that 
expressed an interest, five (16.6%) met at least one of the exclusion criteria for the 
study: one patient (3.3%) had a current diagnosis of OSA, and a further four patients 
(13.3%) were taking sleep medication. The rate of eligibility of those assessed to 
participate was therefore 83.3% (25/30). Of those who were eligible, a further three 
(12%; 3/25) did not consent to the study. Of these, two declined to participate towards 
the enrolment stage due to poor health, and one patient was no longer able to 
participate due to pregnancy. 22 patients (73.3%; 22/30) were enrolled onto the study 
and underwent a 2-week pre-assessment including: wrist actigraphy, sleep diary and 
questionnaires. Following this phase of the protocol all patients continued to 
participate in the study process, and so a 0% rate of attrition provided a preliminary 
indication that the pre-assessment phase of the study was acceptable to this CFS 
patient group (see study flow diagram presented in Figure 6.2). 
 
Over the 12-month study period, it was also feasible to recruit 25 normal sleepers 
(Figure 6.2). Of note, exclusion of normal sleeper controls throughout the study 
process (n =2) was based on their declining to participate, not due to having an existing 
primary sleep disorder.  
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Notes: AHI, Apnea/Hypopnea Index. AHI combines apneas (pauses in breathing of 10 seconds or more) and 
hypopneas to provide an overall sleep apnea severity score, evaluating both number of sleep disruptions and degree 
of oxygen desaturation (low blood oxygen).(AHI values are typically categorized as 5–15/hr = mild; 15–30/hr = 
moderate; and > 30/h = severe.) (AASM criteria, Ruehland et al., 2009) 
 
Figure 6.2: Flow Diagram of Study (recruitment, protocol and analytical) Process 
 
 
All 22 patients continued onto complete night one (habituation) of home-based 
Polysomnographic assessment. Following the first study night, and based on an 
examination of the Apnoea Hypopnoea Index (AHI) and PLM indices, two (1 male 
and 1 female) of the original 22 patients who underwent night 1 (9.1%), met the 
AASM criteria for sleep apnoea (i.e. considered moderate; AASM criteria for Sleep 
Apnoea, AHI ≥15, Ruehland et al., 2009), and therefore did not meet the inclusion 
criteria to continue the study beyond night 1.  
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Of those eligible to partake in the study, all patients completed the three overnights of 
home-based polysomnographic assessment and all three study days (wrist actigraphy, 
sleep diary, saliva sampling). This 0% rate of attrition for patients who took part in the 
3 day sleep and cortisol assessment, indicates that the protocol is acceptable to this 
CFS patient group. 
 
By considering participant dropouts from the study as a measure of protocol 
feasibility/acceptability, on reflection of the study flow process (Figure 6.1), the 
pattern and rates of attrition indicate that this protocol was both feasible and acceptable 
to patients who were eligible to take part in this study. 
 
At the analysis stage of the study, one patient (5%; 1/20) had incomplete PSG data, in 
that no actual ‘sleep’ was recorded on night two, during the allotted 15 hour recording 
period the battery affords for. Having gone to bed at 10pm, the patient only 
commenced sleep at 9am (the morning following recording commenced) waking at 
12:40pm with a sleep duration of 03:45min (225 mins), so the recording did not pick 
up any actual ‘sleep’.  
 
A key aspect of determining the feasibility of the comprehensive sleep and cortisol 
assessment is the extent to which patients were able to successfully adhere to the 
protocol. The following sections will report on patient’s fidelity to the procedures and 
techniques, including their experience of the 3-day sleep and cortisol assessment. 
 
6.3.2.2 Adherence to Sleep Assessment Protocol 
Given the study met the feasibility/acceptability criteria based on a 0% patient drop out 
of those eligible to take part (as described above), the following section will discuss 
the level of adherence to procedural elements of the study, including fidelity to timing 
protocol. 
 
Both protocol adherence and fidelity to timing protocol were monitored on an on-
going basis by taking field notes throughout the study process and keeping a record of 
deviations from protocol via a tally. Timing references required for accuracy in sleep 
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analysis were based on self-reported times from sleep diaries and by a marker press on 
the head box device, which was required by the participant to indicate the times at 
which they turned the ‘lights off’ to retire to bed and again to indicate ‘lights on’ upon 
wake. 
 
With regard to completion of the 2-week sleep diary and wearing the actiwatch 
throughout the pre-assessment phase, all patients adhered to this protocol successfully, 
only removing the wrist device for showering and other water immersion activity as 
required. In addition, all patients were able to fully complete the questionnaire booklet 
provided (functional and symptom assessments) throughout this period. This 100% 
adherence indicated that the techniques included in the study were acceptable to 
patients. 
 
With regards to patient’s fidelity to timing protocol by pressing markers on the PSG 
box (important for determining lights out and lights on timings when researcher is not 
present), 18/20 (90%) were consistent in doing so on all three nights, and all 20 
(100%) patients did so on nights two and three. This demonstrates how the first 
habituation night is also a useful opportunity for ‘learning’ a detailed protocol that 
would not interfere with the subsequent assessment nights. Furthermore, after a 
retrospective check across the reported timings provided by patients on their sleep 
diary and the recorded times for the marker press on the PSG head box, it was evident 
that all patients were accurately reporting their timings for ‘lights out’ and ‘wake’ 
based on the times at which they pressed their marker on the PSG head box to indicate 
‘lights off’ and ‘lights on’ respectively, over the 3-day period.  
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6.3.2.3 Adherence to Saliva Sampling Protocol 
For accurate timing of sample points across the day and to enable potential to compare 
patients based on specific time-points, it is critical that samples were taken according 
to the protocol guidelines (wake, +15, +30, +45, +60, mid-afternoon, pre-bed). Any 
deviations from this protocol had the potential to off-set the projected diurnal profile 
and make such profile incomparable between patients. By on-going monitoring of 
fidelity to the saliva sampling timing protocol via keeping records of patient’s wake 
and bed times (sleep diary) and saliva sampling time-logs, it was possible to determine 
the level of adherence to the saliva sampling protocol. 
 
The adherence checklist for saliva sampling (Table 6.1) demonstrated a 95% 
adherence to sampling protocol, with all but one patient being able to take their 7 
samples per day over all 3 days. Only one patient (5%; 1/20) did not complete the 
saliva sample at one time point (wake+60 sample), from the 21 required during the 3-
day period. This was due to sickness: the patient felt too poorly at that time point in the 
morning. Overall, of 420 total possible saliva samples across the study, 419 (99.8%) 
were provided by patients. 
 
The fidelity to saliva sampling table (table 6.2) provides a calculation of the 
discrepancy in time between wake and first saliva sample (which should be provided at 
participant’s wake time), based on values of wake timing (taken from sleep diaries) 
alongside first-sample times (taken from sample log) for each patient. This is 
important in that such a discrepancy could have implications for the saliva profile for 
the patient that could potentially result in a blunted CAR, and off-set the cortisol 
awakening response profile/slope for the day. Timing discrepancies between wake 
time and time of first sample ranged from 0 (being taken on actual time of waking) to 
45 minutes (first sample not provided until 45 minutes post-wake). Across the 3 days, 
timing discrepancy was on average 5.1 (±6.9 minutes) (day one ~2.3 minutes, day two 
~7.8 minutes, day three ~5.2 minutes). 
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Notes: N = 20. T, time point; a/n, afternoon sample (between 2-4pm). 
 
Table 6.1: Patients’ adherence to saliva sampling protocol across 3-day period. 
 
P
a
ti
e
n
ts
 
Sample Time Points Across 3-Day Period  
 
 
% 
Complete 
Day 1 Day 2 Day 3 
T1 
Wake 
T2 
+15 
T3 
+30 
T4 
+45 
T5 
+60 
T6 
a/n 
T7 
Bed 
T1 
Wake 
T2 
+15 
T3 
+30 
T4 
+45 
T5 
+60 
T6 
a/n 
T7 
Bed 
T1 
Wake 
T2 
+15 
T3 
+30 
T4 
+45 
T5 
+60 
T6 
a/n 
T7 
Bed 
 
Patient 1                      100 
Patient 2                      100 
Patient 3                      100 
Patient 4                      100 
Patient 5 excl                       
Patient 6                      100 
Patient 7                      100 
Patient 8                      100 
Patient 9 excl                       
Patient 10                      100 
Patient 11                      100 
Patient 12                      100 
Patient 13                      100 
Patient 14                      100 
Patient 15                      100 
Patient 16                      100 
Patient 17                      100 
Patient 18     x                 95.24 
Patient 19                      100 
Patient 20                      100 
Patient 21                      100 
Patient 22                      100 
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Table 6.2: Fidelity to saliva sampling timing protocol. (N=20). 
 
 
 
 
 
 Day 1 Day 2 Day 3  
 Wake 
(hh:mm) 
Sample 
(hh:mm) 
Diff 
(min) 
Wake 
(hh:mm) 
Sample 
(hh:mm) 
Diff 
(min) 
Wake 
(hh:mm) 
Sample 
(hh:mm) 
Diff 
(min) 
Average 
(min) 
P1 
08:35 08:35 0 08:50 08:50 0 08:54 08:54 0 0 
P2 06:30 06:30 0 06:45 06:45 0 06:45 06:45 0 0 
P3 07:12 07:13 +1 07:32 07:33 +1 07:55 07:56 +1 1 
P4 05:55 05:55 0 05:20 05:20 0 05:35 05:38 +3 1 
P5excl           
P6 07:40 07:40 0 07:34 07:38 +4 07:30 07:39 +9 4.3 
P7 08:30 08:30 0 08:30 08:32 +2 08:25 08:27 +2 1.3 
P8 10:30 10:33 +3 10:30 10:55 +25 11:30 11:45 +15 14.3 
P9excl           
P10 09:00 09:00 0 10:30 10:30 0 08:00 08:00 0 0 
P11 06:55 06:55 0 06:00 06:05 +5 06:05 06:10 +5 3.3 
P12 09:20 09:20 0 09:30 09:35 +5 09:30 09:30 0 1.7 
P13 06:15 06:16 +1 06:29 06:30 +1 06:15 06:22 +7 3 
P14 06:30 06:30 0 07:30 07:33 +3 06:55 06:55 0 1 
P15 07:30 07:35 +5 06:50 07:30 +40 07:30 07:30 0 15 
P16 08:00 08:15 +15 07:00 07:45 +45 06:40 06:50 +10 23.3 
P17 10:30 10:35 +5 12:45 12:49 +4 12:40 12:40 0 3 
P18 08:00 08:00 0 08:20 08:20 0 07:45 08:00 +15 5 
P19 07:30 07:45 +15 07:30 07:40 +10 07:30 08:00 +30 18.3 
P20 07:30 07:30 0 07:25 07:26 +1 07:20 07:20 0 0.3 
P21 10:55 10:55 0 11:00 11:10 +10 08:40 08:45 +5 5 
P22 10:38 10:39 +1 11:11 11:11 0 10:53 10:54 +1 0.7 
Average 
(min) 
   
2.3 
   
7.8 
   
5.2 
 
5.1 
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6.3.2.4 Patient-specific experience of the protocol – field observations. 
An important aspect in determining the feasibility of the protocol is to identify parts 
that may not be well tolerated or perhaps problematic for patients. Monitoring the 
patient experience of the study process, through taking field notes over the course of 
the study, it was possible to identify any problems with equipment or procedures in 
this patient group. The table below details the experience of the procedures for each 
patient throughout the study process; 
 
 
Patient  Observations 
 
Patient 1 
 
Patient stated on the morning following night 1 of the PSG – exhausted – 
will need to change her sleep pattern as a result of the procedure (PSG), 
said will sleep during day.  
It is noteworthy that the daytime sleep will in turn have an effect and 
disturb her sleep in night 2 of PSG study. Finger clip (night 1) irritating 
fingertips, nerve endings sensitive (Hyperesthesia). Paste on scalp - 
temporary tingling sensation (almost burning) subsides after several 
minutes. Overall, found the procedures ok with only minor sensations 
from some of the equipment. 
 
Patient 2 Washing hair daily (to remove paste) is very difficult and demanding on 
energy levels. Patient stated she wouldn’t have come into a sleep lab - too 
much, tiring, felt that it is better that it is carried out at her own home. 
Lightweight feel, expected the electrodes and wires to be much heavier on 
head. By Night 3 patient felt “absolutely worn out” couldn't do another 
night (it's washing hair each morning) activities that are usually paced are 
made compulsory in this protocol - wash hair every morning arms aching. 
In the days during study period, patient experienced the “bad symptoms” 
that are usually caused through “over doing it”.  
 
 
 
 
continued over page 
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Patient 3 Wake nearly every night; usually wake for a while early morning then 
back to bed. By ensuring patient pressed the marker for ‘lights off’ and  
‘lights on’ this was technically not a problem, and combined with the self-
reported timings provided on the sleep diary, it was possible to identify 
the actual start and end of the sleep period. 
 
Patient 4 Rescheduled study dates after patient’s ENT specialist gave an 8-week 
treatment of steroid drops and sprays for facial pain and sinus problems. It 
was logical to wait until this treatment had finished before commencing 
the sleep study, which involves applying electrodes to the facial area. 
Early to bed so arrived early each evening to set up equipment and allow 
patient to relax prior to retiring to bed. Initially, concerns over nasal 
thermistor (night 1) and facial electrodes due to facial pain she 
experiences, but overall found the equipment ok and non-intrusive. 
 
Patient 5  
 
excl after night 1 ; AHI Index ޓ 15 
 
Patient 6 
 
No problems regarding technical aspects or equipment. Patient felt that 
planning for the timings of procedural elements (saliva sampling, 
researcher picking up equipment) of the study was beneficial, to help with 
maintain the daytime schedule she had set in place for university work. 
 
Patient 7 
 
No issues with procedural aspects or equipment, but felt that her sleep 
must have been affected somewhat on first night due to feeling terrible 
throughout the following day. Overall, at the end of the three days patient 
felt very “drained” but otherwise, managed the study ok with no real 
issues. 
 
Patient 8 
 
Long sleep duration realised after night 1. Re-configured the recording 
box to record for longer duration and also went to patient’s home later to 
set up to ensure enough battery power for recording. No issues with PSG, 
patient felt it was difficult and unpleasant taking the saliva samples soon 
after waking.                                                                                     continued over page 
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Patient 9  
 
excl after night 1; AHI Index ޓ 15 
 
Patient 10 
 
Patient noted their legs are always a problem, with achy muscles that can 
be painful and so was initially worried about wearing the extra equipment 
on night one (leg wires), but overall found it did not exacerbate any 
existing pain. 
 
Patient 11  
 
Legs a problem and fidget a lot in bed because uncomfortable, so was 
concerned about leg wires (night 1) initially, but overall found it ok and 
not problematic. 
 
Patient 12  
 
Patient stated she usually spends lots of time in bed and lays awake for 
hours, sometimes until 5/6am, poor sleep efficiency (baseline mean 
41.8% from 2-week diary) average 5 hrs sleep. During the study she 
found all aspects (procedural and equipment) ok, but where usually she 
would spend more time in bed in the morning after a restless night, found 
it a struggle to ensure she was awake on time for the researcher to collect 
equipment.  
 
Patient 13 
 
Legs a problem usually, often in pain and uncomfortable but felt the leg 
wires (night one) were not problematic. 
 
Patient 14 
 
PSG equipment and procedures all ok. Due to work commitments, patient 
had to plan for the morning saliva sampling and adjust their wake time, 
also taking the lunchtime sample to work and refrigerating before 
returning home. 
 
Patient 15 
 
Due to work commitments, patient had to consciously plan ahead for the 
morning procedures (sampling timings and researcher collecting 
equipment), to ensure sufficient time available to prepare for the day 
ahead. Patient felt the first night of the study was difficult and affected 
their sleep quality and how they felt throughout the following day, but 
noted that this improved during the study.                    continued over page 
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Patient 16 
 
Poorly during night 1 - sickness meant missing one of the CAR 
(wake+60) saliva samples on the first day of saliva sampling protocol. 
The scalp was slightly sensitive and so it was necessary to be extra gentle 
with marking reference points on the head. Otherwise, felt the procedures 
were ok and not intrusive to usual sleeping. 
 
Patient 17 
 
Patient had an irregular sleeping pattern and so pre-planned times were 
arranged for the setting up and collection of equipment each day. 
Following night one, the timings had to be adjusted to be better suited to 
the patient’s needs. It was noticeable that sleep duration was longer than 
anticipated and so the recording box was reconfigured to ensure the 
monitoring sleep for a corresponding period on nights two and three. 
Also, the researcher adjusted the time they went to patient’s home to set 
up equipment to be later on nights two and three to ensure complete 
recording for battery power available. Patient also noted they sleep during 
daytime and this is their usual sleep pattern. This should be noted for 
future assessment (PSG for daytime sleep) 
 
Patient 18 
 
Wore equipment on bare skin as too hot at night. Patient also noted that 
he regularly slept during the day and made note of the times he had done 
so. 
 
Patient 19 
 
Due to commitment to voluntary work in the morning, procedural aspects 
had to be considered with regards to planning timing of saliva sampling 
and the researcher collecting the equipment. Otherwise no problems with 
the equipment. 
 
Patient 20 
 
Equipment placed on skin under bed wear due to experiencing hot flushes 
during the night. Patients found the first night difficult in terms of gaining 
quality sleep, but felt this improved throughout the course of the study. 
 
 continued over page 
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Patient 21 
 
Patient felt more comfortable adjusting placement of shoulder strap each 
night, to prevent discomfort. No problems with other procedural aspects, 
but felt sleep quality was affected on night one after feeling unwell during 
the following day, but felt his sleep gradually improved over the three 
nights. 
 
Patient 22 
 
Housebound, application of equipment done whilst patient remained in 
the bed. Carer aided in washing hair each day (to remove paste), changed 
the shoulder strap each night (different shoulder each night) for comfort. 
Equipment ok except nasal thermistor felt uncomfortable, and Actiwatch 
noticeable during sleep i.e. hitting self in face. Patient found the study 
only manageable because researcher came to her home each evening and 
morning. 
 
 
6.4 Discussion 
This is the first study to systematically assess and report on the feasibility and 
acceptability of a comprehensive 3-night and 3-day sleep and cortisol assessment in a 
group of patients with CFS. The data indicates that the 3-night ambulatory 
Polysomnographic assessment and gold-standard protocol for saliva sampling to assess 
cortisol was possible in this patient group, and further that the patients tolerated the 
protocol successfully.  
 
6.4.1 Feasibility and Acceptability 
6.4.1.1 As indicated by recruitment and attrition 
There was a very low refusal rate in the study. Of those patients considered eligible for 
enrolment, only three did not consent to take part in the study; their reasons being 
health-related and not associated to the study. This suggests that the idea of the study 
and its procedures was acceptable to all patients. The acceptability of the study was 
further confirmed by the 0% drop out rate. All patients who were eligible to continue 
on with the assessment beyond night one (screening), did so. Those that did 
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continue (N =2) were those who met the exclusionary criteria based on AHI Index ޓ15, 
making them ineligible. In general, patients were all highly motivated to take part in 
the study.  
6.4.1.2 As indicated by adherence to the assessment protocol 
The protocol was possible in all eligible patients that took part, which emphasises the 
feasibility of incorporating all the included procedures of a detailed 3-night PSG sleep 
assessment with a gold-standard measure for saliva sampling. Overall, the protocol 
was well tolerated, with only minor issues relating to individuals and their experience 
of the equipment (sensitivity, planning, energy depletion), also it is worth emphasising 
how several patients brought to light of the issue of daytime sleep, and this also posed 
a problem with regard to analyses, where a night of PSG data for one patient had to be 
excluded due to no nocturnal sleep having been recorded. With regard to fidelity to 
procedures; all patients were consistent in pressing the marker on the PSG box 
(important for determining lights out and lights on timings when researcher is not 
present) on nights two and three, and accurate in reporting their retrospective sleep and 
wake times on the sleep diary as affirmed by the marker press. Patients were also 
consistent in their saliva sampling, with only one individual sample not taken, and this 
being for health-related issues. Whilst patients adhered to the study procedures, after 
an evaluation of timing discrepancies between self-reported wake time and the time of 
first saliva sample, there was an average discrepancy of 5.1 (± 6.9) minutes. It should 
be noted that the accuracy in patients reporting their wake and sample timings was the 
key outcome for fidelity here and, despite two (P16, P19) patients delaying the 
provision of their first sample, their honesty in reporting the discrepancy between these 
timings is what was most important. 
 
From the viewpoint of feasibility, these findings indicate that the sleep and cortisol 
protocol was indeed acceptable to these patients. This is ideal from the clinical 
viewpoint of conducting quality procedures for sleep and cortisol assessments with 
CFS patients, where thorough screening and measures are warranted, and one night of 
assessment is inadequate (Le Bon, et al., 2003). The feasible nature of this protocol is 
also of value to the research domain, where prospective sleep studies can utilise a 
detailed sleep protocol effectively with CFS patients, without a need for less than gold-
standard measures, thus affording for more quality research.  
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6.4.2 Limitations and future directions 
It is important to note that this study was an assessment of protocol feasibility and did 
not intend to infer definitive judgements with regard to patients’ sleep and cortisol 
profiles. The preliminary characterisation of sleep in these patients (see chapter 7) was 
in itself an outcome of feasibility success, and adds support for the heterogeneity of 
sleep in CFS as a topic for further exploration. 
 
As identified throughout the monitoring process, several patients were sleeping during 
the daytime and did this on a regular basis as part of their usual sleeping pattern. This 
was problematic for the procedural aspects of the nocturnal assessment, where 
recording ambulatory PSG relies somewhat on battery life, it was not possible in these 
circumstances to record beyond the nocturnal sleeping period. This should be made a 
consideration for future ambulatory sleep assessments with patients who may be likely 
to spend a notable amount of their sleep schedule outside of the nocturnal period. 
Thus, to ensure complete feasibility of this protocol in CFS patients, it should allow for 
the daytime monitoring of sleep to account for these irregular patterns, through 
sufficient planning and by ensuring equipment is able to tolerate the timings. 
 
In addition to the alpha activity/arousability association (Perlis, et al., 1997), beta EEG 
activity in insomnia has been linked with central nervous system hyperarousal (Perlis 
et al., 2001). Beta activity, like alpha, is also high frequency and occurs in the lighter 
stages of sleep. This appears to be relevant in light of the findings of the present study. 
Patients may present as having normal amounts of stage 2 sleep (45-55%) but, this 
sleep may be more high frequency. Future work may want to consider utilising 
techniques that enable the assessment of these frequencies, such as the Q- EEG 
(quantitative electroencephalography), where electrical patterns can be measured and 
for example, alpha and beta waves could be identified according to their frequency.  
 
Physiologically, the study has developed a standardised protocol for the assessment of 
salivary cortisol in an ambulatory setting with CFS patients. This demonstrates how 
we have the ability to measure basal HPA functioning in a naturalistic setting with this 
patient group, an environment that is not stressful or medicalised. The feasibility of 
this protocol in conjunction with the detailed assessment of sleep warrants moving 
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forward with more mixed methods study designs. This is important for research that 
looks to explore the interaction between sleep processes (circadian rhythm, melatonin) 
and HPA axis functioning within the same patient. It echoes the holistic view of CFS 
and its’ pathogenesis, where it is the reciprocal interaction of processes that serves to 
keep the condition going (Moss-Morris, Deary & Castell, 2013).     
 
In consideration of sleep interventions, outcomes for CBT-I (cognitive behavioural 
therapy for insomnia) and its efficacy in somatoform disorders such as fibromyalgia 
has been demonstrated (Sánchez, et al., 2012), however, it is yet to be trialled in a CFS 
population.  Using PSG to measure its efficacy, CBT-I has been shown to be effective 
in significantly improving objective sleep parameters, specifically in reducing the 
amount of light sleep (stages 1 & 2) and awakenings in patients, and increasing deep 
sleep (stages 3 & 4) (Sánchez, et al., 2012). Furthermore, sleep restriction, a 
componential aspect of CBT-I has been shown to reduce cortical processing (Vallieres 
et al., 2013). The findings from these studies may also have therapeutic potential for a 
CFS population, and, if such interventions are shown to be effective, they offer the 
potential to be useful in the multidisciplinary management of CFS. 
 
6.4.3 Conclusion 
This study was a process of determining feasibility and acceptability of the 3-night 
sleep and cortisol assessment in a small group of CFS patients. As previously 
mentioned, there are no sleep studies with CFS patients that utilise such detailed 
protocol. It is proposed that the protocol described in this study (integrating the 
methods and procedures as shown to be well tolerated), is a valuable means of sleep 
and cortisol assessment. It affords more detailed exploration of sleep parameters than 
what is currently being used in practice with CFS patients, and is able to identify (and 
exclude on this basis) primary sleep disorders after one single PSG assessment night.  
Importantly though, it is the acceptability of this protocol to patients which highlights 
how methodologically, the procedures and equipment are not intrusive or detrimental 
to their existing experience of their CFS. This protocol has the potential to be utilised 
in future sleep studies and could be used for clinical screening of sleep-related 
disturbances in CFS.  
125 
CHAPTER SEVEN                                                                                     
PRELIMINARY SLEEP RESULTS FROM A 3-NIGHT AMBULATORY PSG 
SLEEP ASSESSMENT IN PATIENTS WITH CFS  (STUDY 4) 
 
 
 
 
 
 
 
 
7.1 Introduction 
The 3-night sleep protocol (fully described in chapter 6) was considered both feasible 
and acceptable by the group of CFS patients. This is important for future studies 
pursuing sleep-based research with this patient-group, where a detailed, thorough 
assessment of sleep is key, particularly with regard to methodological uniformity and 
upholding standardised means of reporting results.  The current chapter intends to 
describe the preliminary sleep characteristic results of the study. These results will 
provide an insight into the sleep complaints presenting in this patient group, and the 
extent to which they differ from normal sleep parameters. 
 
7.2 Methods 
7.2.1  Objectives (secondary) of Study 4  To clinically characterise patients on symptom severity and functional status;  To preliminary characterise sleep (subjective and objective) in patients with 
CFS, based on measures derived from the methods utilised in the 3-night 
ambulatory sleep assessment (Chapter 6). 
 
These objectives were measured through scores derived from symptom and functional 
assessments, retrospective reports of patient’s sleep, and the objectively-derived PSG 
measures taken from night two and three of assessment. 
In this chapter, the preliminary findings from the sleep assessment feasibility study 
(Chapter 6) are described. This chapter is not intended to present effectiveness data, but 
instead offer a preliminary characterisation of sleep and cortisol profiles in these patients. 
Finally, the stability of the polysomnograpic measures of patient’s nocturnal sleep are 
discussed with a view to informing future studies. 
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7.2.2  Outcomes (secondary) 
The secondary outcomes of study 4 were the descriptive measures taken to clinically 
characterise patients based on their symptom and functional assessments; subjective 
and objectively-derived sleep variables. These outcomes were assessed with regard to 
their variability across the patient sample. Outcomes for sleep characteristics were also 
assessed with regard to; 1) their variability across nights two and three (evaluated by 
comparing mean sleep variables measured by nocturnal polysomnography on night 
two and the same sleep variables for night 3, to determine temporal stability of the 
continuity and main architectural sleep variables); 2) a comparison of subjectively 
(diary) reported sleep and objectively (PSG) measured sleep parameters (SOL, WASO, 
TST, SE), and their level of concordance, based on average across nights two and three 
of the assessment; and 3) outcomes for sleep characteristics were further evaluated in 
relation to comparative quantitative benchmarks of sleep disturbance (Edinger. et al., 
2004), and criteria for normal architectural parameters (Carskadon & Dement, 2011). 
(Refer to table 4.1 for description of abbreviated sleep variables).  
 
7.2.3  Statistical methods 
To analyse the secondary outcomes of the study, 1) paired samples t-tests were used to 
compare sleep variables (see table 7.2 for included sleep variables on t-test), as 
measured by nocturnal Polysomnography on night two, and the same mean sleep 
variables, as measured by nocturnal Polysomnography on night three, as a determinant 
of temporal stability; 2) a correlational analysis was used to determine the level of 
concordance between objective and subjectively derived measures of sleep by 
comparing SOL, WASO, TST and SE as measured by nocturnal Polysomnography 
with SOL, WASO, TST and SE as measured by the Sleep Diary respectively; 3) 
additionally, descriptive statistics, including frequencies and percentages, were used to 
describe the sample in terms of their objectively measured sleep variables, comparing 
these sleep characteristics to quantitative benchmarks of sleep disturbance (Edinger. et 
al, 2004), and the criteria for normal architectural parameters (Carskadon & Dement, 
2011).  
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7.3 Preliminary Results 
7.3.1 Baseline data 
7.3.1.1 Patient characteristics 
The descriptive measures taken to clinically characterise patients were based on their 
symptom and functional assessments, including self-reported retrospective sleep 
assessment. (Table 7.1 shows the baseline demographic and clinical characteristics of 
patients in the study, including the mean scores obtained on each of the functional and 
symptom assessments; Table 7.2 shows the subjective sleep characteristics based on 
self-report measures of sleep). 
 
Demographically, there were a smaller proportion of men to women (25%; 5/20 and 
75%; 15/20 respectively), with a mean age of 43.9 (±10.1) years at the time of study. 
The mean time since diagnosis (length of illness at time of study) was 131 (±100) 
months, but highly variable across the group, ranging from 7 to 312 months. Most 
patients were not in employment (80%; 16/20), with 9 (56.3%; 9/16) on disability. Of 
those who were in employment at the time of the study (25%; 5/20), only one patient 
was working on a full-time basis, with 80% (4/5) working part-time hours. All but two 
patients took some form of medication, mostly pain relief and herbal remedies, with 
nine patients taking a form of anti-depressant (45%; 9/20). All patients were non-
smokers and only four (20%; 4/20) patients consuming alcohol on a daily basis. The 
mean Body Mass Index (BMI) of patients in the study was 25.83 (±3.97), only slightly 
above what is classified the healthy range (18.5-24.9) for adults. 60% (12/20) of 
patients were able to integrate a form of exercise into their lifestyle, on at least one day 
per week, with a quarter of these patients (25%; 3/12) factoring in exercise every day. 
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Notes: data presented as mean (SD), N=20. npv, no published values for caseness score cut-offs on 
scale/measurement. BMI, body mass index; GHQ-28, general health questionnaire; DSQ, DePaul symptom 
questionnaire; SF-36, short form 36-item health survey; CFQ, Chalder fatigue questionnaire; HADS, hospital 
anxiety and depression scale; IPQ, illness perception questionnaire; WSAS, work and social adjustment scale; PSS, 
perceived stress scale. 
 
 
Table 7.1: Clinical and demographic characteristics of patients with CFS. 
 
 
 
Characteristics of sample  Caseness 
N (%) 
Demographics   
        Gender (M:F) M: 5/20(25%) F: 15/20(75%) - 
        Age (years) 43.85 (10.11) - 
        Time since diagnosis (months) 131.05 (100.01) - 
        BMI 25.83 (3.97) - 
Functional & symptom assessment   
        GHQ-28 
        DSQ (frequency) 
        DSQ (severity) 
29.95 (10.02) 
117.55 (33.63) 
110.70 (28.18) 
15 (75%) 
11 (55%) 
11 (55%) 
        SF-36 (general health perceptions) 29.50 (17.91) 16 (80%) 
        SF-36 (physical functioning) 25.00 (14.42) 19 (95%) 
        SF-36 (role physical) 6.25 (13.75) 19 (95%) 
        SF-36 (energy/fatigue) 19.00 (15.78) 19 (95%) 
        SF-36 (social functioning) 35.13 (22.23) 12 (60%) 
        SF-36 (pain) 36.75 (17.86) 15 (75%) 
        CFQ (physical) 15.55 (4.95) npv 
        CFQ (mental) 8.85 (3.31) npv 
        CFQ (total) 24.40 (7.78) 19 (95%) 
        HADS anxiety 7.80 (3.68) 11 (55%) 
        HADS depression 8.55 (3.09) 12 (60%) 
        IPQ 51.40 (8.60) npv 
        WSAS 28.45 (6.46) 19 (95%) 
        PSS 29.50 (7.15) npv 
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Patient’s mean General Health Questionnaire scores exceeded the caseness threshold 
of 22 (Goldberg & Williams, 1988), with 75% of patients scores equalling or 
exceeding the threshold based on their total GHQ-28 scores.  
 
As a representation of illness burden, mean total DSQ scores for frequency and 
severity of symptoms (117.55 ± 33.63, and 110.70 ± 28.18, respectively), exceeded the 
recommended threshold criteria (total frequency score ≥108, total severity score ≥108, 
based on individual item scores ≥2) that differentiates controls from CFS (Brown and 
Jason, under review); more than half of patients exceeded the threshold for frequency 
and this was comparable for severity.  
 
Patients’ quality of life scores were lower than the general population norm on all QoL 
domains measured by the SF-36 (Ware & Sharebourne, 1992); over half had scores 
representing impaired social functioning. The majority of patients had lower than 
normal functional scores on general health perceptions and bodily pain, and 95% of 
patients had functional impairment on their limits in physical activities, limits in usual 
role activities due to physical health, and  on vitality (energy/fatigue). 
 
In consideration of the CFS case definition recommendation for meeting disability 
criteria (Reeves et al., 2005) and representing significant reductions in occupational, 
educational, social, or recreational activities, all patients (20/20) met the defined scores 
on physical functioning (≤70) and on social functioning (≤75). 95% of patients (19/20) 
met the criteria on role physical functioning (≤50). 
 
Based on the CFQ, a measure of the severity of symptomatic fatigue, patients’ mean 
fatigue levels (24.40 ± 7.78) were higher than what is considered within the normal 
range for fatigue, based on the Likert-based scoring threshold (ޒ18) (White et al., 
2013), with 95% of patients having scores equalling to or greater than 18 on the 
questionnaire.  
 
On HADS (Zigmond and Snaith, 1983), where the caseness cut off for anxiety and 
depression is 8 on both subscales (Crawford et al., 2001), average depression (8.55 ± 
3.09) and anxiety (7.80 ± 3.68) scores, showed patients met caseness for depression, 
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and were approaching caseness on anxiety. In consideration of individual patient 
characteristics, over half of the sample met caseness for depression and for anxiety.  
 
In assessing illness perception in patients, i.e. the degree to which they perceived their 
illness as threatening (IPQ), there are no published indicators of “caseness” for the 
scale, but higher scores represent a more threatening view of the illness, thus on 
average mean illness perception scores were moderate (51.40 ± 8.60) and ranged from 
33-68 out of a possible 80.  
 
Average WSAS scores exceeded the clinical threshold for severe functional 
impairment (ޓ20) (Mundt et al., 2002), with all but one patient‘s scores exceeding 20 
on the scale. One patient scored in the range (10-20) that is still associated with 
significant functional impairment but less severe clinical symptomology.  
 
On the PSS, mean scores (29.50  ± 7.15) indicated a high degree of perceived stress 
among patients. Scores ranged from 14-44 out of a possible 80. 
 
 
7.3.2 Preliminary characterisation of sleep variables 
7.3.2.1 Patient sleep profiles; self-reports 
The table below (table 7.2) displays the sleep characteristics of CFS patients in the 
study, based on retrospective sleep questionnaires (PSQI, FIRST, ISI) completed 
during the pre-assessment phase of the study. It also shows the included continuity and 
main architectural sleep variables from the PSG-derived measures, taken from night 2 
and night 3 of the sleep assessment. As detailed in the study flow section, complete 
sleep measures (night 2 and night 3) were not available for one participant, thus all 
objective sleep-related analyses were carried out on the sleep data of the remaining 19 
patients (note N varies in Table 7.2 below). 
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Notes: PSQI, Pittsburgh sleep quality index; FIRST, ford insomnia response to stress test; ISI, insomnia severity 
index; PSG, polysomnography; SOL, sleep onset latency; WASO, wake after sleep onset; TST, total sleep time; 
%N1, percentage of stage 1 sleep; %N2, percentage of stage 2 sleep; %N3, percentage of slow wave sleep; %REM, 
percentage of rapid eye movement sleep; NWAK. number of awakenings; SEI, sleep efficiency index; TSP, total 
sleep period 
 
Table 7.2: Sleep characteristics of patients derived from retrospective and objectively - 
(PSG) derived measures. 
 
 
 
Sleep Characteristics Mean (SD) 
Self-report (N = 20)  
             PSQI (subjective sleep quality) 1.55 (0.69) 
             PSQI (sleep latency) 0.85 (0.93) 
             PSQI (sleep duration) 0.65 (0.93) 
             PSQI (habitual sleep efficiency) 0.80 (1.06) 
             PSQI (sleep disturbances) 1.75 (0.44) 
             PSQI (use of sleep medication) 0.60 (1.14) 
             PSQI (daytime dysfunction) 1.55 (0.94) 
             PSQI (global) 8.75 (3.45) 
             FIRST 25.6 (6.73) 
             ISI 13.75 (4.68) 
PSG Variables (N = 19) (n2) (n3) (average n2 & n3) 
            TST (min) 465.42 (97.43) 442.39 (85.85) 453.91 (73.74) 
            SOL (min) 16.00 (16.38) 28.95 (29.55) 22.47 (20.49) 
            WASO (min) 32.11 (17.45) 42.16 (42.26) 37.13 (24.32) 
            SEI (%) 93.42 (3.53) 91.64 (7.35) 92.53 (4.18) 
            %N1 (of TST) 4.81 (2.93) 4.33 (2.11) 4.57 (2.26) 
            %N2 (of TST) 54.47 (11.59) 53.15 (11.58) 53.81 (10.57) 
            %N3 (of TST) 18.40 (10.64) 17.07 (10.38) 17.74 (9.74) 
            %REM (of TST) 22.33 (5.72) 25.45 (8.11) 23.89 (5.80) 
            REM Latency (min) 142.39 (80.87) 140.00 (84.33) 141.20 (70.60) 
            NWAK (over TSP) 
            % wake (over TSP) 
Subjective Sleep Diary (N = 19) 
            TST (min) 
            SOL (min) 
            WASO (min) 
            SEI (%) 
17.58 (8.36) 
9.54 (4.70) 
(n2) 
452.79 (111.26) 
34.47 (31.53) 
46.05 (56.34) 
77.83 (14.95) 
18.37 (10.34) 
13.01 (9.39) 
(n3) 
446.47 (113.34) 
33.16 (22.62) 
46.05 (56.34) 
77.83 (14.95) 
17.97 (7.90) 
11.27 (5.74) 
(average n2 & n3) 
448.68 (101.31) 
33.95 (21.67) 
41.58 (56.48) 
78.89 (13.51) 
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Data were also collected for 22 normal sleepers. However, because these were 
considered in the normal range and the study was not intending to make between-
groups comparisons, the data for normal sleeper participants can be found in 
(Appendix BB) 
 
All patients had PSQI global scores of 5 or more, exceeding the threshold that is 
indicative of poor quality sleep (≥5). Scores ranged from 5 to 17 points, with a group 
mean of 8.75 (± 3.45). For individual components (subjective sleep quality, sleep 
latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping 
medication, daytime dysfunction), each with a possible range of 0-3, the observed 
ranges were 0-3. 
 
In considering the severity of patients’ self-reported sleep difficulties, mean ISI scores 
(13.75 ± 4.68) indicated the sleep difficulties reported by this patient group were 
‘subthreshold insomnia’, with 50% (10/20) of patients reporting as having sleep 
difficulties meeting criteria for this category (8-14). 40% of patients (8/20) met 
‘caseness’ for clinical insomnia (ISI score 15-21)), and one patient’s sleep difficulties 
were classified as ‘severe’. 10% of patients (2/20) were not considered as having 
clinically significant insomnia (total ISI score ≤ 7) (Morin et al., 2011). 
 
In light of Stress-related vulnerability to sleep disturbance, patients were considered as 
‘high scorers’ (total FIRST score ޓ 20) (Drake et al., 2004), (mean 25.6 ± 6.73), with 
patient’s scores in the range of 12-36: 85% (17/20) of patients in this group were 
considered high scorers.  
 
7.3.2.2 Patient sleep profiles; Polysomnography 
When characterising patient’s sleep based on the objectively derived PSG measures, 
sleep continuity parameters were considered within the ‘normal’ range, using 
quantitative benchmarks of sleep disturbance outlined by Edinger et al (2004). On 
average, total sleep duration was 7.6 hours (453.91 minutes) (± 1.2 hours (73.74 
minutes)), with all but one patient (94.7%; 18/19) exceeding the minimum threshold 
for ‘normal sleep’ (ޒ 6 hours is considered problematic).  It can also be seen that 
patients fall in the ‘normal’ range for sleep latency (SOL ≥ 30 minutes denotes a sleep 
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problem), taking on average 22.47 (± 20.49) minutes to reach their first episode of 
stage 2 sleep from lights out. Of note is the variability in the sample, SOL ranged from 
1.75-64.25 minutes, and 36% (7/19) did exceed the 30 minute threshold. Patient’s 
sleep efficiency index (92.53 ± 4.18%), met the criteria for what is considered ‘normal 
sleep’ (≥85% sleep efficiency is considered normal), with 94.7% (18/19) patients 
showing a sleep efficiency index greater than 85%. 11 patients exceeded the threshold 
for what is considered a problematic duration of wake (WASO ≥ 30 minutes denotes a 
sleep problem), with an average 37.13 (±24.32) minutes of recorded wake time 
following the first episode of stage 2 sleep, 57.9% (11/19) of patients were spending 
longer than 30 minutes awake during the sleep period. It should be noted that WASO 
was also highly variable across the sample, and ranged from 8.75 minutes to as much 
as 110.50 minutes wake during the night. Patients on average had longer REM 
latencies (mean 141.20 ± 70.60 minutes) than what is usual for ‘normal sleep’ (90 
minutes is considered the ‘normal’ length of time to get to first REM stage). 63.2% 
(12/19) of patients had REM latencies greater than 90 minutes. It was also highly 
variable; a range of 65.5 minutes to as long as 291.8 minutes was observed in the 
sample. 
 
Further, when comparing the percentages of each sleep stage in ‘normal’ adult sleepers 
(i.e., ޒ5% wake, between 2% and 5% stage 1, between 45% and 55% stage 2, between 
13% and 23% SWS and between 20% and 25% REM (Carskadon & Dement, 2011)) 
to those observed in the present sample, patients on average fell within the ‘normal’ 
parameters for time spent in each of the sleep stages (see Table 7.2 for mean and SD of 
architectural sleep variables). They do however, exceed the threshold for the amount of 
wakefulness during the sleep period; with a mean of 11.27 (±5.74) % wake time, with 
a range from 5.05% to 26.75%, all patients spent more than 5% of their sleep awake. 
Architecturally, the sample does not present objective sleep difficulties with regard to 
time spent in the sleep stages. They are however, spending a marked amount of time 
awake. Of note though, is the architectural variability in the sample. With this in mind, 
it is of particular interest to highlight that stage 2 sleep ranged from 28.1% to as much 
as 72.9% of the night, with more than half of patients spending over 55% of the night 
in this lighter stage of sleep (52.6%; 10/19).  
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7.3.3 Stability of sleep variables across night 2 and night 3 
After building a sleep profile of patients from the sleep parameters identified, it is of 
interest to establish whether these sleep characteristics are stable across different 
nights. By assessing the temporal stability of Polysomnographic variables across 
different nights of assessment, it adds to the evaluation of protocol feasibility in terms 
of what might be considered a sufficient number of study nights to gain the most 
accurate characterisation of patients’ sleep. It should be noted that the first night of 
PSG data was discarded. This is typical of multi-night PSG sleep assessments due to 
the novelty of the procedure to patients.  
 
To assess the temporal stability of the sleep variables, a paired samples t-test was 
carried out to compare the selected sleep variables (continuity and main architectural 
variables) on the two assessment nights (2 and 3). The paired comparisons showed that 
sleep onset latency (SOL) was the only variable to be statistically different from night 
2 to night 3. SOL was significantly longer on night 3 (28.95 ± 29.55 minutes), than on 
night 2 (16.00 ±16.38 minutes) (refer to table 7.2 for means and SDs for individual 
study nights), t(18) = -2.30, (95% CI 1.10 - 24.79 minutes) (see table 7.3 for mean 
differences from the paired comparisons). However, after conducting statistical 
corrections for multiple comparisons (.05/11), an adjusted Bonferroni alpha level of 
.005 resulted in no statistically significant differences observed from night 2 to night 3 
on all sleep variables. This demonstrates that a third study night may not be needed, 
for the purposes of research constraints. 
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Notes: N = 19, *p ޒ .05. SOL, sleep onset latency; WASO, wake after sleep onset; TST, total sleep time; N1, stage 
1 sleep; N2, stage 2 sleep; SWS, slow wave sleep; REM, rapid eye movement sleep; SEI, sleep efficiency index;  
TSP, total sleep period; NWAK, number of awakenings 
 
 
Table 7.3.: Mean differences following the second assessment night on equivalent 
sleep variables (t-test: paired samples). 
 
 
 
 
 
 
136 
This finding demonstrates the temporal stability of variables across study nights. Those 
variables that were identified as being outside of the ‘normal’ sleep parameters 
(WASO, REML, %WAKE) when profiling patients, remained abnormal over both 
nights; REML, as previously identified as being abnormally long, was shown to be 
consistently so across both nights. WASO as previously identified as longer than what 
is seen in normal sleep, was also consistently abnormal across both nights. The 
remaining sleep variables (TST, SEI, NWAK, % stage 1, % stage 2, % SWS, % 
REM,), remained within the parameters for ‘normal’ sleep (as identified previously in 
the profile), consistently across both nights. This stability of the sleep variables across 
study nights is a good indication that two nights are sufficient to determine objective 
sleep profiles in CFS patients, and move forward with this protocol for future studies 
with larger samples. 
  
7.3.4 Subjective vs Polysomnographic assessment of sleep  
Interestingly, based on the retrospective measures of sleep (PSQI, ISI, FIRST), 
patients scored highly across all assessments for reporting sleep difficulties and poor 
quality sleep. On the other hand, the objectively-derived PSG measures shed a 
different light; patients’ sleep profiles on the whole appeared to reflect 'normal sleep' 
parameters, presenting abnormalities on only one continuity variable (WASO), and  in 
the architectural variables of %WAKE and REM latency. 
 
It is therefore of interest to explore this discrepancy further. To evaluate the level of 
concordance between the two assessment modalities; self-reported measures of sleep 
based on the sleep diary; and the objectively derived Polysomnographic variables 
(PSG), a Pearson product-moment correlation was carried out to determine the level of 
agreement between corresponding sleep variables (TST, SOL, WASO and SE) derived 
from the two assessment modalities (based on an average of night 2 and night 3). 
 
TST as measured by the PSG (453.91 ± 73.74 minutes) and TST self-reported on the 
sleep diary (448.68 ± 101.31 minutes) were significantly correlated, r = .65, p < .01, 
indicating a strong positive relationship between objectively derived (PSG) measures 
of total sleep time and total sleep time as self-reported (sleep diary) by patients (See 
table 7.4). Patients were therefore accurately estimating their sleep duration. However, 
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there was a nonsignificant correlation of .21 (p = n.s) between SOL measured by the 
PSG and SOL self-reported on the sleep diary.  There was also a nonsignificant 
correlation of .32 (p = n.s) between WASO measured by the PSG and WASO self-
reported on the sleep diary, and a further nonsignificant correlation of .37 (p = n.s) 
between SE measured by PSG and SE derived from sleep diaries. This indicates that 
patients were overestimating the amount of time it took them to get to sleep and the 
amount of time they were spending awake during the night. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: N =19 aValues are means; values in parentheses are standard deviations.*p ޒ .01  
TST, total sleep time; SOL, sleep onset latency; WASO, wake after sleep onset; SE, sleep efficiency; PSG, 
polysomnography 
 
 
Table 7.4: Comparison of Sleep Parameters: PSG vs. Sleep Diary: Pearson Product-
Moment Correlation Coefficients. 
 
 
Patients appear to be misestimating their wake duration, sleep latency and overall sleep 
efficiency. This highlights the importance of accurate measurement of sleep to 
evaluate the severity of patients’ sleep complaints, which is critical in being able to 
adequately manage sleep disturbances that are commonly reported by CFS patients. 
 
 Means
a
 Correlation  
Sleep Parameters PSG Diary Pearson r p (2-tailed) 
     
TST (min) 453.91 
(73.74) 
448.68 
(101.31) 
 
.65 .003
* 
SOL (min) 22.47 
(20.49) 
33.95 
(21.67) 
 
.21 .379 
WASO (min) 37.13 
(24.32) 
41.58 
(56.48) 
.32 .179 
 
SE (%) 
 
78.89 
(13.51) 
 
92.53 
(4.18) 
 
.37 
 
.123 
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7.4 Discussion 
As previously mentioned, study 4 was carried out to determine the feasibility and 
acceptability of a comprehensive 3-night and 3-day sleep and cortisol assessment in 
CFS. In addition to determining feasibility, the study protocol also enabled the 
preliminary characterisation of sleep profiles in patients with CFS; including the 
assessment of sleep variables’ temporal stability, and the level of concordance between 
the subjective and objective measures of sleep. 
 
7.4.1 Sleep findings 
Prior to the sleep assessment, patients self-reported their sleep as disturbed and of poor 
quality, as demonstrated by the retrospective measures. However, on initial 
examination of patients’ sleep profiles, based on the objectively derived measures 
(PSG), on average they fell into the parameters of ‘normal’ sleep.  However, the 
variability in values derived on each of the sleep parameters is of relevance; it 
highlights how a significant minority of the sample fell outside of the ‘normal’ 
parameters, a reflection of the heterogeneity of sleep, and is also characteristic of 
patient’s sleep profiles as identified in the previous studies. For example, increased 
amounts of stage 2 sleep mirrors what has been shown in patients characterised by the 
second phenotype identified in the cluster analysis of CFS patients from study 3, (as 
described in Chapter 5), and its association with information processing, arousability 
and the perception of sleep in fibromyalgia patients has also been demonstrated  
(Perlis, et al., 1997). Alpha activity (a shallow form of sleep), has been associated with 
an increased tendency to arouse to external stimuli in fibromyalgia patients, and to the 
perception of more shallow sleep, but interestingly not related to pain (Perlis, et al., 
1997). This increased arousability could be trans-diagnostic for functional symptoms; 
the tendency for patients to arouse more during sleep may result in more fragmented 
sleep, as suggested by Shneider-Helmert and Kumar (1995), which in turn has been 
implicated in daytime fatigue and nonrestorative sleep, (Stepanski et al., 1984), 
fundamental symptom complaints of patients with CFS.  
 
Combining methods of sleep assessment enabled the examination of sleep variables 
derived from the different assessment modalities (subjective sleep diary vs objective 
PSG). Patients were accurate in their estimation of sleep duration. However, 
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estimations of wake duration and the time it took them to get to sleep were not 
concordant with the objectively derived measures. This finding mirrors the discrepancy 
found between subjective and objective measures of sleep, previously seen in CFS; 
Watson and colleagues (2003) demonstrated no differences between the healthy and 
CFS twins on objective measures of sleep abnormalities despite significant self-
reported sleep complaints from the CFS twins. This suggests CFS patients require an 
objective assessment of their sleep pattern, and these objective methods, and the PSG 
and Actigraph have been shown to be feasible in this population.  An overestimation of 
SOL and underestimation of TST, relative to objective measures, mirrors what is seen 
in patients with insomnia. Explanations for these important discrepancies have been 
offered by Perlis et al (1997), suggesting a potential preoccupation with sleep or 
cortical arousal during the onset of sleep. The presence of high frequency EEG activity 
around sleep-onset is associated with a range of waking cognitive functions, such as 
attention, perception, problem-solving, and memory, which results in blurred 
phenomenological distinction between sleep and wakefulness. However, the 
identification of such cortical arousal during the onset of sleep is measured by 
quanitative EEG (qEEG) and is therefore a consideration for future sleep studies. 
 
Another finding of this feasibility study was that all sleep variables were shown to be 
stable across two nights of measured sleep. The PSG protocol therefore offers temporal 
stability and affords, if needed, the efficacy to carry out two rather than three nights of 
recording.  
 
7.4.2 Conclusion 
In addition to establishing protocol feasibility in this patient group, study 4 was also 
able to provide preliminary sleep results based on the data obtained from patients 
across the 3-day period. The study afforded the opportunity to establish a profile of 
sleep in patients. It also confirmed the temporal stability of sleep continuity and main 
architectural variables across two nights of assessment. Of note, variability of sleep 
was confirmed to exist in this population, and, as such, the establishment of a 
successful protocol for effective and thorough sleep assessment is a key advancement 
in this domain. 
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CHAPTER EIGHT                                                                                  
DISCUSSION 
 
 
8.1 Introduction 
This thesis intended to examine the role of sleep in CFS from a number of 
methodological perspectives, from the personal through to the biological. Firstly, a 
qualitative interview study with patients focused specifically on the patients’ lived 
experience of sleep. This preceded an evaluation of patient sleep diaries and the 
examination of sleep quality and its association with key dimensions of the illness 
experience. A third study examined the largest PSG dataset of CFS patients to date, 
revealing a significant proportion of the sample had a PSD, and identified four sleep-
specific phenotypes in the remaining patients. The final study combined subjective and 
objective methods of assessment and demonstrated feasibility of the most 
comprehensive sleep and cortisol protocol ever attempted in a group of CFS patients.  
 
Importantly, the research has established that a range of research methods are possible 
and acceptable to CFS patients, and, the grounds have been established for a 
comprehensive protocol to assess sleep. It is evident from this work, and from existing 
sleep research in CFS, that sleep needs to be measured more effectively, and the 
feasibility study has demonstrated that this is possible. Further, by considering how 
sleep serves to exacerbate or maintain other symptoms in CFS patients, we can expand 
our existing theoretical models and integrate a fuller account of sleep into the interplay 
of social, behavioural, psychological and autonomic components that may contribute 
to this illness. These factors should be considered mutually, in both research and 
clinical settings when working with CFS patients to assess and manage/treat their sleep 
problems.  
 
The following section will summarise the main findings of this biopsychosocial 
research programme, and will move on to revisit the biopsychosocial model and the 
specific role of sleep in CFS. The subsequent sections will describe a recommended 
gold standard protocol for sleep assessment in CFS, followed by the study limitations 
and the implications of this research programme for future clinical and research work. 
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8.2 Main Findings 
The qualitative study highlighted how patients regarded their disturbed sleep as 
playing a key role in the maintenance of their symptoms and having a large impact on 
their quality of life; bodily pain, confusion and concentration problems were all 
exacerbated by poor sleep. Similarly, in the diary study, sleep emerged as a significant 
predictor of impaired daytime functioning; specifically, longer periods of wake time 
were associated with more daytime fatigue. In addition, afternoon napping (in 
combination with higher depression scores) was particularly detrimental to patients’ 
objective cognitive functioning.  
 
Sleep measured objectively via PSG in patients was shown to deviate from normal 
sleep parameters (Edinger, 2004). However, it is important to note that no consistent 
pattern in sleep abnormalities was identified. This lack of homogeneity in sleep 
complaints may be a reflection of the different phenotypes identified in study 3 
(chapter 5). That study is the first to suggest, and identify, specific sleep-phenotypes in 
a large sample of patients with CFS. The critical finding here was that the sleep in 
those with CFS, without Sleep Apnoea or PLM Disorder, centred around four specific 
sleep-disturbed phenotypes, each group demonstrating a unique combination of sleep-
specific complaints. These four sleep phenotypes are a crucial, albeit preliminary, 
finding, but may offer an indication as to why existing PSG studies with CFS patients 
may have gathered mixed results (Jackson & Bruck, 2012). Above all, the information 
from this cross-sectional study can be useful to inform, in conjunction with other 
assessments, actual clinical practice, discussed further in section 8.6.  
 
Notably, the differential PSG findings from chapter 5 (marked objective sleep 
complaints) and chapter 7 (normal sleep) may be attributed to a potential “first-night 
effect” in the single night study. Alternatively, the discrepancies could be the result of 
sleep phenotypes, which were not accounted for in the mixed methods study (chapter 
7). For example, a small % of SWS by one participant might be mirrored by a large % 
of SWS in another, and so averaging across the entire sample would blur extremes to 
give a relatively normal proportion of SWS.   
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Interestingly, when the subjective and objective methods were combined in the 
feasibility study, an evaluation of patients sleep derived from these measures 
discovered discrepancies between patient’s retrospective evaluation of their sleep 
(baseline diaries & self-report sleep assessments prior to the study), and the 
objectively-derived measures (PSG) of their sleep continuity. Patients, despite being 
accurate in estimating their sleep duration, mis-estimated their sleep on all other 
continuity parameters. These discrepancies mirror what has been shown in previous 
sleep studies in patients with CFS (Watson et al., 2003; Neu et al., 2007), and this 
potential sleep-state misperception (SSM) may have implications for treatment, 
specifically, where sleep-based interventions such as CBT-I are effective in improving 
perceived sleep quality in patients. 
 
A key underpinning message that emerged throughout all studies was the 
heterogeneity of patient’s sleep problems. The variability in the nature and severity of 
sleep disturbances was first observed in the qualitative interviews with patients and 
continued to become apparent in the findings that developed throughout the trajectory 
of studies carried out. Analysis of self-reported sleep diaries (studies 2 & 4) 
demonstrated considerable variability in patients’ sleep, and equally, the objectively 
derived sleep assessments (PSG; studies 3 & 4) established variance across each of the 
patient samples.  
 
Taken together, the overall findings from this mixed methods research programme, 
demonstrate that sleep is a considerable issue in CFS. Importantly, the feasibility study 
that combined multiple methods of assessment, showed how a highly detailed 
protocol, combining a range of methods for sleep and cortisol assessment is acceptable 
to CFS patients. Ultimately this is the key finding, which suggests further research can 
feasibly apply this mixed-methods biopsychosocial sleep assessment, in an ambulatory 
setting with patients. However, it is debateable as to whether such a comprehensive 
and potentially costly programme of research would be commissioned and thus applied 
clinically. Perhaps the utilisation of effective self-report measures such as PSQI and 
ISI, are a more practical option to identify sleep complaints clinically without a PSG. 
Further, the ESS may offer a useful means of distinguishing between insomnia and 
hypersomnolence disorder (and identifying other PSDs) in patients in the clinic early 
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on, before moving on to consider implementing the complete mixed-methods 
assessment protocol. 
 
8.3 Revisiting the model 
To revisit the biopsychosocial model of CFS outlined in chapter 1, this model 
hypothesises that the combination of predisposing, precipitating and perpetuating 
factors serve to keep the condition going (Deary, Chalder & Sharpe, 2007). This model 
is particularly important when considering factors that might come into play in terms 
of mediating the exacerbation of sleep-related complaints in CFS. The perpetuating 
factors range from the physical, through to the behavioural, physiological and 
cognitive contributors, which may all serve to maintain symptoms, and disturbed sleep 
in particular. These factors are described below in relation to the study findings.  
 
 
8.3.1 The role of sleep in CFS 
Light sleep, restlessness and arousability 
What has emerged throughout the findings of each of the studies presented throughout 
this thesis is the recurrent theme of ‘light’ and restless sleep, what might be expressed 
as arousability in patients. In study 1, most patients described frequently awakening 
during the night and over half of them considered their sleep to be disturbed by 
feelings of mental alertness. Interestingly, the second sleep phenotype identified in 
study 3 was also characterised by restlessness, a predominance of light sleep and 
feeling unrefreshed. This second phenotype displayed the highest percentage of stage 2 
sleep and the highest number of arousals per hour, and markedly, this was the second 
largest group out of the four phenotypes. This stage 2 sleep has been associated with 
hormonal and autonomic dysregulation (Brandenberger et al., 2005) which are likely to 
relate to both higher levels of autonomic and cortical arousal which in turn play a role 
in inhibiting deep sleep. This links in with the concept of arousability and HPA axis 
dysfunction that has been shown in patients with CFS (Tomas, Newton & Watson, 
2013).  This warrants further investigation and future research should not only study 
cortisol but also the relationship between hormonal profiles and sleep (melatonin, 
cortisol) in patients. We have certainly shown that such mixed protocols are feasible. 
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REM Instability  
REM sleep is the period by which learning and memory consolidation are believed to 
occur, it therefore seems plausible to consider this stage of sleep and how it may be 
involved in CFS, given this condition features key symptoms such as brain fog, 
memory and concentration difficulties. Also, in light of the findings from study 3 
(chapter 5) where REM featured differentially between groups (i.e. longer REML and 
low amounts of REM in type 1, shorter REML and high amounts of REM in type 3), 
the concept of REM sleep instability (RSI) and its association with poor quality sleep 
(Riemann et al., 2012), might be a potential factor in keeping disturbed sleep going 
and in turn, impacting negatively on other symptoms, thus developing a perpetuating 
cycle.  
 
The concept of RSI represents the most highly aroused brain state during sleep and 
appears the most vulnerable to fragmentation in individuals who demonstrate 
persistent hyperarousal.  The instability of REM (i.e. increased micro- and macro- 
arousals during REM sleep) has been proposed as a contributor to the experience of 
disrupted and nonrestorative sleep, a result of enhanced arousal and more conscious 
perception of the environment during sleep (Riemann et al., 2012). REM sleep 
fragmentation over time can also lead to depression-like sleep abnormalities (REM 
sleep rebound) i.e. shortening of REM latency and increased REM density (Riemann, 
Berger & Voderholzer, 2001). RSI is also related to a reduced latency to the first REM 
cycle, in particular, these shorter REM latencies have been associated with depression 
(Palagini et al., 2013) and neurodegenerative diseases such as Parkinson’s. Together, 
such disruptions in the normal sleep process might suggest that RSI may be an 
objective marker for these conditions. 
 
The significance of vivid dreaming as highlighted by patients in the qualitative 
interview study (chapter 3) is also of interest. Vivid dreams are also observed in 
autoimmune conditions (i.e. Guillain-Barre syndrome (Cochen et al., 2005)) and is also 
associated with other CNS degenerative disorders (i.e. Parkinson’s). Such instances 
highlight the biological nature of the dreaming state, and again emphasis 
architecturally, the importance that REM could have in CFS. 
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Coping and living 
Overall, it is evident that patients utilise as much medical knowledge regarding CFS 
and their sleep as they can and in turn, utilise this information to maximise and manage 
their lifestyle. These more social factors became apparent in study 1 (chapter 3), 
factors that can have implications in the course and progression of CFS. Attempts at 
coping with sleep difficulties in conjunction with attempts at sleep-management were 
seen as additional “work” for patients already trying to manage their energy levels and 
pace daily activities. This was an additional contributory factor that created a 
disruption in the day to day living of these patients and mirrors the “illness burden” 
that is described by Bury (1982). Despite these attempts at self-managing their 
condition, the problems persist. As such, there is much scope to develop improved 
quality sleep interventions that would help patients to effectively manage their 
symptoms and thus optimise their lifestyle.  
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Figure 8.1: A theoretical model of sleep in CFS
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Taking into account the range of findings presented throughout this thesis, and the 
existing biopsychosocial model of CFS, it is proposed that we should be mindful of a 
number of factors, which interact throughout the course of illness and ultimately keep 
disturbed sleep an ongoing problem in patients. In individuals who are more 
vulnerable to developing CFS (i.e increased arousal), sleep may act as a mediating 
factor between stress and disability and thus precipitate illness onset. A combination of 
socio-emotional factors (i.e. lack of support and understanding of the condition) in the 
early stages of the illness, and socio-economic factors (i.e. not being able to work, 
adapting to living on disability) that occur during the illness course, may contribute to 
CFS and feed into symptoms such as fatigue. A consequence of these factors being an 
irregular sleeping pattern which contributes to reductions in sleep efficiency, less deep 
(SWS) sleep, circadian and homeostatic dysregulation. Disruptions in these four 
features of sleep may lead to a sleep disorder which in turn reinforces the existing 
fatigue. The disordered sleep may also feed into HPA irregularities and autonomic 
dysregulation, and also have an impact on the cognitive and behavioural components 
of sleep with regard to patient’s beliefs about their required amounts of sleep and the 
resulting sleep behaviours (i.e. SSM and napping). This reinforces the symptom of 
fatigue and thus the continuation of an irregular sleeping pattern (Figure 8.1). 
 
Where other bio(psychosocial) models have been proposed (Maes et al., 2009; Harvey 
& Wessely, 2009), these emphasise the role of precipitants and the eventual 
perpetuation of symptoms in CFS. They focus on explaining how precipitating and 
perpetuating factors (i.e., prior stress, personality traits) induce the biological 
pathophysiology that accounts for specific symptoms. The proposed model above 
(Figure 8.1) therefore acknowledges such vulnerability factors that may predispose 
individuals to CFS. Prospective studies may wish to explore these further using birth 
cohorts, given it may infer arousability as a generic risk factor for ill health. 
 
Considered together, this programme of studies of sleep in CFS has identified new 
biopsychosocial factors which may explain a process by which fatigue develops, is 
maintained and continues via a cycle of irregular sleeping patterns, biological 
dysregulation and cognitive and behavioural responses. This preliminary theoretical 
model of the role of sleep in CFS has been developed to integrate sleep into the 
picture, whilst being mindful to fit with existing models of CFS. The model might be 
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considered as a useful basis for CFS research and clinical work, helping to generate 
more multidisciplinary mixed methodology work to further understand this complex 
illness. 
 
8.4 A gold-standard protocol 
8.4.1 Measuring sleep in CFS 
In a recent paper, Thabane et al (2010) note how the importance of pilot studies has 
been somewhat neglected. They argue that a true pilot study has the principle aim of 
assessing feasibility, not effectiveness. Our feasibility study was carried out in the 
same sense as Lancaster et al.’s (2004) and Thabane et al.’s (2010) use of the word 
pilot – a study on which a larger study can be built. The short answer to whether the 3-
day sleep and cortisol assessment was feasible and acceptable to patients was “yes”. In 
what had the potential to be too demanding for a patient group already experiencing a 
host of debilitating symptoms, the mixed methods study was shown to be acceptable to 
the group of CFS patients.   
 
The findings are fundamental, because they provide an indication of the kinds of 
problems that might need to be addressed in the design of a larger study. The methods 
that were included in this protocol, measure and address the likely mediators of 
disturbed sleep that were discussed in the previous section; factors ranging from a 
possible instability in REM, increased amounts of light, restless sleep, through to 
functional impairment and a possible hypocortisolism. And so the success of this 
protocol is promising for a body of research that seeks to address this condition in a 
multidisciplinary fashion. The main issues and modifications for future work are 
highlighted and discussed in the following sections.   
 
 
Recommendations 
The understanding of sleep and its role in the early phases of CFS remains uncertain. 
This at times may coincide with the occurrence of misdiagnosis. As such, there is a 
necessity for thorough sleep assessment in this patient group to rule out other possible 
PSDs and to gauge the nature and severity of sleep complaints presenting in these 
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patients. The problems that have emerged from previous sleep studies in CFS have not 
only developed from the samples and diagnostic criteria difficulties, but quite notably 
the procedural aspects of these studies. Reflecting on this, it is essential to assess sleep 
in this patient group as early as possible and via the most effective and accurate means 
that are acceptable to patients.  
 
To redress this, administering a standardised sleep diary during initial assessment 
stages would identify disturbed sleep early on. It is the early stages that are generally 
the most disturbed part of the illness, particularly in the coming to terms with the 
condition. Early assessment would enable the clinician to rule out a potential 
coexisting or misdiagnosed PSD, and even if no PSD is present, treating/managing 
sleep problems early on may help in the overall quality of life of patient in their 
experience of their CFS.  
 
There are minor practical and technical issues to consider, as identified through reports 
by patients in the feasibility study, particularly in relation to pain and sensitivity to 
equipment and its application. It is recommended that as part of the study process, 
there should be a focus on working with the patients and their needs. Modifications to 
protocol may be required, for example, adaptations in the home, altering the type of 
paste used if needed, alternating the shoulder strap to a different side each night for 
comfort if needed.  
Taking everything into account, these are some key elements to consider when 
measuring sleep in CFS;   
  Consider the patient as an individual, each with their own unique collection of 
symptoms. Physical and mental limitations will differ for each patient. What 
one person finds comfortable, another may not. And so equipment and 
techniques of application should meet the tolerance of the individual. 
  Be mindful of environmental and social factors that may restrict the usual 
conduct of assessment procedures, i.e, in an ambulatory setting, the 
household/bedroom may be limiting and social commitments of the patient 
could require scheduling modifications and advanced planning to be made. 
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 One night of PSG is enough to identify a PSD (Apnea and PLM) in patients, 
and tease apart the four other distinct sleep phenotypes. Two nights of PSG are 
sufficient to gain a basic characterisation of a patient’s sleep. A third night, 
although ideal, is not compulsory, providing two consecutive nights of 
complete recordings are obtained. 
  After ruling out PSDs, patients should be interviewed about their sleep (over 
the last month), given actigraphy (for identifying irregular sleep schedules) and 
a sleep diary (also measuring frequency and duration of daytime napping), to 
provide a subjective account that could be matched to the four phenotypes to 
inform a tailored treatment approach for the individual. 
  In adjunct to direct measures of patient’s sleep, there should be additional 
biological (cortisol), cognitive and psychological assessments, to clarify 
symptomatic correlates and any changes in severity. 
 
Taken overall, the effective assessment of sleep in CFS patients has implications both 
in a clinical and research capacity. Working towards better modes of assessment and 
being mindful of different factors that could be contributing (i.e. taking on a holistic 
approach), can improve our understanding of sleep and its role in this illness.  
 
8.5 Limitations  
I have considered the limitations of the individual stages of this thesis as I have gone 
through each of the study chapters. However, it is worth reflecting on them as a whole 
prior to evaluating the collection of studies in their entirety. 
 
As noted in chapter 1, there is much contention around the competing models that seek 
to explain CFS, and so, the identification of the multifactorial biosocial model to guide 
the trajectory of my research was perhaps a reflection of my own prior bias, partly 
based on a lack of other models integrating explanations from multiple angles. That 
said, the biopsychosocial model offered a flexible framework through which I was able 
to comprehend and describe the results that emerged over the course of studies, in a 
structured way.  
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In chapter three, despite the qualitative methodology that afforded the exploration of 
sleep-specific patient insights in great depth, it was not possible to express the full 
range of the topics raised in the narratives, topics that extended beyond the scope of 
sleep and its role in CFS. This should perhaps form the direction of further analyses of 
these transcripts, which could draw upon other elements of importance to the patients 
and their lived experience of their condition. 
 
The shortcomings of the assessment-based studies of sleep in this programme of 
research, have been considered in their individual chapters (chapters 4, 5 and 6), but 
perhaps their imperfections are best addressed by ensuring that any future sleep studies 
in CFS, or sleep-based assessments with patients, are performed in light of the 
recommendations that are set out in section 8.6.3. These suggestions for conducting 
further work have been developed based upon a reflection of the issues identified 
throughout the research process, the limitations encountered and by being mindful of 
other factors that might present with CFS populations. Any future study, if performed 
as per the recommendations, will offer more robust data collection, given the potential 
for larger patient cohorts and more formal and detailed analysis of sleep variables 
amongst the patients under assessment. 
 
Another flaw lays in partial data, mainly in chapter five and its respective phenotype 
PSG study findings. It was not possible to determine length of illness from the dataset. 
This would have been of interest in terms of identifying whether the sleep phenotypes 
are consistent across the illness course, i.e. to see if the phenotype is specific to the 
individual patient irrespective of illness duration or if the patients progressed through 
different sleep-phenotypes over time. This warrants further investigation using a 
longitudinal design. 
 
As identified throughout the studies in chapters 3, 4 and 6, another flaw concerns the 
milieu of the results described. With several patients sleeping during the daytime as 
part of their usual sleeping pattern, there is the potential for this to have implications 
for their night-time sleep and in turn the ability to representatively evaluate it. This 
daytime sleep is a significant factor, given it may reflect the presence of a circadian 
dysregulation. Further, although the sleep diary utilised in the 3-day sleep assessment 
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feasibility study does provide a precise indication of the patient’s perception of their 
sleep and fits with AASM criteria, it is missing the index of daytime napping, which, 
becomes a real issue in trying to interpret the data. Modification of this self-report tool 
(i.e. integrating a measure of frequency and duration of daytime naps into sleep 
diaries) should thus be a consideration for prospective sleep assessments. Finally, 
expansion of the objective PSG in terms of its recording duration, would ensure it 
captures patient’s entire sleep period. 
 
A further imperfection could be in the perspective of limited analyses performed on the 
sleep data. As discussed in chapters 6 and 7, whilst it was acknowledged throughout 
that the analysis of data from a feasibility study should be mainly descriptive 
(Lancaster, 2004), the nature of the analyses carried out on the cohort data might be 
considered premature; as such those data should be interpreted with a degree of 
caution. However, as expressed in chapter 7, these analyses were performed as a 
means of offering the reader a preliminary characterisation of sleep and cortisol in a 
small group of patients with CFS who undertook the first, most detailed protocol of its 
kind. Methodologically though, the study could be strengthened by a healthy control 
group, that would helpfully allow for results to be compared to healthy norms.. 
Ultimately, the statistical findings from this work should be used only as a means of 
informing the next stage of research and indicate what the parameters of interest for 
future research might be.  The way this data will inform future work of our group is 
described in section 8.6.2. It will be the work of this subsequent study to demonstrate 
the effectiveness of utilising this protocol with a larger group of patients with CFS. 
Meanwhile, the reader is invited to take the data of the feasibility study as an early 
insight of what might be established in future studies of well-assessed sleep in CFS. 
 
8.6 Implications (Clinical and Research) 
Taking forward the findings that have been established throughout this thesis, derived 
from different modes of assessment, and the success of a protocol combining multiple 
sleep assessment modalities, it is possible to describe the implications for future work 
in the area of sleep in CFS. The following sections will consider implications for the 
clinical setting and research domain, in light of the research undertaken. 
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Clinical Implications 
The therapeutic management of CFS is moving towards more psychosocial 
interventions. This mirrors recent work that shows the management of emotional 
distress is associated with lower levels of fatigue-related illness burden (Lattie et al., 
2013). Considering the management of CFS from a multifactorial perspective, it is 
likely that this will lead to improved treatment outcomes for patients, given all 
potential mediators are targeted.  
 
The best evidence treatments for CFS (GET and CBT) all involve a sleep management 
component, but it is not yet clear how significant the sleep component may be on its 
own, or how it specifically contributes to the efficacy of the overall treatments. As 
such, if sleep interventions such as CBT-I are utilised as an adjunct therapy to usual 
treatment in CFS, it could form a valuable component to the overall management 
process. It is therefore important that more attention is paid to sleep in the clinic. As a 
starting point, standardised sleep diaries should be incorporated into routine care to 
gauge the degree of sleep problems that present in the patient. The diary study, which 
established functional impairments via a self-reported sleep diary assessment, also 
provide the rationale to move forward with helping patients address and deal with the 
daytime complaints (i.e. cognitive symptoms), during treatment; tackling these 
coexisting symptoms will help to maximise quality of life for the patient. In chapter 6, 
patient’s adherence to the consecutive completion of the sleep diaries is an important 
finding. These self-report measures of patient’s sleep are vital in forming part of the 
therapeutic process in CBT-I. By continually reviewing the sleep diary, it is possible to 
monitor and reflect upon the improvements in sleep quality that occur as a result of 
sleep management during CBT-I.  
 
Sleep is vital, but it is important to look at sleep in the broader context of other factors 
and the interplay between them all. Understanding the connection between the way the 
brain works and its connection with the biological processes that occur within the body 
is key.  Most importantly the heterogeneity of CFS combined with the variability of 
sleep complaints identified highlights the necessity of patient-centred medicine. This 
way, the assessments and the treatments that follow, will be tailored to the patient.  
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It is important that the assessment process begins with the structured clinical interview, 
to understand the patient and their illness completely. This in combination with the use 
of a standardised diagnostic tool will be a move toward more standardised case 
definitions, which ultimately will aid the understanding of CFS and inevitably its 
treatment process. Given that the definition for CFS varies across different settings and 
countries between more standardisation will help both clinical and research work. 
Initiatives such as Jason et al's (2010) use of the DSQ as diagnostic tool in different 
settings (both research and clinical), will create an opportunity to increase the 
reliability of the criteria by reducing criterion variance.   
 
 
Research Implications 
Taken overall, the research findings demonstrate the usefulness of mixed methods of 
sleep assessment in CFS, and how these can be utilised to explore the condition in 
different ways. Ultimately, the role of sleep is only likely to be understood at its best 
by utilising the most effective measures available. First and foremost, there remains a 
lack of good quality assessment in CFS sleep research, and so utilising the range of 
methods established throughout the course of studies, would be a move forward 
methodologically in CFS sleep-related research. We have established a successful 
protocol for the comprehensive assessment of sleep and cortisol in patients with CFS, 
demonstrating the feasibility of using a range of assessment modalities Patient’s 
fidelity to this complex protocol and 0% attrition rate is promising for recruitment in 
future studies. 
 
As identified by the qualitative interview study, CFS affects not only the patients, but 
also immediate family members. This highlights the importance of considering others 
as part of the research process. Interview-based research in particular has the potential 
to include accounts from family members or friends, which could offer more insight 
into the impact of CFS as a whole and the role of sleep in particular.   
 
The necessity for more objective tests for daytime sleep is warranted, given daytime 
sleep is often a usual pattern of sleep in CFS patients. The discouragement of napping 
during the course of sleep management interventions such as CBT-I, is a reflection of 
the negative impact such sleeping behaviours pose to the homeostatic drive (Manber et 
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al., 2012). Although research indicates brief naps (< 15min) can be beneficial to 
cognitive performance, it is the longer duration of napping and the circadian placement 
of these naps (i.e. when the nap is taken with respect to the 24h circadian rhythm) that 
are considered to have a negative impact upon the homeostatic sleep drive (process S), 
and thus impair the quality of night-time sleep (Lovato & Lack, 2010). This also has a 
reciprocal effect for daytime functioning the following day. Thus napping is a key 
factor and should be measured as part of the overall assessment of sleep in CFS.  
 
Objective sleep studies in CFS may wish to also consider daytime PSG assessment, 
thus extending the monitoring of patient’s sleep to ensure their entire sleep period is 
characterised. Given objective measures are key, sleep-based CFS research may also 
want to consider MSLTs or maintenance of wakefulness tests (MWT), this would 
address the difficulties that remain with regard to separating the symptoms of fatigue 
and daytime sleepiness (Neu et al., 2008); this is also pertinent in that these two 
complaints have different implications for diagnosis and treatment. In addition, the 
actigraph could also be used to disentangle discordance between subjective and 
objective sleep report, as it was shown to be possible to combine the methods, as 
detailed in chapter 6.  
 
The first night effect has been regarded an issue in CFS (Le Bon, 2003) albeit a 
tentative one, and so two nights of PSG assessment are likely to be better than one. 
Adding to this, the stability of the sleep continuity and main architectural 
polysomnographic variables in the feasibility study is noteworthy. It provides the 
confidence for further research to be able to gain a true characterisation of patient’s 
sleep via two rather than three nights of assessment. As well as this, we have 
demonstrated that a single night of PSG assessment is sufficient to identify patients as 
meeting criteria for a PSD and thus enable the exclusion from subsequent analyses in 
the research. Thus, it is possible after only one night of assessment, to tease apart a 
PSD from CFS, and this is also key in a clinical setting as early identification of PSD 
prevents misdiagnosis, enables the direction for correct treatment and prevents 
incorrect treatment delivery.  
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Future Directions; clinical and research work 
Establishing the feasibility of the detailed sleep assessment protocol in patients forms a 
central part of informing the design and development of an intervention development 
project. Moving forward from a therapeutic viewpoint, it is of interest to determine the 
efficacy of sleep treatments in CFS, a group where sleep problems have been 
objectively confirmed.  
 
The next proposed study of our group will identify and characterise in detail the sleep-
related disturbances in CFS patients, and systematically develop and pilot a tailored 
sleep management intervention study to reflect these. By delivering a CBT-I 
intervention to CFS patients, it will be possible to determine whether CBT-I is an 
effective treatment in itself for improving perceived sleep quality, and if this in turn 
leads to improvements in daytime physical and mental symptoms in this condition. 
Conducting this CBT-I study will thus serve as a component analysis of existing CBT 
and activity management strategies that incorporate sleep management.  
 
There is currently no research on the efficacy of CBT-I alone in CFS. Instead, we can 
make assumptions based on the effects of CBT-I in patients with Fibromyalgia (FM), 
and these have been shown to be beneficial, both in improving patients’ subjective 
sleep, with additional favourable outcomes for pain and mental wellbeing (Edinger et 
al., 2005), but also in objectively increasing deep sleep and improving sleep efficiency 
in these patients (Sánchez et al., 2012). A recent randomised controlled trial also 
confirmed the effectiveness of CBT-I in FM, reporting significant improvements to 
sleep, fatigue and daily functioning, post-treatment, and emphasising the usefulness of 
CBT-I in the multidisciplinary management of this condition (Martínez et al., 2013). 
Based on these relatively new studies, it seems that CBT-I could offer a promising 
intervention for sleep disturbance and even daily functioning in CFS. CBT-I involves 
sleep hygiene/management components (i.e., establishing a consistent sleep routine, 
avoiding napping), and we know that these are necessary and already integrated into 
current CFS management programmes (GET, CBT), but is this sufficient? And might 
CBT-I be more effective? It will be interesting to assess how much it has an impact on 
the overall therapy for CFS.  
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The recent launch of the UK ME/CFS Research Collaborative (CMRC) (Krishna, 
2013) shows how the government and associated funding bodies are making a 
commitment to pursue research into the understanding and treatment of this 
debilitating condition. If research progress is made, it is possible that we will see an 
enhanced understanding of CFS from a number of angles (HPA axis dysregulation, 
immune processes, symptoms and psychological aspects of CFS including sleep). Such 
facets should be examined by drawing upon multiple disciplines to determine the 
interplay of the factors that serve to maintain CFS. This may eventually lead to the 
furthering our understanding of the underpinning a etiology, which remains incomplete 
Future work should also consider CFS not a unitary construct but a syndrome that 
represents multiple illnesses with different causes albeit with similar symptom 
patterns. 
 
8.7 Conclusions 
CFS remains a complex and somewhat heterogeneous condition and equally, the sleep-
related complaints that present in patients reflect this. Each patient experiences their 
very own personal combination of symptoms and, through a range of social, 
behavioural, cognitive and biological factors; these are maintained and often 
exacerbated. It is in this light, that the importance of the theoretical biopsychosocial 
model became crucial to the studies carried out in this thesis, (Deary, Chalder & 
Sharpe, 2007; Moss-Morris, Deary & Castell, 2013). This multi-factorial model 
enabled a structure of research to be established; utilising different assessment 
techniques that addressed sleep from a number of angles. The model was also 
fundamental when examining the data from these studies. It helped to understand how 
the sleep findings might feed into a model of mediating (biological, psychological and 
social) factors, and thus better explain the role of sleep in CFS. 
  
The preliminary sleep findings from the feasibility of sleep protocol study mirrored the 
course of the other studies: all demonstrated the variability of sleep and sleep problems 
in CFS.  As such, the establishment of a successful protocol for effective and thorough 
sleep assessment is key. It enables the identification of a PSD at an early stage. It  
affords a much more detailed examination of continuity and main architectural sleep 
variables than is currently being performed in research and in the clinic. Importantly, 
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the success of the three-night mixed-methods sleep protocol in patients underscores 
that methodologically, these (necessary) procedures and equipment are not regarded as 
invasive or detrimental to patient’s experience of their CFS. 
 
As suggested, sleep and its assessment in CFS needs to be considered from a number 
of angles, both clinically and through future research. Likewise, the management of 
CFS should be multi-disciplinary, addressing the biological, behavioural and 
psychological components that shape this condition. Specifically, any sleep 
management intervention should be delivered with the heterogeneity of sleep in CFS in 
mind, considering the nature of sleep disturbances presented by the individual prior to 
delivering treatment. 
 
Above all, CFS continues to be only partially understood. A full understanding can 
only develop after we characterise this condition at every level from the biological 
through to the social, and understand how these mechanisms interact. By focussing in 
depth on one aspect - sleep - a greater understanding of the condition as a whole has 
emerged. As highlighted throughout, there is no cure for CFS, only symptom 
management. It is hoped through the dissemination of this work, and the insights 
gained, that this work will not only inform future research practice but also lead to 
enhanced therapeutic delivery, with more focus on the central role of sleep in CFS. 
This can only be to the benefit of those suffering from CFS.  
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APPENDIX A: Chapter 2 Table of study characteristics: Sleep in CFS 
 
Author,  
Year 
Methods Population Sample Size Study Outcomes Conclusions Drawn 
Morriss et 
al., 1997 
Self-report Oxford 
Diagnosed 
CFS Patients 
69 CFS without 
psychiatric 
disorder 
58 CFS with 
psychiatric 
disorder 
38 patients with 
chronic 
depressive 
disorders 
45 healthy 
controls 
Higher prevalence of sleepiness and 
daytime naps in CFS patients 
compared to depressed subjects and 
healthy controls. Periodic limb 
movements are more common in 
CFS patients than controls. 
Difficulty maintaining sleep is the 
principle sleep complaint in CFS patients. 
Disrupted sleep appears to complicate the 
course of CFS and sleep complaints are 
unrelated to depression/anxiety in CFS. 
Unger et al., 
2004 
Self-report  Fukuda 
diagnosed CFS 
339 
(24 met the 
Fukuda criteria) 
others fell into 
fatigue groups. 
The Sleep Assessment Questionnaire 
(SAQ) revealed CFS subjects had 
increased risk of abnormal scores on 
the non-restorative and restlessness 
factors compared to non-fatigued, 
but not for factors of sleep apnea or 
excessive daytime somnolence. 
Consistent with studies finding that, 
while fatigued, CFS subjects are not 
sleepy. 
SAQ factors describe sleep abnormalities 
associated with CFS and provide more 
information than the Epworth score. 
186 
Mariman et 
al., 2012 
Self-report Fukuda 
diagnosed CFS 
415  High mean ESS and PSQI values 
(daytime sleepiness and poor sleep 
quality). 
Very low sleepiness and high levels 
of sleep disturbance clustered 
together, as well as high sleepiness 
and low sleep disturbance. 
The associations at both ends of the ESS 
spectrum correspond to a clinical profile 
of insomnia and hypersomnia (insomnia 
– complaints of sleep disturbance 
associated with increased alertness; 
hypersomnia – excessive daytime 
sleepiness persists despite normal 
nocturnal sleep) 
Ohinata et 
al., 2008 
Actigraphy Children (16-
18) with 
Fukuda 
diagnosed CFS 
12 CFS children 
12 age-matched 
controls 
Compared to controls, total sleep 
time was longer in CFS children and 
physical activity lower. Also the CFS 
children with irregular sleep had an 
impaired sleep/wake cycle, caused 
by disrupted night sleep and daytime 
napping. 
Using actigraphy, several characteristics 
of sleep patterns could be identified. 
Actigraphic analysis is useful in detecting 
sleep/wake problems in children with 
CFS. 
Rahman et 
al., 2011 
Actigraphy  Fukuda 
diagnosed CFS 
15 CFS 
15 controls 
Activity levels throughout the day 
did not differ between groups, 
although afternoon activity levels 
increased evening levels of fatigue in 
the CFS group. Patients and controls 
did not differ on sleep timing, 
duration or quality, so no evidence of 
impaired circadian rhythm in CFS. 
Activity-symptom relationship 
demonstrated in a naturalistic setting 
(increased activity associated with 
increased symptoms of fatigue in CFS 
patients)  
Buchwald et 
al., 1994 
PSG (1 
night) 
50% met 
Holmes and 
modified CDC 
criteria for 
CFS 
(Schluederberg 
et al., 1992) 
38 CFS 
21 Non-CFS 
fatigue patients 
No differences found in sleep 
symptoms or sleep disorders when 
comparing patients who met the CFS 
criteria and those that did not. Sleep 
disorders were equally as common in 
patients who did (82%) and did not 
(81%) meet the criteria for CFS. 
Chronically fatigued patients have 
coexisting sleep disorders that are not 
considered to be associated with meeting 
the criteria for CFS. 
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Manu et al., 
1994 
PSG (1 night) CFS patients 
who met 
modified CDC 
criteria for 
CFS 
(Schluederberg 
et al., 1992) & 
patients with 
chief 
complaint of 
fatigue 
15 CFS 
15 other chronic 
fatigue  
Majority of CFS patients had 
nonpsychotic major depression – but 
not considered associated with alpha-
delta sleep 
Alpha-delta sleep is not considered a 
marker of CFS but may contribute to the 
illness of nondepressed patients with CFS 
(as was more common among patients 
who had chronic fatigue without major 
depression) 
Fischler et 
al., 1997 
PSG (2 and 3 
nights) 
Oxford 
Diagnosed 
CFS Patients 
49 CFS 
20 Healthy 
Controls 
Sleep initiation problems – namely a 
significantly longer SOL was shown 
in CFS group compared to controls. 
Sleep continuity disturbances were 
characterised by significantly higher 
percentage movement time, number 
of awakenings greater than 1 min 
and number of stage/shifts per hour.  
Both initiation and continuity anomalies 
contributed to significantly lower sleep 
efficiency index in CFS compared to 
controls. Sleep initiation and sleep 
maintenance disturbances are evident in 
CFS compared to healthy controls. This 
is also the first study to show 
significantly lower percentage stage 4 
sleep in CFS. 
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Stores et al., 
1998 
Home PSG 
(1 night) 
case-control 
design 
Teenagers with 
CFS 
(internationally 
agreed criteria 
– adapted 
fatigue 
duration for 
teenagers) 
18 CFS 
18 matched 
controls 
Compared with controls, CFS 
teenagers showed significantly 
higher levels of sleep disruption 
(both brief and longer awakenings). 
Disruption of sleep may contribute to 
daytime symptoms of young people with 
CFS. 
Le Bon et 
al., 2003 
PSG (2 
nights) 
Fukuda 
diagnosed CFS 
(without 
primary sleep 
disorders, 
46/83 had at 
least one 
psychiatric 
diagnosis) 
83 Significant observed differences 
from night 1-2 in TST, SE, NREM 
Sleep, SOL and Number of Sleep 
Cycles. Outcome attributed to first 
night effect. 
CFS to be added to list of conditions 
where a clinically significant habituation 
effect takes place. 
Ball et al., 
2004 
PSG (2 
nights) 
Fukuda 
diagnosed CFS 
22 CFS-
discordant twin 
pairs 
No abnormalities observed in sleep 
architecture among CFS twins. 
No strong evidence for role of 
abnormalities in sleep architecture in 
CFS. Co-twin control methodology 
highlights Importance of selecting well-
matched control subjects. 
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Reeves et 
al., 2006 
PSG (2 
nights) 
Fukuda 
diagnosed CFS 
43 CFS 
43 non-fatigued 
controls 
No confirmation of statistically 
significant associations between 
sleep parameters and CFS. 
Sleep abnormalities an unlikely 
contributor to pathophysiology of CFS. 
The illness may include sleep-state 
misperception. 
Armitage et 
al., 2007 
PSG (3 
nights: sleep 
assessed 
night 2, sleep 
delayed by 
4hrs night 3) 
 
Fukuda 
diagnosed CFS 
13 CFS-
discordant twin 
pairs  
CFS and healthy co-twins did not 
differ on slow wave activity. 
Only after sleep challenge did CFS twins 
show less slow wave activity than co-
twins. 
Le Bon et 
al., 2007 
PSG (2 
nights – 
without 
habituation) 
Fukuda 
Diagnosed 
CFS (without 
primary 
sleep/psychiatr
ic disorders) 
28 CFS 
27 Sleep Apnea-
Hypopnea 
syndrome 
patients 
27 Healthy 
Controls 
 
Stage 4 and SWS are more elevated 
in CFS. 
Increase of deep sleep over light sleep in 
‘pure’ cases of CFS 
Kishi, et al., 
2008 
PSG (1 night) Fukuda 
diagnosed CFS 
22 CFS 
22 Healthy 
Controls 
Altered sleep-stage transition 
patterns. Lower REM to non-REM 
sleep transition in CFS than controls. 
Normal continuation of sleep in light or 
REM sleep is disrupted in CFS. 
Armitage et 
al., 2009 
PSG (3 
nights: only 
night 2 was 
used for 
purposes of 
Fukuda 
diagnosed CFS  
13 CFS-
discordant twin 
pairs 
No evidence of macro- or micro-
architectural changes. Power spectral 
characteristics of sleep EEG do not 
differentiate twins with CFS from 
their healthy co-twins. 
The sleep measures utilised cannot 
explain the chronic disabling fatigue 
experienced by the CFS twins. 
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this study – 
night 3 
reported by 
Armitage et 
al., 2007) 
Decker et 
al., 2009 
PSG (2 
nights) 
Fukuda 
diagnosed CFS 
35 CFS 
40 Non-fatigued 
matched 
Controls 
Sleep architecture did not differ 
(published as Reeves et al). Power 
spectra of EEG frequencies reduced 
in REM sleep 
Reduced spectral power observed in CFS 
demonstrates impaired sleep homeostasis. 
Kishi, et al., 
2010 
PSG (1 night) Fukuda 
diagnosed CFS 
14 CFS (without 
FMS) 
12 CFS (with 
FMS) 
26 Healthy 
Controls 
 
Transitions between sleep stages 
differ between CFS (alone) and CFS 
(with FMS).  
Suggests differences between CFS and 
FMS relating to different problems of 
sleep regulation 
Krupp et al., 
1993 
Mixed 
Methods 
(Subjective 
reports and 
PSG (1 
night)) 
Holmes 
diagnosed CFS 
patients 
72 CFS 
40 Healthy 
controls (PSG 
performed in 16 
CFS) 
CFS had significantly elevated seep 
disturbance, depression and fatigue 
(from subjective reports)  
6 – major depression (only 2 with 
shorter REM latencies) 
1 - CFS diagnosis changed to 
narcolepsy  
4 – PLMD 
 
In addition to severe fatigue and 
depressive symptoms, subjective sleep 
disturbance is common in CFS and some 
CFS patients may have sleep disorders. 
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Morriss et 
al., 1993 
Mixed 
Methods 
(Subjective 
reports and  
home PSG (1 
night)   case-
controlled) 
Fukuda 
diagnosed CFS 
12 CFS 
12 matched 
controls 
CFS patients spent more time in bed 
but slept less efficiently than 
controls, and had more time awake 
after initial sleep. 
The disordered sleep in most CFS 
patients is likely to contribute to day time 
fatigue 
Sharpley et 
al., 1997 
Mixed 
Methods 
(Subjective 
reports and 
home PSG (1 
night)) 
Fukuda 
diagnosed CFS 
(without 
primary 
sleep/psychiatr
ic disorders) 
20 CFS 
20 matched 
controls 
Complaints of poor quality sleep and 
unrefreshing experience of sleep. No 
sig abnormalities but more time in 
bed trying to sleep making sleep less 
efficient. 
Abnormalities in sleep continuity only 
occur in a minority of CFS patients. 
Abnormalities of sleep not likely to be 
important in maintenance of symptoms. 
Fossey et al., 
2004 
Mixed 
Methods 
(Subjective 
reports and 
PSG (1 
night)) 
Fukuda 
diagnosed CFS 
37 CFS 
24 Narcolepsy 
24 Controls 
58% CFS group had previously 
undiagnosed primary sleep disorder. 
High rates of nonrestorative sleep in 
CFS group. 
Primary sleep disorders (i.e. apnea, RLS, 
PLMD) are overlooked /misdiagnosed in 
CFS. Psychological disturbances may be 
result of living with poorly understood 
condition. 
Watson et 
al., 2004 
Mixed 
Methods 
(Self report 
and PSG (2 
nights)) 
Fukuda 
diagnosed CFS 
22 CFS-
discordant twin 
pairs 
CFS twins experienced more 
subjective sleepiness than their 
healthy co-twins despite similar 
mean sleep latencies. 
CFS patients may mistake their chronic 
disabling fatigue for sleepiness. Future 
studies should examine mechanisms of 
the discrepancy between self-reported 
and measured sleep parameters in CFS. 
Guilleminau
lt et al., 2006 
 
Mixed 
Methods 
Self-report 
scales and 
PSG (1 
night)) 
Patients with 
unexplained 
chronic fatigue 
14 unexplained 
fatigue 
14 Controls 
Complaints of chronic fatigue and 
unrefreshing sleep associated with 
abnormal CAP rate. 
Abnormal sleep progression and NREM 
instability. Patterns related to 
undiagnosed sleep-disordered breathing 
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Majer et al., 
2007 
Mixed 
Methods 
(Self report 
and PSG (2 
nights)) 
Fukuda 
diagnosed CFS 
35 CFS 
40 non-fatigued 
controls 
CFS reported more sleep problems 
yet objective measures of 
architecture did not differ between 
groups 
CFS patients may monitor their sleep 
behaviour more closely, which may 
contribute to their perceived sleep 
problems. 
Neu et al., 
2007 
Mixed 
Methods 
(Self report 
scales and 
PSG (2 
nights 
without 
habituation)) 
Fukuda 
diagnosed CFS 
(without sleep 
or mood 
disorders) 
28 ‘pure’ CFS 
12 controls 
PSQI – CFS significantly poorer 
subjective sleep quality than 
controls. SEI and amount of SWS 
did not differ between groups 
Either a sleep quality misperception is 
present in CFS or the neurophysiological 
disturbances involved in the 
nonrecovering sensation are not 
expressed by sleep variables such as SEI 
or sleep stage distributions. 
Van Hoof et 
al., 2007 
Mixed 
Methods 
(Self report 
and PSG (2 
nights)) 
Fukuda 
diagnosed CFS 
48 CFS Show extended onset latency 
compared to Fischler et al., (2007) 
patients. 
The high alpha-delta intrusion (% 
alpha waves in SWS) group reported 
the most self-reported anxiety 
Shows extended sleep latency – as 
already suggested in the literature. Alpha-
delta intrusion is associated with anxiety. 
Neu et al., 
2008 
Mixed 
Methods 
(Self report 
scales and 
PSG (2 
nights 
without 
habituation)) 
Fukuda 
diagnosed CFS 
(without sleep 
or mood 
disorders) 
16 CFS 
13 Apnea-
Hypopnea 
syndrome 
patients 
12 Controls 
Higher levels of fatigue, anxiety and 
depression in CFS group. Also high 
level of idiopathic microarousal 
index in CFS group– almost as high 
as the SAHS group (even after 
PLMD and apnea were excluded – a 
usual contributor). 
Subjective scales showed CFS the 
most tired, SAHS most sleepy. 
The data confirm the likely overlap in the 
perception of sleepiness and fatigue. This 
combined with discordance between 
subjective and objective sleepiness 
warrants the need to find more precise 
tools/analysis. 
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Togo et al., 
2008 
Mixed 
Methods 
(Self report 
and PSG (1 
night)) 
Fukuda 
diagnosed CFS 
(without 
psychiatric 
disorders) 
 
26 CFS (14 with 
coexisting 
fibromyalgia) 
26 controls 
CFS patients showed sleep 
disruption. They showed 
significantly reduced total sleep time, 
reduced sleep efficiency and shorter 
bouts of sleep than controls. 
The sleep disruption may explain the 
fatigue, unrefreshing sleep and pain in 
this patient group. 
Creti et al., 
2010 
Mixed 
Methods 
(Self-report 
scales, 
PSG (1 
night), 
Actigraphy) 
Fukuda 
diagnosed CFS 
49 CFS CFS reported poor sleep quality, 
non-refreshing sleep and daytime 
fatigue/sleepiness. But self-report 
TST was parameter most 
consistently reflected by objective 
measures. 
65% met criteria for chronic 
insomnia. High percentage also had 
apnea. 
Sleep apnea syndrome is considered a 
comorbidity of CFS rather than an 
exclusion criterion. 
Schoofs, et 
al., 2004 
Qualitative 
telephone 
interview  
 
Fukuda 
diagnosed CFS 
(and FMS)  
16 Social support, unlike healthcare 
support is related to quality of life 
Subjects suffering from CFS/FMS do not 
experience high levels of social support. 
Physician-specific themes. 
Anderson & 
Ferrans, 
1997 
Qualitative 
semi-
structured 
interviews 
 
Holmes 
diagnosed CFS 
patients 
22 Explained quality of life in CFS Cognitive dysfunction and disruption in 
social activities main concern. 
Clarke, 1999 Qualitative 
Interviews 
via telephone 
Non-specified 
diagnosed CFS 
59 Gender differences in experience of 
CFS and treatment by medical 
profession 
Main symptoms experienced –extreme 
fatigue, disabling pain and cognitive 
problems. Treatment options offered, 
varied by gender. 
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Notes: ESS, Epworth sleepiness scale; PSQI, Pittsburgh sleep quality index; SAQ, sleep assessment questionnaire; TST, total sleep time; SWS, slow wave sleep; SAHS, sleep apnoea-hypopnea 
syndrome; EEG, electroencephalography; SE, sleep efficiency; SOL, sleep onset latency; NREM, non-rapid eye movement; REM, rapid eye movement; CAP, cyclic alternating pattern; PLMD, 
periodic limb movement disorder; RLS, restless legs syndrome.
Lovell,  
1999 
Qualitative 
Interviews 
 
Oxford 
Diagnosed 
CFS Patients 
12 Symptoms 
Possible Causes 
Main symptoms reported were 
debilitating fatigue, unrefreshing sleep, 
muscle and joint pain. 
Soderlund, 
et al., 2000 
Qualitative 
Focus Groups 
Fukuda 
diagnosed CFS 
12 Symptom Experience Severe exhaustion and pain perceived as 
related to memory and concentration and 
sleep disturbances. 
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APPENDIX B: Chapter 3: Qualitative Interview Study Patient Consent Form 
 
 
Qualitative Interview Informed Consent  
v 1.0 03.03.2012 
 
Interviews to explore the experience of sleep in CFS 
 
Please initial in the appropriate box and sign below if appropriate for you 
1. I confirm that I have read and understand the information 
sheet (Version 1.0, dated 03.03.2012) provided for the above 
study and have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving any reason, and 
without my medical care or legal rights being affected. 
3. I understand that relevant sections of the data (including 
personal details) collected during the study may be looked at 
by responsible individuals from regulatory authorities or from 
the Newcastle upon Tyne NHS Foundation Trust, where it is 
relevant to my taking part in this research.  I give permission 
for these individuals to have access to my data. 
4. I understand that if a significant disclosure is made, then 
appropriate action will be taken to ensure my safety, as a 
participant taking part in this study. 
5. I understand that I am free to stop the interview at any time, or 
refuse to answer any question, without this affecting my 
current or future care. 
6. I understand that notes will be taken and the session will be 
audio recorded and that these records will be anonymised and 
confidentially stored by the interviewer. 
7. I agree to take part in the above study. 
 
 
Name of participant  Date  Signature 
Name of researcher  Date  Signature 
 
One copy of this signed consent form will be kept by the researcher, one copy will 
be placed in your medical records and one copy will be given to you for your own 
records.  
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APPENDIX C: Chapter 3: Qualitative Interview Schedule 
 
Interviews about Sleep in CFS: 
Interview Schedule for Patients 
 
Researcher makes introductions.  
Hello, my name is Zoe & I am a PhD researcher from Northumbria University. The focus of my research 
is Chronic Fatigue Syndrome, otherwise called M.E. and I have a specific interest in sleep problems that 
people experience with the condition. Firstly, how would you like me to refer to your condition 
[CFS/ME/post-viral fatigue]? 
 
You have kindly agreed to take part in an interview to talk about your experience of [CFS/ME]. The 
purpose of the interview will be to discuss your experience of this condition in some depth, with 
particular attention to your experience of sleep. This study will help us to better understand the links 
between this condition and sleep disturbances, which will help people like yourself – by allowing for 
more informed diagnoses & treatments.  
 
The interview will last no longer than 90 minutes and if at any point you wish to stop the interview you 
may do so. Likewise, If you feel you do not want to speak about a particular topic or respond to a 
question then that is also fine. As you know, the interview will be audio recorded; however, these 
recordings are kept completely anonymous and in no way linked to you as an individual. All recordings 
will be transcribed following the interview and these too will be in no way linked to your name, but 
instead a code. I will switch on the Dictaphone now. 
 
Having read the information sheet, do you have any questions before we begin? 
       
Interview Questions: 
 
1. Can you please tell me a bit about your experience of having CFS/ME. 
How does it make you feel? 
How does it affect your lifestyle/behaviour/ activities? 
How does it affect your relationship with others? 
 
2. What 3 things bother you the most about having CFS/ME? 
How often do you experience this? 
How much of a problem is it for you? 
How does it affect your daily activities/behaviour? 
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How does it affect your relationships with others? 
What makes this [better/worse]? 
What kinds of things do you currently do to manage this? 
 
3. Can you describe a typical 24 hours.. 
- Good 
- Bad 
When you wake up, how do you feel, what do you do, do you doze, nap in day? What do you 
do next? 
Time you start to feel tired, time to bed, difficulty getting to sleep, things you do to help 
yourself get  
off to sleep, length of time sleeping, quality of sleep, interruptions during sleep, up during 
night, what  
Ǉou do ǁheŶ Ǉou͛re up iŶ Ŷight, tiŵe aǁake iŶ ŵorŶiŶg, hoǁ Ǉou feel ǁheŶ Ǉou ǁake, ǁhat 
you do  
ǁheŶ Ǉou get up… ǁhat Ŷeǆt.. 
 
4. (If struggling to get to sleep) What kind of things do you do to manage this? What strategies 
would you use to help? (bed early, book, snack, TV, herbal remedy, medication, meditative 
breathing/relaxation techniques, tea/coffee, lie in, napping in day) 
Sleeping environment (pitch black, night light, full light, bed partner)?  
 
5. How is your sleep now compared to before having CFS/ME? 
Any problems you encounter whilst sleeping that you did not experience before having 
CFS/ME (if not already discussed)? 
 
6. Have you looked up sleep problems on the Web/had any advice? 
7. Have you ever raised sleep as an issue with your GP/clinician? 
8. (Beliefs/Expectations) How much sleep do you feel you need a night in order to function?  
9. How much sleep do you actually get on average a night? 
 
That’s the eŶd of ŵy questioŶs – thank you very much for sharing your experiences & thoughts with 
me about this. But before we finish, is there anything else important that I might have missed? 
 
Thank you very much for your time today. If you have any queries following today, please feel free to 
contact me. 
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APPENDIX D: Chapter 4: 14-day Sleep Diary  
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APPENDIX E: Chapter 4: Epworth Sleepiness Scale (ESS: Johns 1991). 
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APPENDIX F: Chapter 4: Chalder Fatigue Scale (Chalder et al., 1993)  
 
 
 Less than 
usual 
No more than 
usual 
More than usual Much more 
than usual 
Do you have problems with 
tiredness? 
 
    
Do you need to rest more? 
 
    
Do you feel sleepy or 
drowsy? 
 
    
Do you have problems 
starting things? 
 
    
Do you lack energy? 
 
    
Do you have less strength in 
your muscles? 
 
    
Do you feel weak? 
 
    
Do you have difficulty 
concentrating? 
 
    
Do you make slips of the 
tongue when speaking? 
 
    
Do you find it more difficult 
to find the correct word? 
 
    
 Better than 
usual 
No worse than 
usual 
Worse than 
usual 
Much worse 
than usual 
How is your memory? 
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APPENDIX G: Chapter 4: Trail making Test (TMT: Reitan, 1958) 
 
Trail Making Test Part A 
 
Patient’s Name:                                                   Date: 
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Trail Making Test Part B 
 
Patient’s Name:                                                   Date: 
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APPENDIX H: Chapter 4: Cognitive Failures Questionnaire (CFQ: Broadbent et al, 
1982) 
 
CFQ 
 
The following questions are about minor mistakes which everyone makes from time to 
time, but some of which happen more often than others. We want to know how often 
these things have happened to you in the last six months. Please circle the appropriate 
number. 
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APPENDIX I: Chapter 4: Hospital Anxiety and Depression Scale (HADS: Zigmund & 
Snaith, 1983) 
 
 
 
ϭ. I feel teŶse oƌ ͞wouŶd up͟   
Most of the time. . . . . . . . . . . . .   
A lot of the time. . . . . . . . . . . . .  
Time to Time, Occasionally . . . .  
Not at all . . . . . . . . . . . . . . . . . . .  
 
2.  I still enjoy the things I used to enjoy 
Definitely as much. . . . . . . . . . . . .   
Not quite as much. . . . . . . . . . . . .  
Only a little. . . . . . . . . . . . . . . . . .  
Hardly at all . . . . . . . . . . . . . . . . .  
 
3.  I get a sort of frightened feeling as if 
     something awful is about to happen 
Very definitely and quite badly . . .  
Yes, but not too badly  . . . . . . . . .   
Time to Time, Occasionally  . . . . .  
Not at all  . . . . . . . . . . . . . . . . . . .  
 
4.  I can laugh and see the funny side of 
     things 
As much as I always could  . . . . . .  
Not quite so much now . . . . . . . . .  
Definitely not so much now  . . . . .   
Not at all  . . . . . . . . . . . . . . . . . . .  
 
5.  Worrying thoughts go through my mind 
A great deal of the time  . . . . . . . .  
A lot of the time . . . . . . . . . . . . . .  
From time to time but not too often  
Only occasionally . . . . . . . . . . . . .  
 
6.  I feel cheerful 
Not at all  . . . . . . . . . . . . . . . . . . .   
Not often . . . . . . . . . . . . . . . . . . .  
Sometimes . . . . . . . . . . . . . . . . . .  
Most of the time  . . . . . . . . . . . . .   
 
7.   I can sit at ease and feel relaxed 
 
Definitely . . . . . . . . . . . . . . . . . . .  
Usually . . . . . . . . . . . . . . . . . . . . .   
Not Often . . . . . . . . . . . . . . . . . . .  
Not at all  . . . . . . . . . . . . . . . . . . .  
  
8.  I feel as if I am slowed down 
Nearly all the time . . . . . . . . . . . . . .   
Very often  . . . . . . . . . . . . . . . . . . .  
Sometimes  . . . . . . . . . . . . . . . . . . .  
Not at all   . . . . . . . . . . . . . . . . . . . .  
 
9.  I get a sort of frightened feeling like      
     butterflies in the stomach 
Not at all  . . . . . . . . . . . . . . . . . . . .  
Occasionally . . . . . . . . . . . . . . . . . .  
Quite often . . . . . . . . . . . . . . . . . . .  
Very often  . . . . . . . . . . . . . . . . . . .  
 
10.  I have lost interest in my appearance 
Definitely   . . . . . . . . . . . . . . . . . . .  
I doŶ͛t take so ŵuĐh Đare as I should  
I may not take quite as much care . .   
I take just as much care as ever . . . .  
 
11.  I feel restless as if I have to be on the 
       move 
Very much indeed . . . . . . . . . . . . .   
Quite a lot. . . . . . . . . . . . . . . . . . .  
Not very much. . . . . . . . . . . . . . . .   
Not at all   . . . . . . . . . . . . . . . . . . .  
 
12.  I look forward with enjoyment to 
       things 
As much as ever I did . . . . . . . . . .   
Rather less than I used to . . . . . . .  
Definitely less than I used to . . . . .  
Hardly at all  . . . . . . . . . . . . . . . . .   
 
13.  I get sudden feeling of panic 
Very often indeed . . . . . . . . . . . . .   
Quite often . . . . . . . . . . . . . . . . . .  
Not very often  . . . . . . . . . . . . . . .   
Not at all  . . . . . . . . . . . . . . . . . . .  
 
14.  I can enjoy a good book or radio or 
      TV programme 
Often   . . . . . . . . . . . . . . . . . . . . .  
Sometimes . . . . . . . . . . . . . . . . . .  
Not Often. . . . . . . . . . . . . . . . . . .  
Very seldom . . . . . . . . . . . . . . . . .   
 
Read each item and tick the box opposite the reply which comes closest to how you have been feeling in the past week. 
DoŶ͛t take too loŶg oǀer Ǉour replies: Ǉour iŵŵediate reaĐtioŶ to eaĐh iteŵ ǁill proďaďlǇ ďe ŵore aĐĐurate thaŶ a loŶg 
thought-out response. Tick only one box in each section. 
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APPENDIX J: Chapter 6: Expression of Interest Form  
 
 
The Roles of Sleep and Cortisol in CFS 
 
Thank you for taking the time to read the information sheet regarding the 
above research study. Please tick the appropriate box below, and return the 
form in the enclosed reply-paid envelope. If you do not wish to take part you 
don’t have to return the form, but it would be helpful for us if you could. 
 
 
 
Yes, I am interested in taking part in the research study. 
 
  
I understand that I can withdraw my interest at any time 
and that my current and future care will continue exactly 
as before. If I decide to withdraw, no further contact  
will be made with me regarding the study.      
 
 
 
 
 
Name (capitals) 
 
 
 
Date 
 
 
 
Signature 
 
 
 
Telephone number and/or email 
address 
 
 
 
Best time to contact me 
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APPENDIX K: Chapter 6: Informed Consent Form  
        
 
 
The Roles of Sleep and Cortisol in CFS 
 
Please initial in the appropriate box and sign below if appropriate for you 
8. I confirm that I have read and understand the information 
sheet (Version 2.0, dated 01.05.2012) provided for the 
above study and have had the opportunity to ask questions. 
9. I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving any reason, and 
without my medical care or legal rights being affected. 
10. I understand that my sleep will be monitored for 3 nights. 
11. I understand that I will be required to provide my own saliva 
samples at 7 time points throughout each of the 3 days. 
12. I understand that relevant sections of the data (including 
personal details) collected during the study may be looked at 
by responsible individuals from regulatory authorities or from 
the Newcastle upon Tyne NHS Foundation Trust, where it is 
relevant to my taking part in this research.  I give permission 
for these individuals to have access to my data. 
13. I understand that if a significant disclosure is made, then 
appropriate action will be taken to ensure my safety, as a 
participant taking part in this study. 
14. I agree to take part in the above study. 
 
 
Name of participant  Date  Signature 
Name of researcher  Date  Signature 
 
 
One copy of this signed consent form will be kept by the researcher, one copy 
will be placed in your medical records and one copy will be given to you for 
your own records. 
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FOR USE WHEN TISSUE IS BEING REMOVED AND STORED 
 
Project Title: The Roles of Sleep and Cortisol in CFS 
 
Principal Investigator: Zoe Gotts 
 
Participant Number: __________ 
 
I agree that the following tissue or other bodily material may be taken and used for 
the study:  
 
Tissue/Bodily material Purpose Removal Method 
e.g. saliva 
 
e.g. for cortisol analysis e.g. via Salicaps 
Saliva 
 
For cortisol analysis Salivettes 
 
I understand that if the material is required for use in any other way than that 
explained to me, then my consent to this will be specifically sought. I understand that 
I will not receive specific feedback from any assessment conducted on my samples, 
but should any kind of abnormality be discovered then the investigator will contact 
me.  
 
I understand that the University may store this tissue in a Licensed Tissue 
Bank only for the duration of the study, it will then be destroyed. 
 
Method of disposal:    
Clinical Waste               
Other                             
If other please specify........................................................... 
 
I consent to the University distributing this tissue to partners in this research 
study, outside of the University, for further testing (please tick the box if you 
agree).                                                                     
 
                                                        
Signature of participant.......................................................    Date.....……………….. 
         
Signature of researcher.......................................................    Date.....……………….. 
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APPENDIX L: Chapter 6: Standardised Sleep Diary: 14-day (baseline) 
       
 
         Northumbria Centre for Sleep Research 
Sleep Diary 
 
 
Instructions: 
The Sleep Diary is designed to provide a record of your experience of sleep. You will see information about seven nights (one week) can be recorded on each form. Please 
fill in both forms (2 weeks).  
 
Please complete one column of the diary each morning, soon after you wake up. Take a few minutes to do this, trying to be as accurate as you can. It is your best estimate 
that we are looking for, but try not to get into the habit of clockwatching at night. 
 
Please also indicate which day of the week it is (M, T, W, Th, Fr, Sa, Su) on Day 1 of the sleep diary by circling the appropriate response. 
 
 
Study Title:   The Roles of Sleep & Cortisol in CFS 
 
Date  
ID    
Initials    
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MEASURING THE QUALITY OF YOUR SLEEP 
 
1. How well do you feel this morning? 
     0                      1                  2                    3                    4 
            not at all                           moderately                                very 
  
          
 
2. How enjoyable was your sleep last night? 
     0                      1                  2                    3                    4 
            not at all                           moderately                                very               
 
3. How mentally alert were you in bed last night? 
     0                      1                  2                    3                    4 
            not at all                           moderately                                very               
 
4. How physically tense were you in bed last night? 
     0                      1                  2                    3                    4 
                           not at all                           moderately                                very               
MEASURING THE PATTERN OF YOUR SLEEP 
 
Day 1 
M,T,W,Th, 
Fr,Sa,Su 
Day 2 
 
 
Day 3 
 
 
Day 4 
 
 
Day 5 
 
 
Day 6 
 
 
Day 7 
 
 
1. What time did you wake this morning?               
2. At what time did you rise from bed?               
3. At what time did you go to bed last night?               
4. Lights Out:-  At what time did you put the lights out to go to sleep?               
5. How long did it take you to fall asleep (minutes)? (After Lights Out)               
6. How many times did you wake up during the night?               
7. How long were you awake during the night (in total)?               
8. About how long did you sleep altogether (hours/mins)?               
9. How many sleeping pills did you take to help you sleep?               
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MEASURING THE PATTERN OF YOUR SLEEP 
 
Day 8 
 
 
Day 9 
 
 
Day 10 
 
 
Day 11 
 
 
Day 12 
 
 
Day 13 
 
 
Day 14 
 
 
1. What time did you wake this morning?               
2. At what time did you rise from bed?               
3. At what time did you go to bed last night?               
4. Lights Out:-  At what time did you put the lights out to go to sleep?               
5. How long did it take you to fall asleep (minutes)? (After Lights Out)               
6. How many times did you wake up during the night?               
7. How long were you awake during the night (in total)?               
8. About how long did you sleep altogether (hours/mins)?               
9. How many sleeping pills did you take to help you sleep?               
 
MEASURING THE QUALITY OF YOUR SLEEP 
1. How well do you feel this morning? 
     0                      1                  2                    3                    4 
            not at all                           moderately                                very 
  
          
 
2. How enjoyable was your sleep last night? 
     0                      1                  2                    3                    4 
            not at all                           moderately                                very               
 
3. How mentally alert were you in bed last night? 
     0                      1                  2                    3                    4 
            not at all                           moderately                                very               
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4. How physically tense were you in bed last night? 
     0                      1                  2                    3                    4 
                           not at all                           moderately                                very               
 
 
 
For research use only: 
 
 
 
 
 
 
 
 
SOL   WAKE WASO TST TIB SE 
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APPENDIX M: Chapter 6: Instructions for Questionnaire Booklet  
 
ID# ____________________                        Date_____________________ 
     
 
 
Welcome to the Northumbria Centre for Sleep Research (NCSR). The NCSR is designed 
to study and treat disorders of sleep and wakefulness and is located within 
Northuŵďria UŶiǀersitǇ͛s SĐhool of Life SĐieŶĐes. 
 
Our aim is two-fold:  
We conduct research into the mechanisms underlying the transitions between sleep 
and wakefulness and how biological, psychological, social, and environmental 
circumstances affect these normal, albeit complex, transitions.  
 
Our second aim is to help assess, diagnose, and treat sleep disorders, using a variety 
of techniques and methodologies, in different populations (children, adults, older 
adults, those with acute or chronic illnesses).  
 
The NCSR has been designed to conduct research examining sleep and wakefulness 
using psychophysiologic assessment (e.g., EEG, EMG, EOG, ECG, ERP), indices of basal 
functioning of the endocrine and immune systems (e.g., diurnal cortisol, Cortisol 
Awakening Rise, cytokines, melatonin), and a variety of signal processing techniques, 
including power spectral analysis (PSA).  We also utilise Bluetooth connectivity which 
ŵeaŶs that ǁe ĐaŶ do ͚at-hoŵe͛ aŵďulatorǇ studies.  
 
The NCSR affords the opportunity to examine full physiological and sleep / wake 
parameters over the 24 hour cycle for short or long durations. Not only does it allow 
descriptive studies to be undertaken on objective markers of sleep quality, quantity, 
aŶd tiŵiŶg; it also ĐaŶ ďe used as a diagŶostiĐ ŵeasure of ͚ĐliŶiĐallǇ releǀaŶt͛ adǀerse 
nocturnal events which impact on sleep and daytime functioning in physically and 
psychologically ill populations and in patients with neurodegenerative disorders.  
 
HOW TO FILL OUT THIS BOOKLET 
This questionnaire is about your sleep, your general health and mood. The time it 
takes to fill in the questionnaire varies from person to person, but we estimate that it 
should take less or approximately half an hour. Most questions have multiple 
response choices. Choose the answer that best describes your situation. There is no 
right or wrong answer. Unless stated otherwise, give only one answer to each 
question and please answer all questions!  
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APPENDIX N: Chapter 6: DePaul Symptom Questionnaire (DSQ: Jason et al., 2010) 
 
ABOUT YOU & YOUR HEALTH 
  
DSQ 
Please answer the following questions. 
1. What is your height?      
2. What is your weight?     
3. What is your date of birth?      
4. What is your gender?       
 5.  To which of the following race(s) do you belong? 
Black, African-American 
White 
American Indian or Alaska Native 
Asian or Pacific Islander 
Other race (Please specify)        
6.  Are you of Latino or Hispanic origin?  
Yes No 
7.  What is your current marital status?  
  
  
  
  
  
8. Do you have any children? 
  Skip to Question 9) 
8a. How many children do you have?  
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8b. How many of your children are under 18 years old?    
  
9. How many people live in your home?        
10. What grade or degree have you completed in school? 
 
  
  
  
  
  
11. What is your current work status? (Check all that apply)   
 
   
 
   
 
-time   
-time  
11a. If you are on disability, for what condition do you receive disability 
compensation? 
 Please Specify          
12. What is your current occupation?  
Current        
12a. If you are currently not working, what was your most recent occupation? 
 Most Recent            
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For the following questions (13-66), we would like to know how often you have had each 
symptom and how much each symptom has bothered you over the last 6 months. For each 
symptom please circle one number for frequency and one number for severity. Please fill 
the chart out from left to right.   
 
 
 
 
Symptoms 
Frequency: 
Throughout the past 6 months, how 
often have you had this symptom? 
 
For each symptom listed below, circle 
a number from: 
0 = none of the time 
1 = a little of the time 
2 = about half the time 
3 = most of the time 
4 = all of the time 
Severity: 
Throughout the past 6 months, how 
much has this symptom bothered 
you? 
For each symptom listed below, circle 
a number from: 
0 = symptom not present 
1 = mild 
2 = moderate 
3 = severe 
4 = very severe 
13) Fatigue/extreme tiredness 0          1           2          3         4 0          1           2          3         4 
14) Dead, heavy feeling after starting 
to exercise 0          1           2          3         4 0          1           2          3         4 
15) Next day soreness or fatigue after  
non-strenuous, everyday activities  0          1           2          3         4 0          1           2          3         4 
16) Mentally tired after the slightest 
effort 0          1           2          3         4 0          1           2          3         4 
17) Minimum exercise makes you 
physically tired    0          1           2          3         4 0          1           2          3         4 
18) Physically drained or sick after 
mild activity    0          1           2          3         4 0          1           2          3         4 
19) Feeling unrefreshed after you 
wake up in the morning 0          1           2          3         4 0          1           2          3         4 
20) Need to nap daily  0          1           2          3         4 0          1           2          3         4 
21) Problems falling asleep 0          1           2          3         4 0          1           2          3         4 
22) Problems staying asleep 0          1           2          3         4 0          1           2          3         4 
23) Waking up early in the morning 
(e.g. 3am) 0          1           2          3         4 0          1           2          3         4 
24) Sleep all day and stay awake all 
night 0          1           2          3         4 0          1           2          3         4 
25) Pain or aching in your muscles 0          1           2          3         4 0          1           2          3         4 
26) Pain/stiffness/tenderness in more 
than one joint without swelling or 
redness 
0          1           2          3         4 0          1           2          3         4 
27) Eye pain  0          1           2          3         4 0         1           2          3         4 
 Frequency: Severity: 
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Symptoms 
Throughout the past 6 months, how 
often have you had this symptom? 
 
For each symptom listed below, circle 
a number from: 
0 = none of the time 
1 = a little of the time 
2 = about half the time 
3 = most of the time 
4 = all of the time 
Throughout the past 6 months, how 
much has this symptom bothered 
you? 
For each symptom listed below, circle 
a number from: 
0 = symptom not present 
1 = mild 
2 = moderate 
3= severe 
4 = very severe 
28) Chest pain  0          1           2          3         4 0          1           2          3         4 
29) Bloating 0          1           2          3         4 0          1           2          3         4 
30) Abdomen/stomach pain 0          1           2          3         4 0          1           2          3         4 
31) Headaches 0          1           2          3         4 0          1           2          3         4 
32) Muscle twitches 0          1           2          3         4 0          1           2          3         4 
33) Muscle weakness 0          1           2          3         4 0          1           2          3         4 
34) Sensitivity to noise 0          1           2          3         4 0          1           2          3         4 
35) Sensitivity to bright lights 0          1           2          3         4 0          1           2          3         4 
36) Problems remembering things 0          1           2          3         4 0          1           2          3         4 
37) Difficulty paying attention for a 
long period of time 0          1           2          3         4 0          1           2          3         4 
38) Difficulty finding the right word 
to say or expressing thoughts 0          1           2          3         4 0          1           2          3         4 
39) Difficulty understanding things  0          1           2          3         4 0          1           2          3         4 
40) Only able to focus on one thing at 
a time 0          1           2          3         4 0          1           2          3         4 
41) Unable to focus vision and/or 
attention  0          1           2          3         4 0          1           2          3         4 
42) Loss of depth perception  0          1           2          3         4 0          1           2          3         4 
43) Slowness of thought 0          1           2          3         4 0          1           2          3         4 
44) Absent-mindedness or 
forgetfulness 0          1           2          3         4 0          1           2          3         4 
45) Bladder problems 0          1           2          3         4 0          1           2          3         4 
46) Irritable bowel problems 0          1           2          3         4 0          1           2          3         4 
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Symptoms 
Frequency: 
Throughout the past 6 months, how 
often have you had this symptom? 
 
For each symptom listed below, circle 
a number from: 
0 = none of the time 
1 = a little of the time 
2 = about half the time 
3 = most of the time 
4 = all of the time 
Severity: 
Throughout the past 6 months, how 
much has this symptom bothered 
you? 
For each symptom listed below, circle 
a number from: 
0 = symptom not present 
1 = mild 
2 = moderate 
3= severe 
4 = very severe 
47) Nausea 0          1           2          3         4 0          1           2          3         4 
48) Feeling unsteady on your feet, 
like you might fall 0          1           2          3         4 0          1           2          3         4 
49) Shortness of breath or trouble 
catching your breath 0          1           2          3         4 0          1           2          3         4 
50) Dizziness or fainting 0          1           2          3         4 0          1           2          3         4 
51) Irregular heart beats 0          1           2          3         4 0          1           2          3         4 
52) Losing or gaining weight without 
trying 0          1           2          3         4 0          1           2          3         4 
53) No appetite  0          1           2          3         4 0          1           2          3         4 
54) Sweating hands  0          1           2          3         4 0          1           2          3         4 
55) Night sweats  0          1           2          3         4 0          1           2          3         4 
56) Cold limbs (e.g. arms, legs, 
hands) 0          1           2          3         4 0          1           2          3         4 
57) Feeling chills or shivers  0          1           2          3         4 0          1           2          3         4 
58) Feeling hot or cold for no reason 0          1           2          3         4 0          1           2          3         4 
59) Feeling like you have a high 
temperature  0          1           2          3         4 0          1           2          3         4 
60) Feeling like you have a low 
temperature  0          1           2          3         4 0          1           2          3         4 
61) Alcohol intolerance 0          1           2          3         4 0          1           2          3         4 
62) Sore throat 0          1           2          3         4 0          1           2          3         4 
63) Tender/sore lymph nodes 0          1           2          3         4 0          1           2          3         4 
64) Fever  0          1           2          3         4 0          1           2          3         4 
65) Flu-like symptoms 0          1           2          3         4 0          1           2          3         4 
66) Some smells, foods, medications, 
or chemicals make you feel sick  0          1           2          3         4 0          1           2          3         4 
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67. Have you always had persistent or recurring fatigue/energy problems, even back 
to your earliest memories as a child? (By persistent or recurring, we mean that the 
fatigue/energy problems are usually ongoing and constant, but sometimes there are 
good periods and bad periods.) 
   roblem with fatigue/energy 
 
 
68. Since your fatigue/energy related illness began, do your headaches either happen 
more often, feel worse or more severe, or are they in a different place or spot? 
  
Yes     
  
69. How long ago did your problem with fatigue/energy begin? 
 
-12 months 
-2 years 
 
 
 
70. Have you been diagnosed with Chronic Fatigue Syndrome or Myalgic 
Encephalomyelitis?    
    
70a. If yes, what year were you diagnosed?    
70b. Do you currently have a diagnosis of Chronic Fatigue Syndrome or Myalgic 
 Encephalomyelitis?  
    
70c. Who diagnosed you with Chronic Fatigue Syndrome or Myalgic 
Encephalomyelitis? 
 -Diagnosed    
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70d. Have any of your family members been diagnosed with Chronic Fatigue 
Syndrome or  Myalgic Encephalomyelitis? 
    
If yes, please list their relation to you and current age     
 
71.  Did you experience any of the following symptoms regularly and repeatedly in the 
months and 
       years before your fatigue/energy problems began? 
 
throat 
 
 
 
 
 
 
 
 
72.  If you rest, does your problem with fatigue/energy go away? (Check one)      
   
   
  (Skip to Question 73)  
  (Skip to Question 73) 
72a. How long do you have to rest for your problem with fatigue/energy to entirely 
or  partially go away?  
-
hours 
73. If you were to become exhausted after actively participating in extracurricular 
activities, sports, or outings with friends, would you recover within an hour or two 
after the activity ended?   
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74. Do you reduce your activity level to avoid experiencing problems with 
fatigue/energy?     
    
75. Do you experience a worsening of your fatigue/energy related illness after 
engaging in minimal physical effort?     
  No   
75a. Do you experience a worsening of your fatigue/energy related illness after 
engaging in mental effort?      
 
75b. If you feel worse after activities, how long does this last? (Check one)   
  - - -13 Hrs       
  -  
 
 
76. Are you currently engaging in any form of exercise?  
         (Skip to Question 77)            
 
76a. If you do not exercise, why aren’t you exercising?  (Check all boxes that you 
agree with)    
  
  
  
 se makes symptoms worse 
77. Over what period of time did your fatigue/energy related illness, develop? 
(Check one)    
  
            
            
            2-6 months           
           -12 months            
           -2 years                 
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78. How would you describe the course of your fatigue/energy related illness? 
(Check one)  
          
          
          
periods)       
nd get worse, but never   
disappear completely)  
  
79. Which statement best describes your fatigue/energy related illness during the last  
       6 months?   (Check one) 
 
     
 
-time. 
-time at work or on some family responsibilities. 
anything else. 
energy   left for anything else.    
energy. 
80. Did your fatigue/energy related illness start after you experienced any of the 
following? (Check one or more and please specify) 
        
An accident          
A trip or vacation         
An immunization (shot at doctor’s office)      
Surgery          
Severe stress (bad or unhappy event(s))      
Other          
I am not ill 
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81. Have you ever consulted a medical doctor or health professional about your 
fatigue/energy problem? 
   (Skip to Question 83)     
82. Do you currently have a medical doctor overseeing your fatigue/energy problem? 
    
 
83. Do you have any medical illness (es) that might be causing your symptoms? 
Yes (Skip to Question 84)   
 
83a. What medical illnesses do you have? 
Illness name(s) and year it began:      
          
           
 
83b. For which of these conditions are you currently receiving treatment? 
 
84.  Are you currently taking any medications (over the counter or prescription)?   
(Skip to Question 86) 
84a. What medications are you taking?  
         
 
85. Do you think any medication(s) is (are) causing your problem with 
fatigue/energy? 
          (Skip to Question 86)  
 (Skip to Question 86) 
85a. Please specify which medications:      
            
 
225 
86. Have you ever been diagnosed and/or treated for any of the following: (Check all 
that apply and write year (s) experienced, years treated, and medication (if 
applicable) in the blank) 
  Major depression         
      
  -depression)      
            
           
           
           
  l sensitivities       
           
            
  Please specify)        
   
87. What do you think is the cause of your problem with fatigue/energy? (Check one)  
 
 
 
 
 
 
88. Do you think anything specific in your personal life or environment accounts for 
your  problem with fatigue/energy?   
          (Skip to Question 89)         
 Skip to Question 89)  
88a. Please specify:         
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89. In the past 4 weeks, approximately how many hours per week have you spent 
doing:  
Household related activities?  hours per week              
Social/Recreational related activities? hours per week          
Family related activities?   hours per week  
Work related activities?   hours per week 
 
90. In the past 4 weeks, have you had to reduce the number of hours you previously 
spent (prior  to your illness) on occupational, social or family activities because of 
your health or  problems with fatigue/energy?     
             (Skip to Question 91)    having a problem with fatigue/energy 
90a. Before your fatigue/energy related illness, approximately how many hours 
did you used to spend on: 
Household related activities?        hours per week      
Social/Recreational related activities?      hours per week           
Family related activities?           hours per week     
Work related activities?   hours per week   
 
91. Please rate the amount of energy you had available yesterday, using a scale from 1 
to 100 where 1= no energy and 100 = your pre-illness energy level.  (If you don't 
have a fatigue/energy related illness, a score of 100 = having abundant energy 
such that you could work full time and complete your family responsibilities) 
    
92. Please rate the amount of energy you expended (used) yesterday, using a scale 
from 1 to 100 where 1 = no energy and 100 = your pre-illness energy expended     
    
93. Please rate the amount of fatigue you had yesterday, using a scale from 1 to 100 
where 1 = no fatigue and 100 = severe fatigue      
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94. For the past week, please rate the amount of energy you had available using a 
scale from 1 to 100 where 1 = no energy and 100 = your pre-illness energy level    
    
95. For the past week, please rate the amount of energy you have expended (used) 
using a scale from 1 to 100 where 1 = no energy and 100 = your pre-illness energy 
expended  
96. For the past week, please rate the amount of fatigue you have had using a scale 
from 1 to 100 where 1 = no fatigue and 100 = severe fatigue    
 
97. Since the onset of your problems with fatigue/energy, have your symptoms caused 
a 50% or greater reduction in your activity level? 
     
 
98. Do you experience frequent viral infections with prolonged recovery periods? 
      
 
99. Are you intolerant of extremes of temperatures (when it is extremely hot or cold)? 
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APPENDIX O: Chapter 6:  SF-36: (Ware & Sharebourne, 1992), from the Medical 
Outcomes Study 
 
MOS SURVEY 
 
INSTRUCTIONS: 
This survey asks for your views about your health.  This information will help keep track of how you feel 
and how well you are able to do your usual activities. Answer every question by marking the answer as 
indicated.  If you are unsure about how to answer a question, please give the best answer you can. 
 
1. In general, would you say your health is:  (Please circle one) 
  Excellent .................................................................... 1 
  Very good .................................................................. 2 
  Good ......................................................................... 3 
  Fair ............................................................................ 4 
  Poor ........................................................................... 5 
 
2. Compared to one year ago, how would you rate your health in general now? (Please circle one) 
  Much better than one year ago ................................. 1 
  Somewhat better now than one year ago ................. 2 
  About the same as one year ago .............................. 3 
  Somewhat worse now than one year ago ................. 4 
  Much worse now than one year ago ......................... 5 
 
3. The following items are about activities you might do during a typical day.  Does your health 
                Now limit you in these activities? If so, how much? 
 
Activities Yes, 
Limited 
A Lot 
Yes,  
Limited 
A Little 
No, Not 
Limited 
At All 
Vigorous activities: running, lifting heavy objects, participating in 
strenuous sports 
1 2 3 
Moderate activities: moving a table, pushing a vacuum cleaner, 
bowling, playing golf 
1 2 3 
Lifting or carrying groceries 1 2 3 
Climbing several flights of stairs 1 2 3 
Climbing one flight of stairs 1 2 3 
Bending, kneeling, or stooping 1 2 3 
Walking more than a mile 1 2 3 
Walking several blocks 1 2 3 
Walking one block 1 2 3 
Bathing or dressing yourself 1 2 3 
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4. During the past 4 weeks, have you had any of the following problems with your work or other 
  regular daily activities as a result of your physical health? 
Problems Yes No 
Cut down on the  amount of time you spent on work or other activities  1 2 
Accomplished less than you would like 1 2 
Were limited in the kind of work or other activities 1 2 
Had difficulty performing the work or other activities (For example, it took 
extra effort) 
1 2 
5. During the past 4 weeks, have you had any of the following problems with your work or other  
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
 
Problems Yes No 
Cut down the amount of time you spent on work or other activities 1 2 
Accomplished less than you would like 1 2 
Didn’t do work or other activities as carefully as usual 1 2 
 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems  
                interfered  with your normal social activities with family, neighbors, or groups? 
                (Please circle one) 
  Not at all .................................................................... 1 
  Slightly ....................................................................... 2 
  Moderately ................................................................ 3 
  Quite a bit .................................................................. 4 
  Extremely .................................................................. 5 
 
7. How much bodily pain have you had during the past 4 weeks? 
  None .......................................................................... 1 
  Very mild ................................................................... 2 
  Mild ............................................................................ 3 
  Moderate ................................................................... 4 
  Severe ....................................................................... 5 
  Very Severe .............................................................. 6 
 
8. During the past 4 weeks, how much did pain interfere with your normal work (including both 
work  outside the home and housework)? 
  Not at all .................................................................... 1 
  Slightly ....................................................................... 2 
  Moderately ................................................................ 3 
  Quite a bit .................................................................. 4 
  Extremely .................................................................. 5 
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9.  These questions are about how you feel and how things have been with you during the past 
                4 weeks.  
 
  For each question, please give the one answer that comes closest to the way you have been 
feeling.   
    
How much of the time during the past 4 weeks 
 
Questions All 
of the 
Time 
Most 
of the 
Time 
A Good 
Bit of 
the 
Time 
Some 
of the 
Time 
A 
Little 
of the 
Time 
None 
of the 
Time 
Did you feel full of pep? 1 2 3 4 5 6 
Have you been a nervous person? 1 2 3 4 5 6 
Have you felt so down in the dumps that 
nothing could cheer you up? 
1 2 3 4 5 6 
Have you felt calm and peaceful? 1 2 3 4 5 6 
Did you have a lot of energy? 1 2 3 4 5 6 
Have you felt down-hearted and blue? 1 2 3 4 5 6 
Did you feel worn out? 1 2 3 4 5 6 
Have you been a happy person? 1 2 3 4 5 6 
Did you feel tired? 1 2 3 4 5 6 
 
 
 
10. During the past 4 weeks, how much of the time has your physical health or emotional 
                problems interfered with your social activities (like visiting with friends, relatives, etc.)? 
 
  All of the time ............................................................ 1 
  Most of the time ......................................................... 2 
  Some of the time ....................................................... 3 
  A little of the time ....................................................... 4 
  None of the time ........................................................ 5 
 
 
11. How TRUE or FALSE is each of following statements for you? 
 
Statements Definitely 
True 
Mostly 
True 
Don’t 
Know 
Mostly 
False 
Definitely 
False 
I seem to get sick a little easier than other 
people 
1 2 3 4 5 
I am as healthy as anybody I know 1 2 3 4 5 
I expect my health to get worse 1 2 3 4 5 
My health is excellent 1 2 3 4 5 
  
231 
APPENDIX P: Chapter 6: Demographic, Diet & Exercise Questions 
 
 
If you are female 
       Yes  No 
Are you currently taking the contraceptive pill?  
(please tick) 
 
Please let us know which stage of your menstrual cycle you are in (the first day of bleeding is 
the first day of your cycle): 
           
  
First half     Second half   Not applicable 
   
 
 
 
Would you describe yourself as: (please tick box)  
 
      Pre-menopausal      ฀ 
  Experiencing the menopause now        ฀ 
     Post-menopausal     ฀ 
 
 
 
 
Diet & Exercise 
 
How many caffeinated beverages do you drink, on average, per day? (eg. cola, tea, coffee, 
hot chocolate)?                   (per day) 
 
How many alcoholic drinks per day, on average, do you have (in units)?           (per day) 
 
Do you smoke? (please tick)     Yes               No             Recently Quit 
  
If yes,  
How many cigarettes (cigars or pipes) per day do you smoke (on average)?            (per day) 
 
How many times per week do you exercise? (please tick) 
           
 Every day 
 
          At least 4 times a week 
 
About 3 times a week 
 
About twice a week 
 
About once a week 
 
Never 
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APPENDIX Q: Chapter 6: The General Health Questionnaire (GHQ-28; Goldberg, 
1978)  
 
GHQ-28 
 
Please read this carefully. 
 
We would like to know if you have had any medical complaints and how your health has been 
in general, over the past few weeks. Please answer ALL the questions on the following pages 
simply by underlining the answer which you think most nearly applies to you. Remember that 
we want to know about present and recent complaints, not those that you had in the past. 
 
It is important that you try to answer ALL the questions. 
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A 
 
B 
 
C 
 
D 
 
Total 
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APPENDIX R: Chapter 6: Chalder Fatigue Questionnaire (CFQ; Chalder et al., 1993) 
 
CHALDER FATIGUE QUESTIONNAIRE 
 
 
 
 
 
 
 
 
 Less than 
usual 
No more than 
usual 
More than usual Much more 
than usual 
Do you have problems with 
tiredness? 
    
Do you need to rest more? 
 
    
Do you feel sleepy or 
drowsy? 
    
Do you have problems 
starting things? 
    
Do you lack energy? 
 
    
Do you have less strength in 
your muscles? 
    
Do you feel weak? 
 
    
Do you have difficulty 
concentrating? 
    
Do you make slips of the 
tongue when speaking? 
    
Do you find it more difficult 
to find the correct word? 
    
 Better than 
usual 
No worse than 
usual 
Worse than 
usual 
Much worse 
than usual 
How is your memory? 
 
    
  
We would like to know more about any problems you have had with feeling tired, 
weak or lacking in energy in the last month.  Please answer ALL the questions by 
ticking the answer which applies to you most closely.  If you have been feeling tired 
for a long while, then compare yourself to how you felt when you were last well.  
(Please tick only one box per line). 
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APPENDIX S: Chapter 6: Hospital Anxiety and Depression Scale (HADS: Zigmond 
and Snaith, 1983) 
 
 
 
1. I feel teŶse oƌ ͞wouŶd up͟   
Most of the time. . . . . . . . . . . . .   
A lot of the time. . . . . . . . . . . . .  
Time to Time, Occasionally . . . .  
Not at all . . . . . . . . . . . . . . . . . . .  
 
2.  I still enjoy the things I used to enjoy 
Definitely as much. . . . . . . . . . . . .   
Not quite as much. . . . . . . . . . . . .  
Only a little. . . . . . . . . . . . . . . . . .  
Hardly at all . . . . . . . . . . . . . . . . .  
 
3.  I get a sort of frightened feeling as if 
     something awful is about to happen 
Very definitely and quite badly . . .  
Yes, but not too badly  . . . . . . . . .   
Time to Time, Occasionally  . . . . .  
Not at all  . . . . . . . . . . . . . . . . . . .  
 
4.  I can laugh and see the funny side of 
     things 
As much as I always could  . . . . . .  
Not quite so much now . . . . . . . . .  
Definitely not so much now  . . . . .   
Not at all  . . . . . . . . . . . . . . . . . . .  
 
5.  Worrying thoughts go through my mind 
A great deal of the time  . . . . . . . .  
A lot of the time . . . . . . . . . . . . . .  
From time to time but not too often  
Only occasionally . . . . . . . . . . . . .  
 
6.  I feel cheerful 
Not at all  . . . . . . . . . . . . . . . . . . .   
Not often . . . . . . . . . . . . . . . . . . .  
Sometimes . . . . . . . . . . . . . . . . . .  
Most of the time  . . . . . . . . . . . . .   
 
7.   I can sit at ease and feel relaxed 
 
Definitely . . . . . . . . . . . . . . . . . . .  
Usually . . . . . . . . . . . . . . . . . . . . .   
Not Often . . . . . . . . . . . . . . . . . . .  
Not at all  . . . . . . . . . . . . . . . . . . .  
8.  I feel as if I am slowed down 
Nearly all the time . . . . . . . . . . . . . .   
Very often  . . . . . . . . . . . . . . . . . . .  
Sometimes  . . . . . . . . . . . . . . . . . . .  
Not at all   . . . . . . . . . . . . . . . . . . . .  
 
9.  I get a sort of frightened feeling like      
     butterflies in the stomach 
Not at all  . . . . . . . . . . . . . . . . . . . .  
Occasionally . . . . . . . . . . . . . . . . . .  
Quite often . . . . . . . . . . . . . . . . . . .  
Very often  . . . . . . . . . . . . . . . . . . .  
 
10.  I have lost interest in my appearance 
Definitely   . . . . . . . . . . . . . . . . . . .  
I doŶ͛t take so ŵuĐh Đare as I should  
I may not take quite as much care . .   
I take just as much care as ever . . . .  
 
11.  I feel restless as if I have to be on the 
       move 
Very much indeed . . . . . . . . . . . . .   
Quite a lot. . . . . . . . . . . . . . . . . . .  
Not very much. . . . . . . . . . . . . . . .   
Not at all   . . . . . . . . . . . . . . . . . . .  
 
12.  I look forward with enjoyment to 
       things 
As much as ever I did . . . . . . . . . .   
Rather less than I used to . . . . . . .  
Definitely less than I used to . . . . .  
Hardly at all  . . . . . . . . . . . . . . . . .   
 
13.  I get sudden feeling of panic 
Very often indeed . . . . . . . . . . . . .   
Quite often . . . . . . . . . . . . . . . . . .  
Not very often  . . . . . . . . . . . . . . .   
Not at all  . . . . . . . . . . . . . . . . . . .  
 
14.  I can enjoy a good book or radio or 
      TV programme 
Often   . . . . . . . . . . . . . . . . . . . . .  
Sometimes . . . . . . . . . . . . . . . . . .  
Not Often. . . . . . . . . . . . . . . . . . .  
Very seldom . . . . . . . . . . . . . . . . .   
 
‘ead eaĐh iteŵ aŶd tiĐk the ďoǆ opposite the replǇ ǁhiĐh Đoŵes Đlosest to hoǁ Ǉou haǀe ďeeŶ feeliŶg iŶ the past ǁeek. DoŶ͛t 
take too long over your replies: your immediate reaction to each item will probably be more accurate than a long thought-out 
response. Tick only one box in each section. 
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APPENDIX T: Chapter 6: Work and Social Adjustment Scale (WSAS: Mundt et al., 
2002) 
WSAS 
 
The Following questionnaire asks how much your illness or condition affects 
different areas of your life, on a scale from Not At All (0) to Very Severely (8). 
Please circle the number you feel is closest to how much your problem 
affects you. 
 
BECAUSE OF MY ILLNESS MY ABILITY TO WORK IS IMPAIRED 
 
 
0          1         2           3           4            5           6           7          8 
Not at all              Slightly                      Definitely                     Markedly            Very Severely                          
 
 
BECAUSE OF MY ILLNESS MY  HOME MANAGAMENT  IS IMPAIRED 
(cleaning, tidying,
 
shopping, cooking, looking after
 
home or children, paying bills) 
 
 
0        1           2            3            4            5            6            7            8 
Not at all              Slightly                      Definitely                       Markedly            Very Severely                         
 
 
BECAUSE OF MY ILLNESS MY SOCIAL LESIURE ACTIVITIES ARE IMPAIRED 
(with
 
other people, such as parties, bars, clubs, outings, visits,
 
dating, home entertainment) 
 
  
0        1           2            3            4            5            6            7            8 
Not at all              Slightly                      Definitely                       Markedly            Very Severely                        
 
 
BECAUSE OF MY ILLNESS MY PRIVATE LEISURE ACITVITIES ARE  IMPAIRED 
(done
 
alone, such as reading,
 
gardening, collecting, sewing, walking
 
alone) 
 
 
0        1           2            3            4            5            6            7            8 
Not at all              Slightly                      Definitely                       Markedly            Very Severely                        
 
 
BECAUSE OF MY ILLNESS MY ABILITY TO FORM AND MAINTAIN RELATIONSHIPS  IS 
IMPAIRED 
(close relationships with others, including those you live with) 
 
0        1           2            3            4            5            6            7            8 
Not at all              Slightly                      Definitely                       Markedly            Very Severely                        
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APPENDIX U: Chapter 6: Perceived Stress Scale (PSS: Cohen et al., 1983) 
 
 
 
 
 
 
  
              
 
 
2.Almost 3.Some 4.Fairly 5.Very 
 1.Never   Never 
 
Times Often Often 
In the last month, how often have you been upset 
because of something that happened 
unexpectedly?   1   2   3   4   5     
In the last month, how often have you felt that 
you were unable to control the important things 
in your life?   1   2   3   4   5     
In the last month, how often have you felt 
nervous and stressed?   1   2   3   4   5     
In the last month, how often have you dealt with 
irritating life hassles?   1   2   3   4   5     
In the last month, how often have you felt that 
you were effectively coping with important 
changes that were occurring in your life?   1   2   3   4   5     
In the last month, how often have you felt 
confident about your ability to handle your 
personal problems?   1   2   3   4   5     
In the last month, how often have you felt that 
things were going your way?   1   2   3   4   5     
In the last month, how often have you found that 
you could not cope with all the things you had to 
do? 
  
1   2   3   4   5     
In the last month, how often have you been able 
to control irritations in your life?   1   2   3   4   5     
In the last month, how often have you felt that 
you were on top of things?   1   2   3   4   5     
In the last month, how often have you been 
angered because of things that happened that 
were outside of your control? 
  
1   2   3   4   5     
In the last month, how often have you found 
yourself thinking about things that you have to 
accomplish? 
  
1   2   3   4   5     
In the last month, how often have you been able 
to control the way you spend your time? 
  
1   2   3   4   5     
In the last month, how often have you felt 
difficulties were piling up so high that you could 
not overcome them? 
  
1   2   3   4   5     
The questions in this scale ask you about your feelings and thoughts during the last month. In each 
case, you will be asked to indicate how often you felt or thought in a certain way. Although some of 
the questions are similar, there are differences between them and you should treat each one as a 
separate question. The best approach is to answer each one as a separate question. That is, don't try 
to count up the number of times you felt a particular way, but rather indicate the number that seems 
like a reasonable estimate. Please circle the most appropriate response. 
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APPENDIX V: Chapter 6: Brief Illness Perception Questionnaire (IPQ; Broadbent, et 
al., 2006) 
 
 
 
 
 
How much does your illness affect your life? 
 0       1      2      3      4      5      6      7      8             9         10 
no affect                                                                                                                                                      severely 
at all                                                                                                                                             affects my life         
                    
 
How long do you think your illness will continue? 
 0        1      2      3      4       5          6       7       8          9         10 
a very                                                                                                                           forever                                      
short time                              
 
 
How much control do you feel you have over your illness? 
 0         1       2      3       4       5        6       7          8           9         10 
Absolutely                                                                                                                                                     extreme 
no control                                                                                                                                      amount of control          
 
How much do you think your treatment can help your illness? 
0         1        2      3      4       5       6      7                8                 9         10  
not at all                                                                                                                                    extremely 
               helpful    
 
How much do you experience symptoms from your illness? 
 0           1        2       3       4       5       6      7             8      9          10 
no symptoms                                                                                                              many severe 
at all                                                                                                                                                  symptoms  
                                                               
    
 
How concerned are you about your illness? 
 0          1         2       3       4       5        6       7           8            9          10 
not at all                                                                                                                                  extremely           
concerned                                                                                                                                               concerned 
                                                                                  
 
How well do you feel you understand your illness? 
 0          1         2        3        4        5        6         7            8            9          10 
don't understand                                                                                                                              understand 
at all                                                                  very clearly 
            
The following questions relate to your views about your illness (CFS). 
For the following questions, please circle the number that best corresponds to your views: 
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How much does your illness affect you emotionally? (eg. does it make you angry, scared, upset or 
depressed?) 
  0           1         2       3        4       5        6         7            8              9          10 
not at all                                                                                                                                  extremely affected 
affected emotionally                                                                                                                              emotionally           
                                                                                                
                                                                                                                                            
        
 
Please list in rank-order the three most important factors that you believe caused your illness.  
The most important causes for me:- 
 
1. __________________________________ 
2. __________________________________ 
3. __________________________________ 
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APPENDIX W: Chapter 6: The Pittsburgh Sleep Quality Index (PSQI: Buysse et al., 
1989) 
 
PSQI 
 
ABOUT YOUR SLEEP 
 
 
 
 
 
 
 
1. During the past month, when have you usually gone to bed at night? 
 
USUAL BED TIME: _____________________ 
(i. e. 10pm or 22.00) 
 
2. During the past month, how long (in minutes) has it usually taken you to fall asleep 
each night? 
 
NUMBER OF MINUTES: ________________ 
 
2b. How long have you usually been awake during the night? 
 
    NUMBER OF MINUTES: ________________ 
 
3. During the past month, when have you usually got up in the morning? 
 
    USUAL GETTING UP TIME: _____________ 
 
4.  During the past month, how many hours of actual sleep did you get at night?  This 
may be different to the number of hours you spend in bed. 
 
HOURS OF SLEEP PER NIGHT: __________ 
 
4b. How many nights per week do you usually have difficulties sleeping? 
 
    NUMBER OF NIGHTS PER WEEK: _______ 
 
 
 
 
 
 
 
 
The following questions relate to your usual sleep habits during the past month only.  
Your answers should indicate the most accurate reply for the majority of days and nights 
in the past month. 
 
Please answer all of the questions. 
 
241 
5. During the past month, how often have you had trouble sleeping because you: 
 
  Not during 
the past 
month 
Less than 
once a week 
Once or 
twice a week 
Three or 
more times a 
week 
(a) Cannot get to sleep within 30 
minutes 
    
(b) Wake up in the middle of the night 
or early morning 
    
(c) Have to get up and use the 
bathroom 
    
(d) Cannot breathe comfortably     
(e) Cough or snore loudly     
(f) Feel too cold     
(g) Feel too hot     
(h) Had bad dreams     
(i) Have pain     
 
Other reason(s), please describe_________________________________________________ 
 
How often during the past month have you had trouble sleeping because of this? 
[  ] Not during the past month 
[  ] Less than once a week 
[  ] Once or twice a week 
[  ] Three or more times a week 
 
6. During the past month, how would you rate your sleep quality overall? 
 
[  ] Very good 
[  ] Fairly good 
[  ] Fairly bad 
[  ] Very Bad 
 
7. DuriŶg the past ŵoŶth, hoǁ ofteŶ haǀe Ǉou takeŶ ŵediĐiŶe ;presĐriďed or ͚oǀer the ĐouŶter͛Ϳ to 
help you sleep? 
 
[  ] Not during the past month 
[  ] Less than once a week 
[  ] Once or twice a week 
[  ] Three or more times a week 
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8. During the past month, how often have you had trouble staying awake while driving, eating 
meals or engaging in social activity? 
 
[  ] Not during the past month 
[  ] Less than once a week 
[  ] Once or twice a week 
[  ] Three or more times a week 
 
9. During the past month, how much of a problem has it been for you to keep up enough 
enthusiasm to get things done? 
 
[  ] No problem at all 
[  ] Only a very slight problem 
[  ] Somewhat of a problem 
[  ] A very big problem 
 
10. Do you have a bed partner or room-mate? 
 
[  ] No bedroom partner or room-mate 
[  ] Partner/ room-mate in other room 
[  ] Partner in same room, but not same bed 
[  ] Partner in same bed 
 
If you have a room-mate or bed partner, ask him/ her how often in the past month you have 
had: 
 
(a) Loud snoring 
 
[  ] Not during the past month 
[  ] Less than once a week 
[  ] Once or twice a week 
[  ] Three or more times a week 
 
(b) Long pauses between breaths while asleep 
 
[  ] Not during the past month 
[  ] Less than once a week 
[  ] Once or twice a week 
[  ] Three or more times a week 
 
(c) Legs twitching or jerking while you sleep 
 
[  ] Not during the past month 
[  ] Less than once a week 
[  ] Once or twice a week 
[  ] Three or more times a week 
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(d) Episodes of disorientation or confusion during sleep 
 
[  ] Not during the past month 
[  ] Less than once a week 
[  ] Once or twice a week 
[  ] Three or more times a week 
 
(e) Other restlessness while you sleep; please describe  
 
 
[  ] Not during the past month 
[  ] Less than once a week 
[  ] Once or twice a week 
[  ] Three or more times a week 
 
 
(f) Do you consider yourself to have a sleep problem? 
[  ] Yes 
[  ] No 
 
If Yes, how long has the problem been present? 
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APPENDIX X: Chapter 6: Insomnia Severity Index (ISI: Morin et al., 2011) 
 
ISI 
 
 
 
 
 
 
1). Please rate the current severity of your insomnia problem(s). 
None  Mild  Moderate   Severe    Very 
 
a. Difficulty falling asleep:     0     1         2             3   4 
b. Difficulty staying asleep:     0     1          2  3   4 
c. Problem waking up too early   0     1         2  3   4 
 
2). How SATISFIED/DISSATISFIED are you with your current sleep pattern? 
 
Very Satisfied                Very Dissatisfied 
0                 1       2                3       4 
 
3). To what extent do you consider your insomnia problem to INTERFERE with your 
daily functioning (e.g. daytime fatigue, ability to function at work/daily chores, 
concentration, memory, mood, etc.). 
 
Not at all  A little  Somewhat  Much  Very much 
Interfering    Interfering    Interfering 
0      1        2       3         4 
 
4). How NOTICEABLE to others do you think your insomnia problem is in terms of 
impairing the quality of your life? 
 
Not at all  A little  Somewhat  Much  Very much 
Noticeable         Noticeable 
0      1        2      3       4 
 
5). How WORRIED/DISTRESSED are you about your current insomnia problem? 
 
Not at all   A little  Somewhat  Much  Very much 
Worried          Worried 
0     1        2      3       4 
 
  
Please rate your current situation (i.e. last month) by selecting one response for each 
question. 
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APPENDIX Y: Chapter 6: Ford Insomnia Response to Stress Test (FIRST: Drake et 
al., 2004) 
FIRST 
 
 
 
 
 
 
Before an important meeting the next day 
 
Not likely Somewhat likely Moderately likely Very likely 
 
After a stressful experience during the day 
 
Not likely Somewhat likely Moderately likely Very likely 
 
After a stressful experience in the evening 
 
Not likely Somewhat likely Moderately likely Very likely 
 
After getting bad news during the day 
 
Not likely Somewhat likely Moderately likely Very likely 
 
After watching a frightening movie or TV show 
 
Not likely Somewhat likely Moderately likely Very likely 
 
After having a bad day at work 
 
Not likely Somewhat likely Moderately likely Very likely 
 
After an argument 
 
Not likely Somewhat likely Moderately likely Very likely 
 
Before having to speak in public 
 
Not likely Somewhat likely Moderately likely Very likely 
 
Before going on holiday the next day 
 
Not likely Somewhat likely Moderately likely Very likely 
 
 
 
THANK YOU! 
Now please return the questionnaire booklet to the 
researcher. 
When you experience the following situations, how likely is it for you to have difficulty 
sleeping? Please circle an answer even if you have not experienced these situations recently 
situations recently. 
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APPENDIX Z: Chapter 6: Saliva Collection Instructions 
 
SALIVA COLLECTION INSTRUCTIONS 
 
To assess concentrations of the stress hormone, cortisol, we would like you to collect saliva on THREE 
CONSECUTIVE WEEKDAYS. You have been provided with three zip lock bags, labelled D1 (day 
1), D2 (day 2) and D3 (day 3). Inside each bag, you will find seven saliva collection tubes**.   
** saliva collection tubes have been labelled to help you decide which tube to use, and at which time 
point** 
Please collect saliva at the following time (T) points, 
Day 1 (D1) 
D1_T1_S : Wake (Immediately after waking)  
D1_T2_S : Wake + 15 min  (15 minutes after you wake)      
D1_T3_S : Wake + 30 min  (30 minutes after you wake)         
D1_T4_S : Wake + 45 min  (45 minutes after you wake)           
D1_T5_S : Wake + 60 min  (60 minutes after you wake)           
D1_T6_S : Afternoon Sample  (between 2-4pm)                             
D1_T7_S : Before Bed (brush teeth after sample is taken)  
 
Day 2 (D2) 
D2_T1_S : Wake (Immediately after waking)         
D2_T2_S : Wake + 15 min  (15 minutes after you wake)           
D2_T3_S : Wake + 30 min  (30 minutes after you wake)           
D2_T4_S : Wake + 45 min  (45 minutes after you wake)                 
D2_T5_S : Wake + 60 min  (60 minutes after you wake)               
D2_T6_S : Afternoon Sample (between 2-4pm)                             
D2_T7_S : Before Bed (brush teeth after sample is taken)    
 
Day 1 (D3) 
D3_T1_S : Wake (Immediately after waking)          
D3_T2_S : Wake + 15 min  (15 minutes after you wake)          
D3_T3_S : Wake + 30 min  (30 minutes after you wake)                  
D3_T4_S : Wake + 45 min  (45 minutes after you wake)                    
D3_T5_S : Wake + 60 min  (60 minutes after you wake)                      
D3_T6_S : Afternoon Sample (between 2-4pm)               
D3_T7_S : Before Bed (brush teeth after sample is taken)    
 
Please also complete the sample log booklet provided. This allows you to note the dates and times of 
your samples, including how you are feeling at those times. 
 
WHAT IS THE BEST WAY TO ACCURATELY COLLECT SALIVA? 
 
- Leave at least 45 minutes between eating any food and taking a sample 
- Rinse your mouth with cold water (not essential) 
- Remove the cotton roll from the collection tube 
- Place in your mouth 
- Chew for 1-2 minutes, until the cotton roll is COMPLETELY saturated 
- Deposit the saturated roll back into the collection tube 
- Make sure the cap is secure  
- Place back into the zip-lock bag & REFRIGERATE until returned to the research team 
 
WHAT SHOULD I DO IF THINGS GO WRONG, OR I HAVE QUESTIONS? 
 
Please contact the researcher, Zoe Gotts, Tel: 0191 243 7018 E-mail: zoe.gotts@northumbria.ac.uk 
 
Please refrain from brushing 
teeth/eating breakfast until 
after the 60 minute sample 
is taken 
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APPENDIX AA: Chapter 6: Standardised Sleep Diary & Saliva Sample Log: 3-day 
(assessment) 
 
 
V1.0_03/02/12 
 
 
 
 
 
              HOW TO FILL OUT THIS BOOKLET 
 
Please complete the questions in this booklet carefully.  On each day please indicate 
the date. Please could you record the time at which you wake and the time at 15 
minutes, 30 minutes, 45 minutes and 1 hour after you wake. Could you also record 
the times at which you take your saliva samples – these should match as far as 
possible the times that you indicate for wake and for the 15 minutes, 30 minutes, 45 
minutes and 1 hour after waking.  
 
For the first hour after you wake, you will not be allowed to eat or brush your teeth 
as this can interfere with the measurements we are taking. Please also do not eat for 
at least 30 minutes prior to taking the afternoon and bed samples. You will be 
allowed to drink water. 
 
Following your 1 hour after waking sample, you will be required to answer questions 
relating to your sleep and mood. You will also be required to record the time you take 
your afternoon sample and bed sample and answer questions relating to your mood 
at these times. 
 
Please complete the booklet carefully in the morning, afternoon and prior to sleeping 
for 3 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ID    
Initials    
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DAY 1 
 
Today’s date ____ / ____ / _______ 
 
MORNING 
 
Please provide the exact time that you provide each of the samples 
 
 Wake Wake +15 Wake +30 Wake +45 Wake +60 
Time      
Time of sample      
 
Please coŵplete the followiŶg ƋuestioŶs followiŶg youƌ ͚Wake +6Ϭ͛ saŵple 
 
 MEASURING THE PATTERN OF YOUR SLEEP 
 
1 What time did you wake this morning? 
  
2 At what time did you rise from bed? 
  
3 At what time did you go to bed last night? 
  
4 Lights Out: At what time did you put the lights out to go to sleep? 
  
5 How long did it take you to fall asleep (minutes)? (After Lights Out) 
  
6 How many times did you wake up during the night? 
  
7 How long were you awake during the night (in total)? 
  
8 About how long did you sleep altogether (hours/mins)? 
  
9 How many sleeping pills did you take to help you sleep? 
  
 
 
 
 MEASURING THE QUALITY OF YOUR SLEEP 
 not at all  moderately  very 
10 How well do you feel this morning? 
 0 1 2 3 4 
11 How enjoyable was your sleep last night? 
 0 1 2 3 4 
12 How mentally alert were you in bed last night? 
 0 1 2 3 4 
13 How physically tense were you in bed last night? 
 0 1 2 3 4 
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Please read each statement then circle the most appropriate point to indicate 
 
how you feel right now 
 
I feel calm  
not at all       very much 
 
I feel tense 
not at all       very much 
 
I am upset 
not at all       very much 
 
I feel relaxed 
not at all       very much 
 
I feel content 
not at all       very much 
 
I feel worried 
not at all       very much 
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AFTERNOON 
 
 
Please proǀide the eǆaĐt tiŵe that Ǉou proǀide the ͚AfterŶooŶ͛ saŵple 
 
 
 
 Afternoon 
Time of sample  
 
 
Please coŵplete the followiŶg ƋuestioŶs followiŶg youƌ ͚AfteƌŶooŶ͛ sample 
 
 
 
Please read each statement then circle the most appropriate point to indicate 
 
how you feel right now 
 
I feel calm 
not at all       very much 
 
I feel tense 
not at all       very much 
 
I am upset 
not at all       very much 
 
I feel relaxed 
not at all       very much 
 
I feel content 
not at all       very much 
 
I feel worried 
not at all       very much 
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BED 
 
 
Please proǀide the eǆaĐt tiŵe that Ǉou proǀide the ͚Bed͛ saŵple 
 
 
 
 Bed 
Time of sample  
 
 
Please complete the followiŶg ƋuestioŶs followiŶg youƌ ͚Bed͛ saŵple 
 
 
 
Please read each statement then circle the most appropriate point to indicate  
 
how you feel right now 
 
I feel calm 
not at all       very much 
 
I feel tense 
not at all       very much 
 
I am upset 
not at all       very much 
 
I feel relaxed 
not at all       very much 
 
I feel content 
not at all       very much 
 
I feel worried 
not at all       very much 
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DAY 2 
 
Today’s date ____ / ____ / _______ 
 
MORNING 
 
Please provide the exact time that you provide each of the samples 
 
 Wake Wake +15 Wake +30 Wake +45 Wake +60 
Time      
Time of sample      
 
Please coŵplete the followiŶg ƋuestioŶs followiŶg youƌ ͚Wake +6Ϭ͛ saŵple 
 
 MEASURING THE PATTERN OF YOUR SLEEP 
 
1 What time did you wake this morning? 
  
2 At what time did you rise from bed? 
  
3 At what time did you go to bed last night? 
  
4 Lights Out: At what time did you put the lights out to go to sleep? 
  
5 How long did it take you to fall asleep (minutes)? (After Lights Out) 
  
6 How many times did you wake up during the night? 
  
7 How long were you awake during the night (in total)? 
  
8 About how long did you sleep altogether (hours/mins)? 
  
9 How many sleeping pills did you take to help you sleep? 
  
 
 
 
 MEASURING THE QUALITY OF YOUR SLEEP 
 not at all  moderately  very 
6 How well do you feel this morning? 
 0 1 2 3 4 
7 How enjoyable was your sleep last night? 
 0 1 2 3 4 
8 How mentally alert were you in bed last night? 
 0 1 2 3 4 
9 How physically tense were you in bed last night? 
 0 1 2 3 4 
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Please read each statement then circle the most appropriate point to indicate  
 
how you feel right now 
 
I feel calm 
not at all       very much 
 
I feel tense 
not at all       very much 
 
I am upset 
not at all       very much 
 
I feel relaxed 
not at all       very much 
 
I feel content 
not at all       very much 
 
I feel worried 
not at all       very much 
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AFTERNOON 
 
 
Please proǀide the eǆaĐt tiŵe that Ǉou proǀide the ͚AfterŶooŶ͛ saŵple 
 
 
 
 Afternoon 
Time of sample  
 
 
Please coŵplete the followiŶg ƋuestioŶs followiŶg youƌ ͚AfteƌŶooŶ͛ saŵple 
 
 
 
Please read each statement then circle the most appropriate point to indicate  
 
how you feel right now 
 
I feel calm 
not at all       very much 
 
I feel tense 
not at all       very much 
 
I am upset 
not at all       very much 
 
I feel relaxed 
not at all       very much 
 
I feel content 
not at all       very much 
 
I feel worried 
not at all       very much 
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BED 
 
 
Please provide the eǆaĐt tiŵe that Ǉou proǀide the ͚Bed͛ saŵple 
 
 
 
 Bed 
Time of sample  
 
 
Please coŵplete the followiŶg ƋuestioŶs followiŶg youƌ ͚Bed͛ saŵple 
 
 
 
Please read each statement then circle the most appropriate point to indicate  
 
how you feel right now 
 
I feel calm 
not at all       very much 
 
I feel tense 
not at all       very much 
 
I am upset 
not at all       very much 
 
I feel relaxed 
not at all       very much 
 
I feel content 
not at all       very much 
 
I feel worried 
not at all       very much 
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DAY 3 
 
Today’s date ____ / ____ / _______ 
 
MORNING 
 
Please provide the exact time that you provide each of the samples 
 
 Wake Wake +15 Wake +30 Wake +45 Wake +60 
Time      
Time of sample      
 
Please complete the following questions following youƌ ͚Wake +6Ϭ͛ saŵple 
 
 MEASURING THE PATTERN OF YOUR SLEEP 
 
1 What time did you wake this morning? 
  
2 At what time did you rise from bed? 
  
3 At what time did you go to bed last night? 
  
4 Lights Out: At what time did you put the lights out to go to sleep? 
  
5 How long did it take you to fall asleep (minutes)? (After Lights Out) 
  
6 How many times did you wake up during the night? 
  
7 How long were you awake during the night (in total)? 
  
8 About how long did you sleep altogether (hours/mins)? 
  
9 How many sleeping pills did you take to help you sleep? 
  
 
 
 
 
 MEASURING THE QUALITY OF YOUR SLEEP 
 not at all  moderately  very 
6 How well do you feel this morning? 
 0 1 2 3 4 
7 How enjoyable was your sleep last night? 
 0 1 2 3 4 
8 How mentally alert were you in bed last night? 
 0 1 2 3 4 
9 How physically tense were you in bed last night? 
 0 1 2 3 4 
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Please read each statement then circle the most appropriate point to indicate  
 
how you feel right now 
 
I feel calm 
not at all       very much 
 
I feel tense 
not at all       very much 
 
I am upset 
not at all       very much 
 
I feel relaxed 
not at all       very much 
 
I feel content 
not at all       very much 
 
I feel worried 
not at all       very much 
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AFTERNOON 
 
 
Please proǀide the eǆaĐt tiŵe that Ǉou proǀide the ͚AfterŶooŶ͛ saŵple 
 
 
 
 Afternoon 
Time of sample  
 
 
Please coŵplete the followiŶg ƋuestioŶs followiŶg youƌ ͚AfteƌŶooŶ͛ saŵple 
 
 
Please read each statement then circle the most appropriate point to indicate  
 
how you feel right now 
 
I feel calm 
not at all       very much 
 
I feel tense 
not at all       very much 
 
I am upset 
not at all       very much 
 
I feel relaxed 
not at all       very much 
 
I feel content 
not at all       very much 
 
I feel worried 
not at all       very much 
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BED 
 
 
Please proǀide the eǆaĐt tiŵe that Ǉou proǀide the ͚Bed͛ saŵple 
 
 
 
 Bed 
Time of sample  
 
 
Please complete the following ƋuestioŶs followiŶg youƌ ͚Bed͛ saŵple 
 
 
 
Please read each statement then circle the most appropriate point to indicate  
 
how you feel right now 
 
I feel calm 
not at all       very much 
 
I feel tense 
not at all       very much 
 
I am upset 
not at all       very much 
 
I feel relaxed 
not at all       very much 
 
I feel content 
not at all       very much 
 
I feel worried 
not at all       very much 
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APPENDIX BB: Chapter 7: Sleep characteristics of normal sleepers derived from self-
reported and objectively (PSG) assessed measures  
 
 
Note: N = 22. PSQI, Pittsburgh sleep quality index; FIRST, ford insomnia response to stress test; ISI, insomnia 
severity index; PSG, polysomnography; SOL, sleep onset latency; WASO, wake after sleep onset; TST, total sleep 
time; %N1, percentage of stage 1 sleep; %N2, percentage of stage 2 sleep; %N3, percentage of slow wave sleep; 
%REM, percentage of rapid eye movement sleep; SEI, sleep efficiency index; TSP, total sleep period.
Sleep Characteristics Mean (SD) 
Self-report   
             PSQI (subjective sleep quality) 0.64 (0.49) 
             PSQI (sleep latency) 0.82 (0.59) 
             PSQI (sleep duration) 0.18 (0.39) 
             PSQI (habitual sleep efficiency) 0.18 (0.50) 
             PSQI (sleep disturbances) 1.00 (0.44) 
             PSQI (use of sleep medication) 0.09 (0.43) 
             PSQI (daytime dysfunction) 0.59 (0.50) 
             PSQI (global) 3.45 (1.77) 
             FIRST 19.14 (4.43) 
             ISI 2.64 (2.19)   
PSG Variables  (n2) (n3) (average n2 & n3) 
            TST (min) 437.82 (32.13) 430.43 (30.08) 434.13 (30.02) 
            SOL (min) 12.39 (9.53) 14.73 (11.41) 13.55 (10.08) 
            WASO (min) 13.82 (10.63) 15.86 (12.41) 14.84 (11.14) 
            SEI (%) 97.04 (1.97) 96.52 (2.37) 96.78 (2.07) 
            %N1 (of TST) 3.34 (1.35) 3.70 (1.39) 3.52 (1.26) 
            %N2 (of TST) 53.84 (5.50) 52.08 (4.47) 52.96 (4.53) 
            %N3 (of TST) 19.34 (4.85) 20.02 (4.43) 19.68 (4.24) 
            %REM (of TST) 23.48 (4.54) 24.33 (4.91) 23.91 (4.01) 
            REM Latency (min) 102.30 (42.59) 89.45 (30.91) 95.88 (35.73) 
            Number of awakenings (over TSP) 
            % wake (over TSP) 
Subjective Sleep Diary  
            TST (min) 
            SOL (min) 
            WASO (min) 
            SEI (%) 
13.68 (5.68) 
5.52 (2.66)  
 (n2) 
455.91 (30.81) 
14.32 (7.76) 
9.77 (10.15) 
87.76 (6.10) 
13.64 (4.88) 
6.54 (3.75) 
(n3) 
450.50 (37.15) 
14.23 (9.60) 
5.00 (6.12) 
86.02 (6.19) 
13.66 (5.07) 
6.03 (3.11) 
(average n2 & n3) 
447.84 (33.77) 
14.48 (7.89) 
6.86 (5.85) 
86.93 (5.55) 
261 
APPENDIX CC 
 
Gotts, Z. M., Deary, V., Newton, J., Van der Dussen, D., De Roy, P., & Ellis, J. G.  
(2013). Are there sleep-specific phenotypes in patients with chronic fatigue syndrome? 
A cross-sectional polysomnography analysis. BMJ open, 3(6). 
 
